Document:

<Page>

                                                                   Exhibit 10.13

                                    AGREEMENT

This Agreement (the "Agreement") is entered into as of the last date of
signature appearing below (the "EFFECTIVE DATE") between NeoGenesis Drug
Discovery, Inc., a Delaware corporation ("NEOGENESIS") and Schering Corporation,
a New Jersey corporation ("Schering"), and sets forth the terms and conditions
that will apply to the provision by NeoGenesis to Schering of certain screening
and analysis services.

                                   BACKGROUND

Schering is interested in identifying potential pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high degree of chemical binding and functional activity to specific
protein targets. NeoGenesis has certain technology and know-how, including
screening processes of libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding activity to targets designated by Schering from among the
NeoGenesis libraries of mass-encoded small molecule compounds and which have
activity in target-specific functional assays. The terms and conditions set
forth below shall govern the performance of such collaborative effort.

1.       DEFINITIONS.

     The following capitalized terms used in this Agreement, whether in the
singular or plural, shall have the meaning set forth below.

         1.1 "ACTIVE COMPOUND" means any Compound identified as having binding
activity when tested against a Target pursuant to the Screening Program and
which (a) has Kd values of [*] and (b) has demonstrated bioactivity in
functional assays against the applicable Target as determined by the Steering
Committee following Schering's performance of the procedure specified in
Paragraph 3 of ATTACHMENT A.

         1.2 "AFFILIATE" means with respect to either party, any Person that,
directly or indirectly, is controlled by, controls or is under common control
with such party. For purposes of this definition, control means, with respect to
any Person, the direct or indirect ownership of [*] or more of the outstanding
voting securities of an entity, or the right to receive [*] or more of the
profits or earnings of an entity, or the possession otherwise, directly or
indirectly, of the power to direct the management, business and affairs of an
entity.

         1.3 "ALIS" means the Automated Ligand Identification System, an
automated, ultra-high throughput ligand selection system proprietary to
NeoGenesis that is used to identify multiple classes of chemical ligands against
a target protein.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

         1.4 "CHEMOTYPE" means a family or group of Compounds closely
structurally related to one or more Active Compounds.

         1.5 "CIP" means "Carriage and Insurance Paid", as that expression is
defined in Incoterms 2000, ICC Publishing S.A.

         1.6 "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to (a)
any objective by either party, reasonable, diligent, good faith efforts to
accomplish such objective as such Party would normally use to accomplish a
similar objective under similar circumstances; and (b) with respect to any
objective relating to the development or commercialization of any Licensed
Product efforts and resources normally used by such party with respect to a
product owned by such party or to which such party has similar rights which is
of similar market potential at a similar stage in the development or life of
such product, taking into account issues of safety, efficacy, product profile,
the competitiveness of the marketplace, the proprietary position of the product,
the regulatory structure involved, profitability of the product and other
relevant commercial factors.

         1.7 "COMPOUND" shall mean all proprietary compounds contained in the
NeoMorph Screening Library or any NeoMorph Focused Libraries which are screened
by NeoGenesis against one or more Targets in performance of the Screening
Program.

         1.8 "COMPOUND PATENT RIGHTS" shall mean any Schering Patent Rights
which claim Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Product, or the manufacture or use thereof.

         1.9 "CONFIDENTIAL INFORMATION" means any proprietary or confidential
information of either party (including but not limited to all Schering Know-How
and all NeoGenesis Know-How) disclosed to the other party pursuant to this
Agreement in written or other tangible medium and marked as confidential, or if
disclosed orally or displayed, confirmed in writing within thirty (30) days of
disclosure.

         1.10 "DERIVATIVE COMPOUND" means a compound which is derived from a
Selected Compound or a Lead Compound by or on behalf of Schering, or by
NeoGenesis in performance of medicinal chemistry optimization pursuant to
Section 2.2(b), and having activity against the same Target as such Selected
Compound and/or Lead Compound. A compound will be deemed to have been "derived"
from a Selected Compound or a Lead Compound if it (i) is the result of a
chemical modification made to a Selected Compound or Lead Compound, (ii) is
otherwise derived from a chemical synthesis program based upon a Selected
Compound or Lead Compound, or (iii) is based on proprietary structure-function
data obtained from Selected Compounds or Lead Compounds. Derivative Compounds
will include, without limitation, all Compounds contained in the NeoMorph
Focused Library(ies).

         1.11 "DESIGNATED COMPOUND" means any Selected Compound or Derivative
Compound which becomes the subject of a development program conducted by
Schering or its Affiliates, as further defined in Section 2.8(b) of the
Agreement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

         1.12 "EMEA" means the European Medicines Evaluation Authority, or any
successor thereto.

         1.13 "FDA" means the United States Food and Drug Administration, or any
successor thereto.

         1.14 "FD&C ACT" means the United States Federal Food, Drug and Cosmetic
Act of 1938, as amended.

         1.15 "FIELD" means the treatment or prevention of any disease or
condition in humans or animals.

         1.16 "FIRST COMMERCIAL SALE" means, with respect to a Licensed Product,
the first sale (or other transfer for value in an arms-length transaction) for
end use of such Licensed Product in a country within the Territory after
obtaining all necessary Regulatory Approvals for the marketing and sale of the
Licensed Product in such country.

         1.17 "FTE" means the equivalent of a full time (12) months (including
normal vacations, sick days and holidays) work of an individual scientist,
carried out by one or more employees or agents of NeoGenesis, who devotes a
portion of his or her time to performing the Screening Program.

         1.18 "GOOD CLINICAL PRACTICE" means the then current standards for
clinical trials for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good clinical practice as are required by the European Union and
other Regulatory Authorities in countries in which the Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Clinical Practices.

         1.19 "GOOD LABORATORY PRACTICE" means the then current standards for
laboratory activities for pharmaceuticals, as set forth in the FD&C Act and
applicable regulations promulgated thereunder, as amended from time to time, and
such standards of good laboratory practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Laboratory Practices.

         1.20 "GOOD MANUFACTURING PRACTICE" means the current standards for the
manufacture of pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good manufacturing practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Manufacturing Practices.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

         1.21 "IMPROVED ACTIVE COMPOUND" means any Compound identified as a
result of initial optimization of one or more Active Compounds by NeoGenesis (as
described in paragraph 4 of ATTACHMENT A) and having binding activity when
tested against a Target pursuant to the Screening Program with a Kd value of
[*].

         1.22 "IND" means an investigational new drug application, as defined in
the FD&C Act and applicable regulations thereunder, or any equivalent document,
filed with the FDA and necessary for beginning clinical trials of any Licensed
Product in humans or any application or other documentation filed with any
Regulatory Authority of a country other than the United States prior to
beginning clinical trials of any Licensed Product in humans in that country.

         1.23 "INTERNATIONAL AGREEMENT" means the contemporaneous Agreement
entered into by NeoGenesis and Schering's Affiliate,Schering-Plough Ltd.
relating to countries and territories outside of the Territory.

         1.24 "INVENTIONS" means any and all discoveries, developments,
inventions and innovations (whether or not patentable) that are conceived and/or
reduced to practice (i) solely by one or more employees or consultants of
NeoGenesis in connection with the performance of the Screening Program; (ii)
solely by one or more employees or consultants of Schering in connection with
the performance of the Screening Program; or (iii) jointly by one or more
employees or consultants of NeoGenesis and one or more employees or consultants
of Schering in connection with the performance of the Screening Program.

         1.25 "LEAD COMPOUNDS" means those Selected Compounds which are
designated by Schering as Lead Compounds (pursuant to Section 2.2(b) of the
Agreement) for the performance of medicinal chemistry optimization by
NeoGenesis.

         1.26 "LICENSED PRODUCT(S)" means any pharmaceutical product which
contains as an active ingredient a Selected Compound or Derivative Compound, and
which is covered by one or more claims of a NeoGenesis Patent Right and/or
Compound Patent Right.

         1.27 "MAJOR MARKET COUNTRY" means the United States, Japan, or any
three or more of the following European countries, the United Kingdom, France,
Germany, Italy or Spain, as the case may be.

         1.28 "NDA" means a new drug application or product license application,
each as defined in the FD&C Act and applicable regulations thereunder, seeking
approval to market and sell a Licensed Product in the United States.

         1.29 "NEOGENESIS KNOW-HOW" means all proprietary information, data and
know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products together with, where applicable, any analogs, derivatives or
fragments thereof, which is (i) owned

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

or controlled by NeoGenesis as of the Effective Date, or (ii) developed by or on
behalf of NeoGenesis during the term of this Agreement.

         1.30 "NEOGENESIS PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by NeoGenesis
(and/or any of its Affiliates), or to which NeoGenesis (and/or any of its
Affiliates) through license or otherwise acquires rights, and which have claims
covering: (i) the NeoMorph Screening Library, the NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS or QSCD; or (ii) any Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products, or the manufacture or use of any of the foregoing; or (iii)
NeoGenesis Inventions (as defined in Section 3.5(a)); or (iv) NeoGenesis' rights
in Joint Inventions (as defined in Section 3.5(b)), as well as all divisionals,
continuations, continuations-in-part, reissues, re-examinations, extensions,
renewals, registrations, supplementary protection certificates and/or foreign
counterparts of any of the foregoing which are owned or controlled by NeoGenesis
and its Affiliates during the term of this Agreement. The NeoGenesis Patent
Rights shall include those listed in ATTACHMENT B pursuant to Section 3.8.

         1.31 "NEOMORPH CHEMISTRY" means the process, proprietary to NeoGenesis,
of forming libraries and sub-libraries of discrete compounds by coupling a broad
set of diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

         1.32 "NEOMORPH FOCUSED LIBRARIES" means any and all compounds or
collections of compounds synthesized by NeoGenesis which are derived from or
based upon Lead Compounds, and which are designed to optimize the structure of
such Lead Compounds with respect to activity against one or more specific
Targets.

         1.33 "NEOMORPH SCREENING LIBRARY" means the entire collection of
libraries consisting of mass-encoded small molecule organic compounds owned by
NeoGenesis and developed with NeoMorph Chemistry, comprising at least twelve
million (12,000,000) different compounds.

         1.34 "NET SALES" means the proceeds actually received by Schering or
any of its Affiliates or sub-licensees on all sales of a Product in the
Territory to an unaffiliated third party (whether an end-user, a distributor or
otherwise), and exclusive of intercompany transfers or sales, less the
reasonable and customary deductions from such gross amounts including: (i)
normal and customary trade, cash and quantity discounts, allowances and credits;
(ii) credits or allowances actually granted for damaged goods, returns or
rejections of a Product and retroactive price reductions; (iii) sales or similar
taxes (including duties, value added taxes or other governmental charges
otherwise measured by the billing amount, when included in billing); (iv)
freight, postage, shipping, customs duties and insurance charges; (v) charge
back payments and rebates granted to managed health care organizations or to
federal, state and local governments, their agencies, and purchasers and
reimbursers or to trade customers, including but not limited to, wholesalers and
chain and pharmacy buying groups; (vi) commissions paid to third parties other
than sales personnel and sale representatives or sales agents; and (vii) rebates
(or equivalents thereof) granted to or charged by national, state or local
governmental authorities in countries

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

other than the United States. If a Product is sold in the form of a combination
product with one or more other active ingredients, Net Sales for such
combination product with one or more active ingredients will be calculated by
multiplying actual Net Sales of such combination product by the fraction A/(A+B)
where:
         "A" is the invoice price of the Product contained in the combination
         product if sold separately by Schering or any of its Affiliates or
         sub-licensee; and
         "B" is the aggregate invoice price of any other active component(s) in
         the combination product if sold separately by Schering or any of its
         Affiliates or sub-licensee.
If one or more of the other active ingredients in the combination product are
not sold separately, then the above formula shall be modified such that:
         "A" shall be the fully allocated manufacturing cost to Schering or any
         of its Affiliates or sub-licensee of the Product, and
         "B" shall be the fully allocated manufacturing cost to Schering or any
         of its Affiliates or sub-licensee of any other active component(s) in
         the combination, such fully allocated manufacturing costs being
         determined in accordance with generally accepted accounting principles.

         1.35 "PERSON" means any individual, corporation, association,
partnership (general or limited), joint venture, trust, estate, limited
liability company, limited liability partnership, unincorporated organization,
government (or any agency or political subdivision thereof) or other legal
entity or organization.

         1.36 "PRELIMINARY COMPOUND" means any Compound identified as having
binding activity when tested against a Target pursuant to the Screening Program
and which has Kd values of [*] or such other binding affinity threshold for a
specific Target as shall be agreed upon by the parties in writing.

         1.37 "QSCD" means Quantisized Surface Complimentary Diversity, a model
proprietary to NeoGenesis, in terms of which discrete chemical compliments to
the surfaces of a Target are defined.

         1.38 "REGULATORY APPROVAL" means, for any country in the Territory,
those authorizations by the appropriate Regulatory Authority(ies) required for
the manufacture, importation, distribution, marketing, promotion, pricing and
sale of the Licensed Product(s) in such country, including, without limitation,
any NDAs, Health Registration Dossiers, supplements, amendments, pre- and
post-approvals, marketing authorizations based upon such approvals (including
any prerequisite manufacturing approvals or authorizations related thereto) and
pricing, third party reimbursement or labeling approval(s), technical, medical
and scientific licenses, registrations or authorizations.

         1.39 "REGULATORY AUTHORITY" means any national, supra-national,
regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity in the Territory, including, without
limitation, the FDA and the EMEA.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

         1.40 "SCHERING KNOW-HOW" means all information, data and know-how which
is owned or controlled by Schering or its Affiliates as of the Effective Date,
or developed by or on behalf of Schering or its Affiliates during the term of
this Agreement, related to the Screening Program, the Targets, Active Compounds,
Improved Active Compounds, Selected Compounds, Derivative Compounds, Designated
Compounds or Licensed Products. Schering Know-How includes, without limitation,
all processes, formulas, discoveries and inventions whether relating to
biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical safety, quality control and clinical data, including, without
limitation, clinical study data related to Designated Compounds and/or Licensed
Products. Schering Know-How also includes relevant medical information relating
to the Licensed Products (such as Regulatory Authority questions, responses
thereto and adverse drug event history) in the possession of Schering, its
Affiliates or sublicensees.

         1.41 "SCHERING PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by Schering (and/or
any of its Affiliates), or to which Schering (and/or any of its Affiliates)
through license or otherwise acquires rights, which have claims covering: (i)
Selected Compounds, Derivative Compounds, Designated Compounds or Licensed
Products, or the manufacture or use of any of the foregoing; (ii) the Targets;
or (iii) Schering Inventions (as defined in Section 3.5(a)) or Joint Inventions
(as defined in Section 3.5(b)), as well as all divisionals, continuations,
continuations-in-part, reissues, re-examinations, extensions, renewals,
registrations, supplementary protection certificates and/or foreign counterparts
of any of the foregoing which are owned or controlled by Schering and its
Affiliates during the term of this Agreement.

         1.42 "SELECTED COMPOUND" means any and all Active Compounds and/or
Improved Active Compounds which have demonstrated bioactivity in secondary
functional assays against the applicable Target as determined by Schering in
accordance with Section 2.7, and which are designated by Schering pursuant to
Section 2.7(a) of the Agreement.

         1.43 "SCREENING PROGRAM" means the screening program described in
ATTACHMENT A (including as it may be amended by the Steering Committee) to
identify Active Compounds and Improved Active Compounds against one or more
Targets.

         1.44 "STEERING COMMITTEE" means the joint steering committee
established by the parties pursuant to Section 2.6 of the Agreement.

         1.45 "SUCCESS CRITERIA" means the success criteria, to be defined by
the Steering Committee with respect to a given Target, for determining whether
or not Selected Compounds and/or Derivative Compounds have a certain desired
degree of chemical binding activity, activity in Target-based functional assays,
and other chemical, biological, pharmacological and toxicological properties,
suitable for drug development.

         1.46 "TARGET" means a specific biological target (including, without
limitation, nucleic acids and proteins, and/or active fragments thereof) that a
small molecule is screened against in

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

order to determine whether the small molecule demonstrates a specific
biochemical or pharmaceutical effect, selected by Schering and accepted by
NeoGenesis in accordance with Section 2.1(b) for which NeoGenesis will perform
the Screening Program.

         1.47 "TERRITORY" means the United States and all of its territories,
possessions and commonwealths, except for the Commonwealth of Puerto Rico.

         1.48 "VALID CLAIM" means a composition-of-matter or method-of-use claim
of an issued and unexpired patent included within (i) the NeoGenesis Patent
Rights or (ii) Compound Patent Rights, and in each case which has not been
revoked or held unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been disclaimed, denied or
admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise.

2.       SCREENING PROGRAM

         2.1      DELIVERY OF TARGETS.

                  (a)  Schering shall deliver one or more of the Targets listed
in ATTACHMENT A to NeoGenesis for screening within [*] following the Effective
Date. Schering shall provide the Targets in the quantities and formats specified
in ATTACHMENT A, along with a written description of the concentration and
volume of the Target.

                  (b)  From time to time during the term of this Agreement,
Schering may select additional Targets for screening under the Screening
Program. In such event, Schering shall notify NeoGenesis in writing of the
additional Target(s) to be provided for screening. NeoGenesis shall notify
Schering in writing within [*] of such notice whether the Target is approved for
inclusion in the Screening Program. Subject to the terms of Section 2.1(c), the
Target will be accepted for inclusion in the Screening Program unless the
proposed Target: (i) is subject to an exclusivity period in an existing
agreement between NeoGenesis and a third party; or (ii) is the subject of an
existing internal research program at NeoGenesis. The parties shall promptly
amend ATTACHMENT A to include each additional Target added to the Screening
Program pursuant to this Section 2.1(b). Schering shall thereafter provide the
Targets to NeoGenesis in appropriate quantities and formats for screening, along
with a written description of the concentration and volume of the Target. The
Steering Committee shall establish a schedule for delivery of the additional
Targets to NeoGenesis based on the time necessary to prepare and validate the
approved Target; PROVIDED, that such period shall not exceed nine (9) months
from NeoGenesis' notice to Schering that a Target is approved.

                  (c)  The parties acknowledge and agree that the Screening
Program will be limited to active screening and/or optimization programs at
NeoGenesis directed to [*] distinct Targets, based upon research support for [*]
FTEs at NeoGenesis. In the event that the screening and optimization programs
directed to a specific Target are completed or discontinued, Schering shall have
the right to select an additional Target to replace such discontinued Target.
Further, in

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

the event that the number of FTEs working on the Screening Program is increased,
pursuant to Section 2.2(f), the limit on the number of active Targets shall be
increased proportionately.

                  (d)  All Targets to be supplied by Schering hereunder shall be
delivered CIP to NeoGenesis' Cambridge facility using a carrier selected by
Schering. The Targets are and shall remain the sole and exclusive property of
Schering. NeoGenesis will only use the Targets for screening in performance of
the Screening Program and will not use the Targets for any other purpose without
Schering's prior written consent.

                  (e)  Schering will identify to NeoGenesis all Targets provided
by Schering for use in the Screening Program. The identity of the Targets and
any other information related thereto will be considered Schering Confidential
Information. During the applicable Exclusivity Period (as defined below) for a
Target, NeoGenesis shall not screen the NeoMorph Screening Library for itself or
for any third party against the same Target, without Schering's prior written
approval. The "Exclusivity Period" for a given Target shall begin on the date
the Target is accepted for inclusion in the Screening Program pursuant to
Section 2.1(b) and shall expire:

                  (i)  if NeoGenesis does not perform any medicinal
                       chemistry optimization activities pursuant to Section
                       2.2(b) to develop NeoMorph Focused Libraries with
                       respect to the Target, [*] after NeoGenesis delivers
                       to Schering the Final Target Report with respect to
                       such Target; or

                  (ii) if NeoGenesis does perform medicinal chemistry
                       optimization activities pursuant to Section 2.2(b) to
                       develop NeoMorph Focused Libraries with respect to
                       such Target, [*] after the later of the date upon
                       which Schering files an IND for a Licensed Product
                       directed to the Target or discontinues the
                       development of Licensed Products against such Target.

Upon the expiration of the Screening Program, and annually thereafter,
Schering shall notify NeoGenesis in writing of the list of Targets with
respect to which Schering has ongoing programs to discover and develop
Licensed Products. Schering shall promptly notify NeoGenesis in writing in
the event that it discontinues the development of Licensed Products against a
Target. For purposes of this Section 2.1(e), Schering shall be deemed to have
discontinued development of Licensed Products against a Target if it ceases
to maintain a minimum of [*] FTEs assigned full time to work on the discovery
and pre-clinical development of Licensed Products against a Target. During
the term of the Screening Program, if NeoGenesis intends to screen the
NeoMorph Screening Libraries (including all newly created Compounds contained
therein) for a third party against a Target with respect to which Schering's
Exclusivity Period has expired pursuant to subsection (i), above, NeoGenesis
shall first offer Schering the opportunity to screen the NeoMorph Screening
Libraries against the Target. Schering shall have [*] in which to accept or
reject such offer. If Schering accepts the offer, such screening shall be
conducted under the terms of this Agreement and Schering shall have a renewed
Exclusivity Period with respect to such Target. If NeoGenesis does perform
medicinal chemistry optimization activities pursuant to Section 2.2(b) to
develop NeoMorph Focused Libraries with respect to a Target, then
notwithstanding the expiration of the applicable Exclusivity Period pursuant
subsection (ii), above, NeoGenesis shall be permanently prohibited from
screening the NeoMorph Screening Libraries against the Target for itself and
in such instance may only perform such screening for third parties. In the
event that NeoGenesis does screen the NeoMorph Screening

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

Libraries against a Target for itself or a third party as permitted under this
Section 2.1(e), NeoGenesis shall not use (i) any Schering Know-How (including
without limitation any of Schering's proprietary information related to the
existence of or uses for the Target), or (ii) any NeoGenesis Know-How related to
the Target and developed in performance of the Screening Program, in connection
with such screening activities.

                  (f)  For purposes of this Agreement, and in particular with
respect to the provisions of Sections 2.1(b) and 2.1(e), a Target identified by
Schering for screening under this Agreement will encompass the nucleic acid or
amino acid sequence of the actual Target to be provided by Schering, and in the
case of a Target which is a human biological molecule, shall be further defined
by the nucleic acid or protein encoded by the specified genomic location of
origin (which will be identified by Schering in the notification to NeoGenesis
of a proposed Target pursuant to Section 2.1(b)) and natural polymorphic
variants thereof such as SNP, insertion, deletion and splice variants or the
synthetic equivalent thereof. If a Target can not be distinguished from another
biological target based on the above, then the Target shall be considered the
same as another biological target if the other biological target comprises a
contiguous region of [*] residues that is [*] to the Target or is derived from
such Target by modification. If a Target is a biological molecule of non-human
origin, then the Target shall be considered the same as another target if they
are both derived from the comparable chromosomal location of related strains of
the applicable species. For example, a target defined by the [*] shall be
considered the same as a target specified by the [*] gene from any other strain
of HCV including targets derived by modification. Similarly, a target specified
by a chromosomal location in one particular strain of [*] shall be considered
identical to a target specified by the analogous location in a second strain of
bacteria. If the chromosomal locations of two targets can not be defined, then a
target shall be considered the same as a second target if it comprises a
contiguous region of [*] residues that is [*] to said second target or is
derived from such a second Target by modification. It is expressly understood
that a non-human target falling outside the criteria defined above may not be
screened using the NeoMorph Screening Libraries with the intent of developing a
product affecting the activity of a human target that would meet the identity
criteria. For clarity, a primate ortholog of a human gene or protein may not be
screened using the Neomorph Screening Libraries if the intent is to develop a
product for human use against an otherwise excluded target. Nothing in this
paragraph shall limit the screening of non-human targets for non-human usage.

         2.2      SCREENING PROGRAM.

         (a)      During the term of the Screening Program, NeoGenesis will
utilize its proprietary technology and methods, including without limitation
the ALIS method, to screen the NeoMorph Screening Library for activity with
respect to each Target for purposes of identifying Active Compounds for
further evaluation and development. Screening will be performed pursuant to
the protocol for the Screening Program, as set forth in paragraphs 1-2 of
ATTACHMENT A. With respect to each accepted Target provided by Schering under
Section 2.1, NeoGenesis shall complete the screening of the NeoMorph
Screening Library within [*] following the date that the Target is delivered
to NeoGenesis. The results of such screening shall be provided to Schering
through the Steering Committee in the form of a Preliminary Target Report (as
defined in

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     10
<Page>

ATTACHMENT A). NeoGenesis shall provide Schering with samples of all Preliminary
Compounds selected by the Steering Committee for further evaluation by Schering
pursuant to paragraph 3 of ATTACHMENT A. Schering will evaluate such Preliminary
Compounds in Target-based functional assays and/or secondary assays to identify
Active Compounds, and will report the results of such evaluations to the
Steering Committee, and NeoGenesis will promptly thereafter provide Schering
with all available structural information for each Active Compound so
identified. NeoGenesis will, at the direction of the Steering Committee, conduct
initial optimization activities, as described in paragraph 4, of ATTACHMENT A,
to identify Improved Active Compounds. It is acknowledged that all compounds
generated from such initial optimization activities and having activity against
the relevant Target shall be deemed to be Improved Active Compounds; provided
that such optimization activities and all Improved Active Compounds arising
therefrom shall not be deemed to be optimization of Lead Compounds for purposes
of Section 2.1(e) or for determining Schering's financial obligations under
Sections 4.3 and 4.4.

         (b)      NeoGenesis will, at the direction of the Steering Committee,
conduct a full program of medicinal chemistry optimization activities, based
upon those Selected Compounds identified as Lead Compounds that are suitable
for optimization. Such optimization activities shall include the design and
preparation of NeoMorph Focused Libraries based upon such Lead Compounds, and
the screening of the NeoMorph Focused Libraries against the relevant
Target(s). The parties acknowledge and agree that, subject to the terms of
Sections 3.5(a), and effective on the date that Schering acquires an
exclusive license to the relevant Selected Compound(s) pursuant to Sections
2.7(c), 3.1 and 3.2, any and all Compounds which are included in NeoMorph
Focused Libraries prepared against the relevant Target shall be the exclusive
property of Schering. NeoGenesis shall not use the NeoMorph Focused
Libraries, any Compounds contained therein, or any structural information or
other know-how related thereto, for any purpose other than the performance of
the Screening Program. NeoGenesis shall not provide any NeoMorph Focused
Libraries, any Compounds contained therein, or any structural information or
other NeoGenesis Know-How related thereto, to any third party without the
prior written consent of Schering. Notwithstanding the foregoing limitations,
it is expressly understood and agreed that NeoGenesis may, through use of the
NeoMorph Screening Library on behalf of third parties independently generate
results or data similar to the results or data generated in the course of the
Screening Program and that the use of such independently generated results or
data shall not constitute a breach of NeoGenesis' obligations under this
Section 2.2(b); PROVIDED, that NeoGenesis has complied with its obligations
to mask Compounds in accordance with Section 2.3 of this Agreement.

         (c)      NeoGenesis shall not perform any tests on or using any of the
Targets that are outside the scope of the Screening Program, or attempt to
modify the Targets supplied by Schering, including, without limitation, the
making of any derivatives, analogs or components thereof. In the event that
NeoGenesis does not consume all of the Targets supplied by Schering in
performance of the Screening Program, NeoGenesis will upon completion of the
Screening Program promptly, return to Schering any quantities of such
Target(s) and any derivatives, analogs or components thereof.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     11
<Page>

         (d)      The term of the Screening Program shall begin on the Effective
Date and shall continue in effect for a period of two (2) years. Schering
shall have the right to extend the term of the Screening Program for up to
three additional one (1) year terms, by providing NeoGenesis with written
notice to that effect at least sixty (60) days prior to the expiration of the
then current term of the Screening Program and subject to the provisions of
Section 4.1 concerning research funding for such extension term. The
Screening Program shall remain in effect for the period specified in this
Section 2.2(d), including as it may be extended, unless sooner terminated in
accordance with Section 8.2 or Section 9.5.

         (e)      During the term of the Screening Program, upon request,
NeoGenesis shall provide Schering with samples of Selected Compounds and
Derivative Compounds from NeoMorph Focused Libraries in a form and quantity
suitable to enable Schering to conduct additional testing to confirm the
specific binding activity of such Compounds and to evaluate and determine the
functional activity of the Selected Compounds and/or Derivative Compounds.
Schering may also elect to perform medicinal chemistry research using such
Selected Compounds and/or Derivative Compounds to discover and evaluate
additional Derivative Compounds. Schering shall keep NeoGenesis reasonably
informed of the results of such activities through the Steering Committee.

         (f)      During the term of the Screening Program NeoGenesis shall
provide appropriately trained dedicated scientific personnel to perform the
Screening Program in accordance with the terms of this Agreement. During the
initial two (2) year term of the Screening Program, NeoGenesis shall provide
such support at the level of [*] FTEs during each year of the Screening
Program, it being understood that NeoGenesis may allocate such FTE time
within any calendar year in a manner consistent with its obligations under
the Screening Program based on the workload for such Screening Program at any
particular time during the Screening Program. In addition, NeoGenesis will,
upon written request by Schering, provide additional FTE support for the
Screening Program of up to an additional [*] FTEs during the term of the
Screening Program. In the event that the term of the Screening Program is
extended pursuant to Section 2.2(d), the Steering Committee shall establish
the number of FTEs to be provided by NeoGenesis for performance of the
Screening Program during the extended term.

         (g)      NeoGenesis shall monitor expenditures, in accordance with
its corporate policies, to ensure that the funds provided by Schering are
spent in accordance with this Agreement. NeoGenesis shall keep and maintain
adequate books and records to furnish information to Schering regarding
calculation of the amounts expended by NeoGenesis on the Screening Program
according to the provisions of this Agreement. During the Screening Program
and for two (2) years following the expiration of the Screening Program,
NeoGenesis shall permit Schering to examine such books and records during
normal business hours, upon thirty (30) days notice to NeoGenesis. Upon the
expiration of the two (2) year period, the calculation of the amounts
expended on each year of the Screening Program shall be binding and
conclusive upon the parties and NeoGenesis shall be released from any further
accountability with respect to the Screening Program.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     12
<Page>

         (h)      NeoGenesis will perform its screening obligations in
accordance with all applicable laws, rules and regulations.

         2.3      COMPOUND MASKING.

                  (a)  Upon the identification of Preliminary Compounds and
Active Compounds through screening of the NeoMorph Screening Library against a
particular Target, NeoGenesis shall mask such Preliminary Compounds and Active
Compounds from the NeoMorph Screening Library by removing such Compounds from
the compound resource information associated with the NeoMorph Screening Library
and shall take all other steps reasonably necessary to ensure that information
with regard to such Compounds is not available or accessible to any third party,
including third parties for which NeoGenesis is screening the NeoMorph Screening
Library against other biological targets. NeoGenesis shall similarly mask any
Improved Active Compounds which are discovered pursuant to Section 2.2(a).

                  (b)  NeoGenesis shall have the right to unmask any Preliminary
Compounds which are not confirmed as Active Compounds and are not in the same
Chemotype as such Active Compounds. In addition, upon expiration of Schering's
right to designate Selected Compounds with regard to a specific Target, pursuant
to Section 2.7(a), NeoGenesis shall have the right to unmask any Active
Compounds and/or Improved Active Compounds identified through screening against
that Target which are not (i) Selected Compounds or (ii) Preliminary Compounds,
Active Compounds and/or Improved Active Compounds of the same Chemotype as such
Selected Compounds.

         2.4      GRANT OF RESEARCH LICENSES.

                  (a)  Schering hereby grants NeoGenesis a nonexclusive,
nontransferable, royalty-free license under the Schering Patent Rights and to
use the Schering Know-How solely for the purpose of conducting the Screening
Program. NeoGenesis will not use Schering Know-How or Schering Patent Rights for
any other purpose, and shall not offer or grant a sub-license to use Schering
Know-How or Schering Patent Rights to any third party, without the express prior
written consent of Schering.

                  (b)  NeoGenesis hereby grants Schering a nonexclusive,
nontransferable, royalty-free license under the NeoGenesis Patent Rights and to
use the NeoGenesis Know-How solely for the purpose of conducting Schering's
activities under the Screening Program. Schering will not use NeoGenesis
Know-How or NeoGenesis Patent Rights for any other purpose, and shall not offer
or grant a sub-license to use NeoGenesis Know-How or NeoGenesis Patent Rights to
any third party, without the express prior written consent of NeoGenesis (not to
be unreasonably withheld).

                  (c)  With respect to Selected Compounds identified pursuant to
Section 2.7(a), NeoGenesis hereby grants Schering, during the relevant Option
Period (as defined in Section 2.7(b)), an exclusive, nontransferable,
royalty-free license under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How solely for the purpose of performing research and

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     13
<Page>

development work necessary to enable Schering to determine whether or not to
exercise its option to obtain an exclusive license with respect to such Selected
Compounds.

         2.5      RECORD KEEPING AND REPORTS.

                  (a)  NeoGenesis will keep and maintain complete and accurate
records of all laboratory data and results generated in the course of the
Screening Program, including records of all Preliminary Compounds, Active
Compounds, and Improved Active Compounds identified, and any Inventions
discovered and/or developed by NeoGenesis, during the Screening Program. All
such written records of NeoGenesis shall be open to inspection by Schering
during normal business hours upon reasonable prior written notice; provided,
however, that except with respect to (i) Improved Active Compounds, (ii) Active
Compounds, and (iii) Preliminary Compounds of the same Chemotype as such
Improved Active Compounds or Active Compounds, NeoGenesis shall not provide
Schering with access to any chemical structures or structural data.

                  (b)  NeoGenesis shall provide Schering with
reasonably-detailed written reports describing the results of the research
performed pursuant to the Screening Program including all Preliminary
Compounds, Active Compounds and Improved Active Compounds identified in the
Screening Program but shall not include any chemical structures or structural
data with respect to any Compounds which are not (i) Improved Active Compounds,
(ii) Active Compounds, and (iii) Preliminary Compounds of the same Chemotype as
such Improved Active Compounds or Active Compounds. Such reports shall be
delivered to Schering at least quarterly during the term of the Screening
Program. In addition, with respect to each Target, promptly following the
completion of screening of the entire NeoMorph Screening Library against such
Target, NeoGenesis will deliver to Schering a Preliminary Target Report (as
defined in ATTACHMENT A) with respect to any and all Preliminary Compounds
identified during the Screening Program as having activity with respect to such
Target. Each Preliminary Target Report shall include the binding affinities for
all such Preliminary Compounds, as well as any information generated by
NeoGenesis with regard to Target specificities and functional activities of
such Preliminary Compounds. NeoGenesis shall also provide Schering with a Final
Target Report (as defined in ATTACHMENT A) in accordance with the provisions of
Paragraph 4 of ATTACHMENT A. NeoGenesis shall also provide Schering with
reports at least one (1) week prior to each Steering Committee Meeting
detailing the results of any Lead Compound optimization activities performed by
NeoGenesis pursuant to Section 2.2(b) and ATTACHMENT A, which reports shall
include the chemical structures and binding affinities of all Derivative
Compounds contained in NeoMorph Focused Libraries prepared by NeoGenesis based
upon such Lead Compound(s) and other information generated by NeoGenesis with
respect thereto.

         2.6      STEERING COMMITTEE.

                  (a)  Promptly after the Effective Date, the parties shall
establish a joint committee (the "STEERING COMMITTEE") having oversight
responsibility for the day-to-day management and performance of the Screening
Program. The Steering Committee shall consist of six (6) members, three (3)
members to be appointed by each of NeoGenesis and Schering. Each party shall
notify the other party of the names and contact information for its members of
the Steering Committee, and thereafter may with notice to the other substitute
any of its members

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     14
<Page>

serving on the Steering Committee. Each member of the Steering Committee will
have one vote and all decisions of the Steering Committee will be [*]. The
quorum for Steering Committee meetings shall be two, provided there is at least
one member from each of NeoGenesis and Schering present. The Steering Committee
will render decisions by [*].

                  (b)  The Steering Committee shall be responsible for the
management and conduct of the Screening Program and shall in particular: (i)
consider, review and amend the Screening Program from time to time in such
manner as may be appropriate; (ii) monitor progress of the Screening Program;
(iii) report regularly to the management of both parties upon the progress of
the Screening Program; and (iv) be the initial medium for transfer of
information between the parties. Schering shall keep the Steering Committee
reasonably informed of the status of Schering's activties with respect to the
discovery and development of Licensed Products against each Target.

                  (c)  During the term of the Screening Program, the Steering
Committee shall hold meetings as mutually agreed by the parties (but in no event
less quarterly) to review the Screening Program. The first meeting of the
Steering Committee shall be held within forty-five (45) days of the Effective
Date and shall be held in Cambridge, MA. Thereafter, meetings may be held by
telephone or video conference if requested by either party in writing to the
other, PROVIDED THAT the parties shall meet in person at least four (4) times
per year during the term of the Screening Program. Minutes of all meetings
setting forth decisions of the Steering Committee relative to the Screening
Program shall be prepared by the host party and circulated to both parties
within fifteen (15) days after each meeting, but minutes shall not become
official until approved and countersigned by both parties (which approval the
parties shall use reasonable efforts to give within thirty (30) days of receipt
of such minutes).

                  (d)  In the event that the Steering Committee is unable to
reach agreement, the issue in dispute shall be referred to an "OVERSIGHT
COMMITTEE" consisting of the Executive Vice President, Discovery Research of the
Schering-Plough Research Institute (an Affiliate of Schering) and NeoGenesis'
Chief Executive Officer, or their respective designees, for resolution. If the
disagreement is not resolved by the Oversight Committee within thirty (30) days,
then Schering shall have the right to make the final decision on such matter;
PROVIDED, that in the event and to the extent that any dispute concerns whether
or not budgeted FTE funding for the Screening Program has been expended in
accordance with the provisions of this Agreement such matter shall be resolved
using the procedure specified in Section 9.1.

         2.7      SELECTED COMPOUNDS.

                  (a)  From time to time during the term of this Agreement,
Schering may designate, by written notice to NeoGenesis, one or more Active
Compounds and/or Improved Active Compounds identified by screening of the
NeoMorph Screening Libraries pursuant to Section 2.2 as Selected Compounds;
provided, that at any given time Schering may not designate Active Compounds and
Improved Active Compounds representing more than [*] different Chemotypes
against a given Target from the NeoMorph Screening Library. The parties
acknowledge and agree that the foregoing limitation does not apply to the
NeoMorph Focused

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

Libraries. [*] Selected Compounds that Schering may designate from the
NeoMorph Focused Libraries. With respect to each Target, Schering shall use
diligent efforts to identify and designate at least one Selected Compound
within [*] following Schering's receipt of the Final Target Report for all
screening against such Target in accordance with Section 2.5(b) and
ATTACHMENT A. In the event that the Schering does not designate any Selected
Compounds with respect to such Target, then upon expiration of the applicable
[*] period, Schering's right to designate Selected Compounds with respect to
such Target shall expire. If the NeoMorph Screening Library is subsequently
re-screened against a given Target pursuant to Section 2.1(e) and new Active
Compounds and/or Improved Active Compounds are identified as a result of such
re-screening, then to the extent Schering's right to designate Selected
Compounds against such Target has previously expired, Schering shall have a
renewed right to designate Selected Compounds arising from such re-screening
on the same terms as set forth above.

                  (b)  Effective upon the date of receipt by NeoGenesis of
notice from Schering, pursuant to Section 2.7(a) that one or more Active
Compounds and/or Improved Active Compounds have been designated as Selected
Compounds, NeoGenesis grants to Schering an exclusive option to obtain the
exclusive license provided for in Article 3 with respect to such Selected
Compounds and related Derivative Compounds (including without limitation any
Compounds contained in a NeoMorph Focused Library prepared based upon such
Selected Compound). The masking of the Selected Compound(s) (and any
Preliminary Compounds, Active Compounds and Improved Active Compounds of the
same Chemotype(s) as such Selected Compound(s)) from the NeoMorph Screening
Library in accordance with Section 2.3 shall be maintained during the
applicable Option Period (as defined below). In addition, within [*]
following receipt of notification from Schering identifying Selected
Compounds, NeoGenesis shall amend ATTACHMENT B to identify any applicable
NeoGenesis Patent Rights not previously identified to Schering. The "OPTION
PERIOD" with respect to each Selected Compound identified pursuant to Section
2.7(a), shall extend until the later of: (i) the [*] anniversary of the
expiration of the Screening Program for the applicable Target, or (ii) in the
event that Schering is conducting an active internal medicinal chemistry
research program to identify Derivative Compounds based upon such Selected
Compound (as documented with written notice to NeoGenesis), a period of [*]
following the termination of such medicinal chemistry program. For purposes
of this Section 2.7(b), Schering shall be deemed to be conducting an active
medicinal chemistry program if at least [*] working full time on the design
and discovery of Derivative Compounds with respect to a given Selected
Compound. Schering shall provide NeoGenesis with written certification, [*]
every [*], during the performance of such medicinal chemistry program for
purposes of monitoring the expiration of the Option Period.

                  (c) Schering shall have the right to exercise the option
granted to it under Section 2.7(b) with respect to one or more Selected
Compounds (and related Derivative Compounds, including without limitation any
Compounds contained in a NeoMorph Focused Library prepared based upon such
Selected Compound) at any time prior to the expiration of the applicable
Option Period, by providing written notice to NeoGenesis to that effect. The
exclusive licenses granted to Schering pursuant to Article 3 with respect to
such Selected Compounds (and related Derivative Compounds, including without
limitation any Compounds contained in a NeoMorph

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      16
<Page>

Focused Library prepared based upon such Selected Compound) shall become
effective upon NeoGenesis' receipt of such notice, and Schering shall pay the
applicable license fee under Section 4.2 to NeoGenesis within five (5) business
days of such notice. As of such date of such notice, the masking of the
applicable Selected Compound(s) (and related Derivative Compounds, including
without limitation any Compounds contained in a NeoMorph Focused Library
prepared based upon such Selected Compound), as well as any Preliminary
Compounds, Active Compounds and Improved Active Compounds of the same Chemotype
as such Selected Compound, from the NeoMorph Screening Library in accordance
with Section 2.3 shall become permanent, and during the term of this Agreement
NeoGenesis shall continue take such other steps as are reasonably necessary to
ensure that information with regard to the Selected Compounds and the relevant
Active Compounds, Improved Active Compounds and Preliminary Compounds of the
same Chemotype as such Selected Compounds are no longer available or accessible
to any third party.

                  (d)  In the event that Schering fails to exercise its option
rights with respect to one or more Selected Compounds prior to the expiration of
the applicable Option Period, then upon expiration of the Option Period
Schering's option right shall expire with respect to the applicable Selected
Compound(s), the licenses provided for in Article 3 with respect to such
Selected Compound(s) shall be void and of no further force or effect, and
NeoGenesis shall be free to unmask such Selected Compound(s) in the NeoMorph
Screening Library.

                  (e)  In the event that during the applicable Option Period,
one or more Selected Compounds with respect to a given Target become
Designated Compounds and Schering has not, as of the effective date of such
designation, exercised the option and paid the license fee due under section
4.2 with respect to Selected Compounds against such Target, then the license
fee shall be paid concurrently with the milestone payment due upon
designation of such Designated Compounds in accordance with Section 2.8.

                  (f)  Schering shall not begin screening any Selected Compound
or related Derivative Compounds against any biological targets other than
Targets until such time as it has exercised its option in accordance with
Section 2.7(c) and paid the applicable licensee fee.

         2.8      PRODUCT DEVELOPMENT.

                  (a)  During the term of this Agreement, Schering shall, at its
expense, conduct a research and development program to evaluate Selected
Compounds and Derivative Compounds as potential candidates for commercial
development as Licensed Products. Such efforts may include the performance of
further medicinal chemical research based upon such Selected Compounds and
Derivative Compounds, as well as biological, pharmacokinetic and toxicology
studies and other preclinical research activities. Schering shall have sole
discretion over the scope of such research and development program, and the
selection of which Selected Compounds and Derivative Compounds will be the focus
of such activities.

                  (b)  Schering shall notify NeoGenesis in writing in the event
that Schering, in its sole discretion (based on Schering's good faith evaluation
of the satisfaction of the applicable

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      17
<Page>

Success Criteria by such Selected Compound or Derivative Compound), decides to
proceed with a development program for any Selected Compounds or Derivative
Compounds as suitable candidates for drug development (thereafter, each a
"DESIGNATED COMPOUND"). A Selected Compound or Derivative Compound will be
deemed to be a Designated Compound upon the earlier of that date on which (i)
Schering (or its Affiliate) formally approves proceeding with full development
of such Compound, or (ii) Schering (or its Affiliate) initiates IN VIVO
toxicology trials necessary, and meeting U.S. FDA (or corresponding European or
Japanese) standards, for obtaining approval for use of such Compound in human
clinical trials, unless Schering sooner designates such Selected Compound or
Derivative Compound as a Designated Compound with notice to NeoGenesis. Upon
Schering's designation of a Designated Compound, Schering shall thereafter, at
its expense, use Commercially Reasonable Efforts to develop and commercialize
Licensed Products incorporating the Designated Compound in the Territory.
Schering shall be solely responsible for determining in which countries in the
Territory to develop and commercialize each Licensed Product, provided that it
shall use Commercially Reasonable Efforts to obtain Regulatory Approval and to
market and sell each Licensed Product in the Major Market Countries.

                  (c)  Subject to Schering's diligence obligations under this
Agreement, the Parties acknowledge and agree that all business decisions
regarding research, development and commercialization of Designated Compounds
and Licensed Products including, without limitation, decisions relating to the
design, development, manufacture, sale, price, distribution, marketing and
promotion of Licensed Products under this Agreement, and the decision of whether
to develop a particular Designated Compound, or to develop and commercialize a
particular Licensed Product, shall be within the sole discretion of Schering.

                  (d)  Schering shall have no quotas or other minimum diligence
obligations with regard to the number of Designated Compounds and/or Licensed
Products to be developed and commercialized hereunder. The parties acknowledge
and agree that so long as Schering is using Commercially Reasonable Efforts to
discover, develop and commercialize [*] Licensed Product in the Territory,
Schering shall be deemed to be in compliance with its diligence obligations
under this Agreement.

         2.9      COMMERCIALIZATION OF LICENSED PRODUCTS. With respect to each
Licensed Product developed and commercialized by Schering, or its designated
Affiliates, under this Agreement, Schering shall be solely responsible, at its
sole expense, for all aspects of the development and commercialization of the
Licensed Product in the Territory, including, without limitation:

         (i)      the manufacture of Designated Compounds and Licensed Products
                  in accordance with the applicable Regulatory Approvals, laws,
                  Good Laboratory Practices and Good Manufacturing Practices;

         (ii)     preparation, filing, obtaining, maintaining and supporting, in
                  its own name or that of its designated Affiliate, with the
                  appropriate regulatory authorities of all regulatory
                  approvals, authorizations, permits and licenses (including,
                  without

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

                  limitation, all Regulatory Approvals) that are
                  necessary to conduct clinical studies of Licensed Products
                  and/or to manufacture, import, distribute, market and sell
                  Licensed Products;

         (iii)    the reporting all adverse events associated with any Licensed
                  Product to the appropriate regulatory authorities in
                  accordance with applicable laws, rules and regulations in the
                  Territory; and

         (iv)     the distribution, marketing, promotion and sale of Licensed
                  Products.

Following the expiration of the Screening Program, Schering shall provide
NeoGenesis with semi-annual reports summarizing the status of Schering's
development and commercialization activities with respect to each Licensed
Product being developed under this Agreement. In addition, Schering shall notify
NeoGenesis in writing upon the filing of each application for Regulatory
Approval of a Licensed Product in the Territory.

         2.10     DILIGENCE EXCEPTIONS. All of Schering's diligence obligations
hereunder with respect to each Licensed Product being developed or
commercialized hereunder are expressly conditioned upon the continuing absence
of any adverse condition or event which warrants a delay in commercialization of
the Licensed Product due to an adverse condition or event relating to the safety
or efficacy of such Licensed Product or unfavorable pricing, pricing
reimbursement, labeling or lack of regulatory approval, and Schering shall have
no obligation to develop or market any such Licensed Product so long as in
Schering's reasonable opinion any such condition or event exists.

         2.11     THIRD PARTY LICENSES. Schering shall be solely responsible for
(a) obtaining any and all licenses from third parties necessary or desirable
to develop or commercialize any Licensed Product and (b) any and all
consideration payable with respect to such licenses. The decision as to
whether or not to obtain any such third party licenses relating to Licensed
Products, and the negotiation and acceptance of the terms and conditions for
any such licenses, shall be within the sole discretion and control of
Schering, and nothing herein shall be construed as obligating Schering to
obtain any such third party licenses.

         2.12     COMPLIANCE WITH LAW. Schering shall be responsible for
ensuring that all activities related to the development and commercialization of
Licensed Products conducted by or on its behalf are performed in compliance with
all applicable laws, rules and regulations (including, but not limited to, those
related to occupational safety and health, public safety and health, protecting
the environment, the disposal of wastes, Good Clinical Practices, Good
Laboratory Practices and Good Manufacturing Practices, as applicable).

3.       LICENSES; INTELLECTUAL PROPERTY RIGHTS

         3.1      LICENSE TO LICENSED PRODUCTS. NeoGenesis hereby grants to
Schering, and Schering hereby accepts, an exclusive (even as to NeoGenesis),
right and license in the Territory

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      19
<Page>

and within the Field under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How to make, have made, use, distribute, promote, market, offer
for sale, sell, import and export Licensed Products. The licenses granted to
Schering under this Section 3.1 include the right to grant sublicenses to
Affiliates or third parties in accordance with the provisions of Section 3.3.
Schering shall mark or have marked all containers or packages of Licensed
Products that are the subject of the license granted under this Section 3.1 in
accordance with the patent marking laws of the jurisdiction in which such
Licensed Products are manufactured, used or sold. For purposes of clarity and
avoidance of doubt, it is acknowledged that the exclusive licenses granted
hereunder shall not be construed as encompassing Compounds other than Selected
Compounds (and Active Compounds, Improved Active Compounds and Preliminary
Compounds of the same Chemotype as such Selected Compounds), Derivative
Compounds and Designated Compounds.

         3.2      LICENSE TO COMPOUNDS. NeoGenesis hereby grants to Schering,
and Schering hereby accepts, an exclusive (even as to NeoGenesis), right and
license in the Territory and within the Field under the NeoGenesis Patent Rights
and to use the NeoGenesis Know-How to research, develop, make, have made,
import, export and use the Selected Compounds (and Active Compounds, Improved
Active Compounds and Preliminary Compounds of the same Chemotype as such
Selected Compounds), Designated Compounds and Derivative Compounds, for research
purposes and to develop Licensed Products. The licenses granted to Schering
under this Section 3.2 include the right to grant sublicenses to Affiliates or
third parties in accordance with the provisions of Section 3.3. Schering shall
mark or have marked all containers or packages of Selected Compounds Derivative
Compounds and Designated Compounds that are the subject of the license granted
under this Section 3.1 in accordance with the patent marking laws of the
jurisdiction in which such Selected Compounds, Derivative Compounds and
Designated Compounds are manufactured, used or sold.

         3.3      SUBLICENSING. Schering's shall have the right to grant
sublicenses under this Agreement to third parties and/or Affiliates; provided
that all such sublicenses shall be consistent with the terms and conditions of
this Agreement, and in particular shall include provisions to ensure that such
sublicense is subject to the obligations set forth in Section 3.1(last
sentence), 4.4, 4.5, 4.6, 4.7 and 8.3(b) (last sentence) of this Agreement.
Schering shall remain responsible to NeoGenesis for all of its sublicensees
financial and other obligations under this Agreement. Schering's sublicensees
shall have no further right to grant sublicenses, and any sublicense granted
by Schering under this Agreement shall not be assigned, transferred or
otherwise conveyed by the sublicensee to any third party, as a matter of law
or through any action by sublicensee, without the prior written consent of
NeoGenesis.

         3.4      RETAINED RIGHTS.

                  (a)  Title to the NeoGenesis Know-How and NeoGenesis Patent
Rights shall at all times remain vested in NeoGenesis, and this Agreement does
not convey to Schering any ownership rights or other interest in any NeoGenesis
Know-How or NeoGenesis Patent Rights, by implication, estoppel or otherwise,
except for those rights and licenses expressly granted under this Agreement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

                  (b)  Title to the Schering Know-How and Schering Patent Rights
shall at all times remain vested in Schering, and this Agreement does not convey
to NeoGenesis any ownership rights or other interest in any Schering Know-How or
Schering Patent Rights, by implication, estoppel or otherwise, except for the
rights and licenses expressly granted under this Agreement.

                  (c)  The parties acknowledge and agree that notwithstanding
the exclusive licenses granted to Schering hereunder, with respect to the
NeoGenesis Know-How and NeoGenesis Patent Rights, NeoGenesis shall retain the
right to continue to use its NeoMorph Screening Library to screen target
proteins (other than Targets) for third parties; PROVIDED that NeoGenesis
complies with all of its obligations with respect to the masking of Preliminary
Compounds, Active Compounds, Improved Active Compounds and Selected Compounds
from the NeoMorph Screening Library.

         3.5      INVENTIONS.

                  (a)  Title to and ownership of all Inventions directly related
to (i) Selected Compounds, Derivative Compounds, Designated Compounds and
Licensed Products, or the manufacture or use thereof, or (ii) Targets provided
to NeoGenesis by Schering, in each case regardless of inventorship, as well as
those Inventions subject to Section 3.5(b)(ii), shall be the sole property of
Schering (hereinafter "SCHERING INVENTIONS") and are included in Schering
Know-How and/or Schering Patent Rights, as the case may be. NeoGenesis hereby
assigns and agrees to assign to Schering all of NeoGenesis' right, title and
interest in such Schering Inventions; such assignment to take effect with
respect to particular Selected Compounds (and related Derivative Compounds,
Designated Compounds and Licensed Products) upon the date NeoGenesis receives
notice from Schering pursuant to Section 2.7(c) that Schering has decided to
exercise its option to exclusively license the Selected Compounds and related
Derivative Compounds; and NeoGenesis shall use Commercially Reasonable Efforts
to perfect such assignment (at Schering's expense). Title to and ownership of
all Inventions directly related to the NeoMorph Screening Library, ALIS
screening technology or QSCD (regardless of inventorship), as well as those
Inventions subject to Section 3.5(b)(i) (hereinafter "NEOGENESIS INVENTIONS"),
shall be the sole property of NeoGenesis and are included in NeoGenesis Know-How
and/or NeoGenesis Patent Rights, as the case may be. Schering hereby assigns and
agrees to assign to NeoGenesis, all of Schering's right title and interest (if
any) in such NeoGenesis Inventions and Schering shall use Commercially
Reasonable Efforts to perfect such assignment (at the NeoGenesis' expense).

                  (b) Title to and ownership of all other Inventions arising
from the Screening Program and which are not covered by Section 3.5(a) shall be
determined as follows:

                  (i)   Inventions made solely by one or more employees or
                        agents of NeoGenesis shall be the sole property of
                        NeoGenesis are NeoGenesis Inventions and are included
                        in NeoGenesis Know-How and/or NeoGenesis Patent
                        Rights, as the case may be.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      21
<Page>

                  (ii)  Inventions made solely by one or more employees or
                        agents of Schering shall be the sole property of
                        Schering, are Schering Inventions, and are included
                        in Schering Know-How and/or Schering Patent Rights,
                        as the case may be.

                  (iii) Inventions made jointly by one or more employees or
                        agents of NeoGenesis and one or more employees or
                        agents of Schering shall be the joint property of
                        NeoGenesis and Schering (hereinafter "JOINT
                        INVENTIONS").

In determining each party's contribution to Inventions arising under this
Agreement, inventorship shall be determined in accordance with United States
patent law.

         3.6      PATENT PROTECTION FOR INVENTIONS. Each of NeoGenesis and
Schering shall promptly disclose to the other knowledge of any Inventions
arising in connection with the Screening Program. Responsibility for the
preparation, filing, prosecution and maintenance of any patent applications
and patents claiming such Inventions shall be determined based upon ownership
of the Inventions and shall be handled in accordance with the provisions of
this Section 3.6. Within forty-five (45) days following disclosure of any
Invention(s), the parties shall classify such Invention as a Schering
Invention, a NeoGenesis Invention or a Joint Invention and shall update
ATTACHMENT C to add such Invention and reflect such classification.

                  (a)  NeoGenesis shall have the right and responsibility to
prepare, file, prosecute, and maintain all patent applications and patent
within the NeoGenesis Patent Rights throughout the Territory at NeoGenesis
sole expense, including, without limitation, those with respect to NeoGenesis
Inventions. NeoGenesis shall have sole discretion as to all such activities
with regard to the NeoGenesis Patent Rights. NeoGenesis shall keep Schering
currently advised as to the status of all patents and patent applications
with respect to the NeoGenesis Patent Rights and shall supply Schering
promptly with copies of all patents, patent applications, substantive patent
office actions, substantive responses received or filed in connection with
such applications. Schering may offer comments and suggestions with respect
to the matters that are the subject of this Section 3.6(a) and NeoGenesis
agrees to consider such comments and suggestions; PROVIDED that nothing
herein shall obligate NeoGenesis to adopt or follow such comments or
suggestions. In the event that NeoGenesis elects not to file for patent
protection for any NeoGenesis Inventions or elects not to continue to
prosecute or maintain a patent or patent application under the NeoGenesis
Patent Rights it shall notify Schering of such decision at least forty-five
(45) days prior to the due date of any action or payment due with respect
thereto. Schering shall have the right, but not the obligation to assume the
responsibility therefor at its own cost and expense.

                  (b)  Schering and NeoGenesis, acting through the Steering
Committee, shall select and retain patent counsel mutually acceptable to each of
them for the purpose of preparing, prosecuting, issuing and maintaining
appropriate patent applications concerning Joint Inventions. NeoGenesis, in
consultation with Schering, shall be primarily responsible for the preparation,
filing (including foreign filing decisions), prosecution and maintenance of such
patent applications and patents relating to Joint Inventions. NeoGenesis shall
furnish or have furnished

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                     22
<Page>

to Schering copies of documents relevant to the same and provide Schering with
the opportunity to review and comment on patent decisions made by patent
counsel. Any disagreements between NeoGenesis and Schering with respect to
preparation, filing, prosecution, issuance and maintenance matters will be
discussed and resolved to their mutual satisfaction using the procedures
specified in Section 9.1, if necessary; PROVIDED, that to the extent that any
disagreement regards only the costs associated with a particular proposed
action, NeoGenesis may assume responsibility for such costs and the requirement
that the parties mutually agree upon resolution of the matter shall not apply.
Each party shall be responsible for fifty percent (50%) of all expenses
associated with the preparation, filing, prosecution, issuance and maintenance
of patents or other intellectual property protection for Joint Inventions. In
the event that either party elects not to pursue a particular action with
respect to which the parties disagree regarding costs, the other party shall
have the right to assume such costs and to have such action taken; PROVIDED
FURTHER that the non-paying party's licenses hereunder shall exclude any
intellectual property rights that are the subject of such action (e.g., patent
coverage in a particular country) unless and until such party reimburses the
other party for one-half (50%) of the costs of such action.

                  (d)  Schering shall have the sole right, but not the
obligation, to file, prosecute, and maintain, at Schering's sole expense, each
of the Schering Patent Rights throughout the Territory. Upon request, and at
Schering's expense, NeoGenesis will provide Schering with reasonable assistance
to prepare, file, prosecute, maintain and defend the Schering Patent Rights, and
will take all steps necessary to enable Schering to perfect its rights and title
to the Schering Patent Rights with respect to any Schering Inventions.
Reasonable assistance shall include, without limitation, providing Schering any
data and information relating to such Schering Inventions and access to the
NeoGenesis employees who are inventors of such Schering Inventions, as well as
causing the execution of any patent assignment or other documents.

         3.7      ENFORCEMENT. Each party shall promptly notify the other of its
knowledge of any actual or potential infringement of the NeoGenesis Patent
Rights, the Schering Patent Rights or any Joint Inventions.

                  (a)  NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Know-How and NeoGenesis Patent Rights. Schering shall
be solely responsible for the defense and enforcement of Schering Know-How and
Schering Patent Rights. In the event that either party recovers any sums in such
litigation by way of damages or in settlement thereof, such party shall have the
right to retain all such sums; PROVIDED that any recovery of ordinary damages by
Schering to the extent based upon third party sales of products that infringe
upon Compound Patent Rights shall be deemed to be Net Sales and Schering shall
pay NeoGenesis an amount calculated in accordance with Section 4.4 to reimburse
NeoGenesis for royalties due on lost sales of Licensed Product represented by
such ordinary damages; PROVIDED FURTHER that this allocation shall not apply
with respect to special or punitive damages, and that Schering shall be entitled
to deduct all litigation costs incurred by it in connection therewith from such
settlement or award prior to calculating such royalties.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

                  (b)  Schering shall have the first option to pursue any
enforcement or defense of any patents claiming Joint Inventions within the
Field and the Territory ("JOINT PATENT RIGHTS"); PROVIDED, that Schering pays
all costs and expenses related thereto. Schering shall have three (3) months
from the date it receives notice of such infringement to obtain a
discontinuance of such infringement or bring suit against the third party
infringer. Schering shall keep NeoGenesis reasonably informed of the status
of such activities. NeoGenesis shall provide reasonable assistance to
Schering in any suit for infringement of a Joint Patent Right brought by
Schering against a third party, and shall have the right to consult with
Schering and to participate in and be represented by independent counsel in
such litigation at its own expense. For purposes of this Section 3.7(b),
reasonable assistance shall mean providing Schering reasonable access to
information, materials and NeoGenesis personnel which Schering reasonably
determines is necessary to enable Schering to conduct the suit. Schering
shall periodically reimburse NeoGenesis for its out-of-pocket costs
(excluding the costs of retaining independent counsel) incurred in
cooperating with Schering. Schering shall incur no liability to NeoGenesis as
a consequence of such litigation or any unfavorable decision resulting
therefrom, including any decision holding any of the Joint Patent Rights
invalid or unenforceable. In the event that Schering recovers any sums in
such litigation by way of damages or in settlement thereof, Schering shall
have the right to retain all such sums; PROVIDED that any recovery of
ordinary damages to the extent based upon third party sales of products that
infringe upon the Joint Patent Rights shall be deemed to be Net Sales and
Schering shall pay NeoGenesis an amount calculated in accordance with Section
4.4 to reimburse NeoGenesis for royalties due on lost sales of Licensed
Product represented by such ordinary damages; PROVIDED FURTHER that this
allocation shall not apply with respect to special or punitive damages and
that Schering shall be entitled to deduct all litigation costs incurred by it
in connection therewith from such settlement or award prior to calculating
such royalties.

                  (c)  If, after the expiration of the three (3) month period
specified in Section 3.6(b), Schering has not overcome the allegation of
infringement, obtained a discontinuance of such infringement, or brought suit
against the third party infringer, then, provided such infringement is
substantial, NeoGenesis shall have the right, but not the obligation, to
bring suit against such infringer under the Joint Patent Right, provided that
NeoGenesis shall bear all the expenses of such suit. Schering shall provide
reasonable assistance to NeoGenesis in any suit for infringement of a Joint
Patent Right brought by NeoGenesis against a third party, and shall have the
right to consult with NeoGenesis and to participate in and be represented by
independent counsel in such litigation at its own expense. For purposes of
this Section 3.6(c), reasonable assistance shall mean providing NeoGenesis
reasonable access to information, materials and Schering personnel which
NeoGenesis reasonably determines is necessary to enable NeoGenesis to conduct
the suit. NeoGenesis shall periodically reimburse Schering for its
out-of-pocket costs (excluding the costs of retaining independent counsel)
incurred in cooperating with NeoGenesis. NeoGenesis shall incur no liability
to Schering as a consequence of such litigation or any unfavorable decision
resulting therefrom, including any decision holding any of the Joint Patent
Rights invalid or unenforceable. In the event that NeoGenesis recovers any
sums in such litigation by way of damages or in settlement thereof,
NeoGenesis shall have the right to retain all such sums.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

                  (d) Each party shall immediately give written notice to the
other of any certification of which it becomes aware filed pursuant to the
Waxman-Hatch Act (21 U.S.C. Sections 355(b)(2)(A), or Sections
355(j)(2)(A)(vii)), or any amendment or successor statute thereto, at least
fourteen (14) days prior to expiration of the forty five (45) day period set
forth in 21 U.S.C. Sections 355(c)(3)(c) (or any amendment or successor statute
thereto).

         3.8      LIST OF NEOGENESIS PATENT RIGHTS. The NeoGenesis Patent Rights
exclusively licensed to Schering pursuant to Sections 3.1 and 3.2 shall be
listed in ATTACHMENT B, which shall be amended from time to time during the term
of this Agreement to reflect additions or changes to the NeoGenesis Patent
Rights in accordance with Section 2.7. For the avoidance of doubt, to the extent
that ATTACHMENT B is not updated to include any NeoGenesis Patent Rights that
are directly related to any Selected Compounds (and Active Compounds and
Improved Active Compounds of the same Chemotype as such Selected Compounds),
Designated Compounds, Derivative Compounds and/or Licensed Products within the
scope of an exclusive license granted to Schering under Sections 3.1 and 3.2,
NeoGenesis agrees that it shall not have any action against Schering in relation
thereto and shall automatically amend ATTACHMENT B to include such NeoGenesis
Patent Rights.

4.       CONSIDERATION

         4.0      ADDITIONAL PAYMENT OBLIGATIONS. The parties acknowledge that
Schering's payment obligations as set forth in Sections 4.1, 4.2, 4.3 and 4.4 of
this Agreement are in addition to the payment obligations of Schering-Plough
Ltd. set forth in Sections 4.1, 4.2, 4.3 and 4.4 of the International Agreement.

         4.1      RESEARCH FUNDING. In consideration for the performance of
the Screening Program and activities related thereto by NeoGenesis, Schering
shall pay to NeoGenesis research funding during the term of the Screening
Program at the rate of [*] term of the Screening Program. Such payments
constitute [*]payment for FTEs at a rate of [*] per year per FTE, with [*] of
such funding to be paid by Schering-Plough Ltd. under the terms of the
International Agreement. The amount of such funding shall be based upon the
actual number of FTEs assigned by NeoGenesis to work on the Screening Program
pursuant to Section 2.2(f), it being understood that except as otherwise
agreed by the parties in writing, research funding shall be paid based upon
[*] FTEs. Research funding shall be payable in equal quarterly installments
during the term of the Screening Program, with the first such payment due
within [*] after the Effective Date and each successive payment due quarterly
in advance on the first day of each calendar quarter starting on October 1,
2001. It is understood and agreed by the parties that first two research
funding payments due under this Agreement [*] represents payment for work
performed by NeoGenesis in connection with the Screening Program during the
entire 2001 calendar year, including activities performed during the period
extending from January 1, 2001 until the Effective Date. In the event that
the term of the Screening Program is extended, the FTE rate payable under
this Section 4.1 in each such extension year shall be increased by the CPI
(as defined below). If Schering is unwilling to provide funding for such
documented cost increases and the parties are unable to resolve such funding
matter to their mutual satisfaction within forty-five (45) days then the
Screening Program shall not be extended for such extension year. If in any

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

quarterly funding period, actual expenditures by NeoGenesis with respect to
FTE's exceed the amount budgeted for the period, the overrun will be carried
forward for the next period and paid for from the next payment(s); PROVIDED,
that Schering payment obligations for any year of the Screening Program shall
not exceed the budgeted amount for such year unless Schering has agreed to fund
additional FTE work beyond that budgeted for such year by means of a written
amendment to this Agreement approved in writing by the parties. For purposes of
this Section 4.1, "CPI" means the Consumer Price Index for [*], as published by
the Bureau of Labor Statistics of the United States Department of Labor. In the
event that the Bureau of Labor Statistics ceases to publish the CPI or
substantially changes its content or format in a manner that precludes its
further use hereunder, Schering and NeoGenesis shall substitute therefor another
comparable measure published by an agreed-upon source.

         4.2      LICENSE FEES/EQUITY PURCHASE.

                  (a)  In partial consideration for the licenses and other
rights granted to Schering hereunder, Schering shall pay to NeoGenesis a
license fee of [*] with respect to each Target for which one or more Selected
Compounds are designated pursuant to Section 2.7. Each such license fee shall
be payable within [*] after the effective date of the licenses to such
Selected Compounds, as provided under Section 2.7(b). The license fee shall be
payable [*], irrespective of the number of Selected Compounds, Designated
Compounds or Licensed Products which may be identified and/or developed with
respect thereto. Payment of any license fees under this Section 4.2(a) shall
be made concurrently with payment of the corresponding license fees under
Section 4.2(a) of the International Agreement.

                  (b)  Schering agrees to subscribe for and purchase, and
NeoGenesis agrees to authorize and issue to Schering, an aggregate five million
dollars and thirty-seven cents ($5,000,000.37) worth of Series E (non-voting)
Preferred Stock, $.001 par value per share, at a price of five and 97/100's
dollars ($5.97) per share. Such equity investment shall be made pursuant to a
separate Series E Preferred Stock Purchase Agreement containing mutually
acceptable terms (the "Stock Purchase Agreement"), which is attached hereto as
ATTACHMENT F. Such equity subscription shall be made within thirty (30) days
following the Effective Date unless the parties agree to extend the time for the
consummation of such subscription.

                  (c)  Effective as of the first anniversary of the Effective
Date and subject to the applicable laws rules and regulations that restrict the
ability of NeoGenesis to permit purchases of shares in connection with its
initial public offering ("IPO"), including any Securities and Exchange
Commission regulations, Schering shall have the option, exercisable in its sole
discretion, to purchase from NeoGenesis, and in such event NeoGenesis shall sell
to Schering, additional shares of NeoGenesis common stock having an aggregate
value of five million dollars ($5,000,000). Such option may be exercised solely
in connection with NeoGenesis' IPO and shall be exercised at a price per share
for such Common Stock equal to the price at which such shares are offered to the
public in such initial public offering. The option set forth in this Section
4.2(c) shall expire and be of no further force or effect if: (i) NeoGenesis does
not complete an IPO by the third anniversary of the Effective Date or (ii) this
Agreement has been terminated prior to the completion of NeoGenesis' IPO.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      26
<Page>

         4.3      MILESTONES. In partial consideration for the licenses and
other rights granted to Schering hereunder, Schering shall pay to NeoGenesis the
following payments upon the occurrence of the indicated milestone event.

                  (a)  with respect to any Designated Compound (and any Licensed
Products based upon such Designated Compound) which is being developed based
upon activity with respect to a specific Target, and was discovered as a result
of optimization of one or more Lead Compounds by NeoGenesis pursuant to Section
2.2(b):

                  (i)   [*] upon designation of such Designated Compound
                        pursuant to Section 2.8;

                  (ii)  [*] upon initiating treatment of the first patient in a
                        Phase I clinical trial for the applicable Licensed
                        Product under an approved IND (or its equivalent);

                  (iii) [*] upon initiating treatment of the first patient in a
                        Phase III clinical trial for the applicable Licensed
                        Product;

                  (iv)  [*] upon filing and acceptance of the first NDA (or its
                        European or Japanese equivalent) for the applicable
                        Licensed Product; and

                  (v)   [*] upon receipt of the first Regulatory Approval for
                        the applicable Licensed Product in a Major Market
                        Country.

                  (b)  with respect to any Designated Compound (and any Licensed
Products based upon such Designated Compound) which is being developed based
upon activity with respect to a specific Target, but was not discovered as a
result of optimization of one or more Lead Compounds by NeoGenesis pursuant to
Section 2.2(b):

                  (i)   [*] upon designation of such Designated Compound
                        pursuant to Section 2.8;

                  (ii)  [*] upon initiating treatment of the first patient in a
                        Phase I clinical trial for the applicable Licensed
                        Product under an approved IND (or its equivalent);

                  (iii) [*] upon initiating treatment of the first patient in a
                        Phase III clinical trial for the applicable Licensed
                        Product;

                  (iv)  [*] upon filing and acceptance of the first NDA (or its
                        European or Japanese equivalent) for the applicable
                        Licensed Product; and

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

                  (v)   [*] upon receipt of the first Regulatory Approval for
                        the applicable Licensed Product in a Major Market
                        Country.

                  (c)  All payments made to NeoGenesis by Schering pursuant to
Section 4.3(a) or (b) shall be due within thirty (30) days after the achievement
of the corresponding milestone and shall be nonrefundable and not creditable
against other amounts due to NeoGenesis. The payments provided for under this
Section 4.3 shall only be payable once upon the first achievement of the
indicated milestone with respect to Designated Compound and/or Licensed Product
developed against a particular Target and no additional payments shall be due on
subsequent or repeated achievement of the same milestone for another Designated
Compound and/or Licensed Product developed against the same Target. No
milestones shall be payable under this Section 4.3 with respect to (i) any
compounds or products other than Designated Compounds and Licensed Products, or
(ii) any Designated Compounds or Licensed Products being developed based upon
[*].

                  (d)  In the event that Schering ceases all clinical
development for a Designated Compound/Licensed Product (a "Discontinued
Product") for which one or more milestones have been paid pursuant to this
Section 4.3, no payment shall be due under this Section 4.3 with respect to the
achievement of the same milestone(s) with respect to the another Designated
Compound or Licensed Product discovered or developed against the same Target as
the Discontinued Product (a "Back-up Product"). In the event that the Back-up
Product achieves milestones which were not previously achieved by the relevant
Discontinued Product, such milestone payments will be paid in accordance with
this Section 4.3.

         4.4      ROYALTIES. In partial consideration for the licenses and other
rights granted to Schering hereunder, Schering shall pay royalties to NeoGenesis
based upon Net Sales of Licensed Products in the Territory.

                  (a)  The royalties payable to NeoGenesis on Net Sales of
Licensed Products in the Territory by Schering, its Affiliates and sublicensees,
shall be determined as follows:

                  (i)   [*] of Net Sales of Licensed Products in the Territory
                        where the Designated Compound in such Licensed Product
                        was discovered as a result of optimization of one or
                        more Lead Compounds by NeoGenesis pursuant to Section
                        2.2(b); or

                  (ii)  [*] of Net Sales of Licensed Products in the Territory
                        where the Designated Compound in such Licensed Product
                        was not discovered as a result of optimization of one or
                        more Lead Compounds by NeoGenesis pursuant to Section
                        2.2(b); or

                  (iii) [*] of Net Sales of Licensed Products in the Territory
                        where the Designated Compound in such Licensed Product
                        is a Derivative Compound derived from an Selected
                        Compound identified through Schering's screening of a
                        Selected Compound against a target other than

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

                        the specific Target(s) for which the Selected Compound
                        was screened by NeoGenesis.

                  (b)  Starting with the First Commercial Sale of each Licensed
Product in the Territory, Schering shall provide NeoGenesis with quarterly
reports of Net Sales by country of each Licensed Product in the Territory. Each
such quarterly report shall be provided to NeoGenesis not later than sixty (60)
days following the close of the relevant calendar quarter, (i.e., following each
March 31, June 30, September 30 and December 31). Concurrently with the making
of such reports, Schering shall pay to NeoGenesis royalties due for such period
at the rates specified in Section 4.4(a). The report due for the quarter ending
December 31 of each year shall also include the aggregate royalties due
NeoGenesis for the entire year.

                  (c)  Schering's obligation to pay royalties with respect to
each Licensed Product shall expire on a country-by-country basis upon the later
of (i) the expiration (or revocation or complete rejection) of the last to
expire (or to be revoked or to be completely rejected) of any NeoGenesis Patent
Right and/or Compound Patent Right having a Valid Claim covering such Licensed
Product in the country, or (ii) [*] from the First Commercial Sale of the
Licensed Product in such country. No royalties shall accrue on the disposition
of any Licensed Product in reasonable quantities by Schering, its Affiliates or
its sublicenses at no charge as samples (promotional or otherwise) or as
donations (for example, to non-profit institutions or government agencies for a
non-commercial purpose) or for clinical studies.

         4.5      REMITTANCE.

                  (a)  All royalties, milestone and other payments required
under this Article 4 shall be made by bank wire transfer in United States
dollars in immediately available funds to an account designated by NeoGenesis.
Royalties shall be deemed payable by the entity making the Net Sales from the
country in which earned in local currency and subject to foreign exchange
regulations then prevailing. Royalty payments shall be made in United States
dollars to the extent that free conversion to United States dollars is
permitted. The rate of exchange to be used in any such conversion from the
currency in the country where such Net Sales occurs shall be in accordance with
the policy set forth in ATTACHMENT D attached hereto.

                  (b)  In the event that any payment due NeoGenesis under this
Agreement is not made when due, the amount due shall accrue interest beginning
on the fifth day following the final date on which such payment was due,
calculated at the annual rate equal to two percent (2%) above the prime interest
rate reported in the WALL STREET JOURNAL for the due date, calculated from the
due date until paid in full. Such payment when made shall be accompanied by all
interest so accrued.

                  (c)  If at any time legal restrictions or prohibitions imposed
by national or international authority prevent the conversion of the local
currency and such currency cannot be removed from such country such that prompt
remittance by Schering of any royalties owed by Schering to NeoGenesis in
respect of sales in such country is prevented, the parties shall consult with a
view to finding a prompt and acceptable solution, and Schering or its designated
Affiliates

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      29
<Page>

will make payment through any means as NeoGenesis may lawfully direct at no
additional out-of-pocket expense to Schering.. Notwithstanding the foregoing, if
royalties in any country cannot be remitted to NeoGenesis for any reason within
three (3) months after the end of the calendar quarter during which they are
earned, then Schering shall be obligated to pay NeoGenesis in the local currency
of such country and shall deposit the relevant royalties in a bank account in
such country designated by NeoGenesis and in the name of NeoGenesis.

         4.6      RECORDS. Schering, its Affiliates and sublicensees shall keep
and maintain complete, true and accurate books of account and records (prepared
in accordance with United States Generally Accepted Accounting Principles,
consistently applied) sufficient to determine the amounts of Net Sales and any
royalty payments due with respect thereto. All such books and records shall be
maintained in accordance with Schering's records retention policies consistently
applied but for a period of at least thirty six (36) months from the date of
each payment of royalties.

         4.7      INSPECTION. Upon prior written notice Schering and its
Affiliates shall, within a period not to exceed forty-five (45) days, permit an
independent certified public accounting firm of nationally recognized standing
selected by NeoGenesis and reasonably acceptable to Schering, at NeoGenesis'
expense, to have access during regular business hours to examine pertinent books
and records of Schering and its Affiliates necessary to verify the accuracy of
the royalty reports and payments by Schering hereunder. The examination shall be
limited to pertinent books and records for any calendar year ending not more
than twenty-four (24) months prior to the date of such request. Such inspection
right shall not be exercised more than once in any calendar year. The accounting
firm employees shall sign confidentiality agreements reasonably acceptable to
Schering as a condition precedent to their inspection. Schering may designate
competitively sensitive information which such auditor may not disclose to
NeoGenesis; PROVIDED, HOWEVER, that such designation shall not encompass the
auditor's conclusions. The accounting firm shall disclose to NeoGenesis only
whether the royalty reports are correct or incorrect and the specific details
concerning any discrepancies. No other information shall be provided to
NeoGenesis. In the event that the accounting firm correctly concludes that a
variation or error has occurred resulting in an underpayment of royalties by
Schering of five percent (5%) or more of the amount actually due for the period
covered by the inspection, Schering shall pay to NeoGenesis in addition to such
underpayment, the costs relating to the inspection, within thirty (30) days of
receipt of an invoice for such amounts. Any overpayment of royalties by Schering
discovered through such audit shall be fully creditable against royalties
subsequently due hereunder. Schering shall include in each sublicense granted by
it pursuant to this Agreement a provision requiring the sublicensee to make
reports to Schering, to keep and maintain records of sales made pursuant to such
sublicense and to grant access to such records by NeoGenesis' independent
accountant to the same extent required of Schering under this Agreement. Upon
expiration of the twenty-four (24) month period immediately following the
receipt by NeoGenesis of Schering's fourth quarter royalty report for a given
calendar year, the calculation of royalties payable with respect to such year
shall be binding and conclusive upon NeoGenesis, and Schering, its Affiliates
and its sublicensees shall be released from any liability or accountability with
respect to royalties for such year, except for instances of fraud or other
intentional misconduct.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

         4.8      TAXES. If at any time, any jurisdiction within the Territory
requires the withholding of income taxes or other taxes imposed upon payments
set forth in this Article 4, Schering shall make such withholding payments as
required and subtract such withholding payments from the payments to be made to
NeoGenesis as set forth in this Article 4, or if applicable, NeoGenesis will
promptly reimburse Schering or its designee(s) of the amount of such withholding
payments that are not subtracted from the payments made to NeoGenesis as set
forth in this Article 4. Schering shall provide NeoGenesis with documentation of
such withholding and payment in a manner that is satisfactory for purposes of
reporting to the U.S. Internal Revenue Service. Any withholdings paid when due
hereunder shall be for the account of NeoGenesis. Withholding payments made by
Schering pursuant to this Section 4.8 shall be made based upon financial
information provided to Schering by NeoGenesis, and to the extent that such
information is incorrect, NeoGenesis shall be liable for any deficiency, and any
fine, assessment or penalty imposed by any taxing authority in the Territory for
any deficiency in the amount of any such withholding or the failure to make such
withholding payment. If Schering is required to pay any such deficiency, or any
fine, assessment or penalty for any such deficiency, NeoGenesis shall promptly
reimburse Schering for such payments.

5.       CONFIDENTIALITY

         5.1      PUBLICITY. Each of the parties hereto agrees not to disclose
to any third party the existence or the terms of this Agreement without the
prior written consent of the other party hereto. Notwithstanding the foregoing,
the parties may agree upon an initial press release to announce the execution of
this Agreement, together with a corresponding Q&A outline for use in responding
to inquiries about the Agreement. In the event of such agreed upon press
release, each party may thereafter disclose to third parties the specific
information contained in such press release and Q&A without the need for further
approval by the other party. Nothing in this Section 5.1 shall prohibit a party
from making such disclosures to the extent required under applicable federal or
state securities laws or any rule or regulation of any nationally recognized
securities exchange. In such event, however, the disclosing party shall use good
faith efforts to notify and consult with the other party prior to such
disclosure and, where applicable, shall diligently seek confidential treatment
to the extent such treatment is available under applicable securities laws.

         5.2      CONFIDENTIALITY.

                  (a)  Confidential Information received by one party (the
"RECEIVING PARTY") from the other party (the "DISCLOSING PARTY") in connection
with this Agreement will be used by the Receiving Party solely for the
performance of the Screening Program or as otherwise expressly permitted by this
Agreement. All Confidential Information will be received and held in confidence
by the Receiving Party, and shall not be disclosed to any third party without
the prior written consent of the Disclosing Party. Each party acknowledges that,
except as expressly set forth herein, it will not obtain any rights of any sort
in or to the Confidential Information of the Disclosing Party as a result of
such disclosure.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      31
<Page>

                  (b)  The Receiving Party will restrict disclosure of the
Disclosing Party's Confidential Information to those of the Receiving Party's
and its Affiliates' employees, officers, directors, consultants and agents to
whom it is necessary to disclose such Confidential Information in connection
with the performance of its obligations under this Agreement. The Receiving
Party shall use all reasonable efforts, which shall be at least fully
commensurate with those employed by the Receiving Party for the protection of
its own Confidential Information, to protect the Confidential Information of the
Disclosing Party.

                  (c)  The confidentiality and use restrictions set forth in
this Article 5 shall not apply to Confidential Information to the extent such
information:

                     (i)   was already known to the Receiving Party, other
                           than under an obligation of confidentiality, at
                           the time of disclosure;

                     (ii)  was generally available to the public or otherwise
                           part of the public domain at the time of its
                           disclosure to the Receiving Party;

                     (iii) became generally available to the public or
                           otherwise part of the public domain after its
                           disclosure and other than through any act or
                           omission of the Receiving Party in breach of this
                           Agreement;

                     (iv)  was independently developed by the Receiving Party
                           without the aid, application or use of the
                           Disclosing Party's Confidential Information, as
                           demonstrated by documented evidence prepared
                           contemporaneously with such independent
                           development; or

                     (v)   was subsequently lawfully disclosed to the
                           Receiving Party, other than under a duty of
                           confidentiality, by a third party that had the
                           right to make such disclosure.

                  (d)  Each party hereto may use or disclose Confidential
Information disclosed to it by the other party to the extent (i) such use or
disclosure is reasonably necessary and permitted in the exercise of the rights
granted hereunder in filing or prosecuting patent applications and prosecuting
or defending litigation, (ii) such disclosure is reasonably required to be made
to any institutional review board of any entity conducting clinical trials with
Designated Compound(s) and/or Licensed Product(s), or to any governmental or
other regulatory agency, in order to gain approval to conduct clinical trials or
to market Designated Compound(s) and/or Licensed Products, (iii) such disclosure
is required by law, regulation, rule, act or order of any governmental
authority, court, or agency, or is made in connection with submitting required
information to tax or other governmental authorities, or (iv) such disclosure or
use is reasonably required in conducting clinical trials, or making a permitted
sublicense or otherwise exercising license rights expressly granted to it by the
other party pursuant to the terms of this Agreement; in each case, provided that
if the Receiving Party is required to make any such disclosure of the Disclosing
Party's Confidential Information, other than pursuant to a confidentiality
agreement, it

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      32
<Page>

will give reasonable advance notice to the Disclosing Party of such
disclosure and, except to the extent inappropriate in the case of patent
applications, will use its reasonable diligent efforts to secure confidential
treatment of such Confidential Information in consultation with the Disclosing
Party prior to its disclosure (whether through protective orders or otherwise)
and disclose only the minimum necessary to comply with such requirements.

                  (e)  Following the termination of this Agreement, or at any
time upon written request by the Disclosing Party, the Receiving Party shall
promptly return to the Disclosing Party all of the Disclosing Party's
Confidential Information, including all copies thereof, in its possession;
provided that the Receiving Party's legal counsel may retain one (1) copy of the
Disclosing Party's Confidential Information in a secure location solely for the
purpose of determining its obligations under this Agreement.

         5.3      PUBLICATION. Each of Schering and NeoGenesis acknowledges
the other party's interest in publishing its results to obtain recognition
within the scientific community and to advance the state of scientific
knowledge. Each party also recognizes the mutual interest in obtaining valid
patent protection and in protecting business interests and trade secret
information. Consequently, either party, its Affiliates, employees or
consultants wishing to make a publication relating to the results of the
Screening Program shall deliver to the other party a copy of the proposed
written publication or an outline of an oral disclosure at least sixty (60)
days prior to submission for publication or presentation. For purposes of
this Agreement, the term "publication" shall include, without limitation,
abstracts and manuscripts for publication, slides and texts of oral or other
public presentations, and texts of any transmission through any electronic
media, any computer access system such as the internet, world wide web, or
similar medium. The reviewing party shall have the right to (i) propose
modifications to the publication for patent reasons, trade secret reasons or
business reasons or (ii) delay the publication or presentation in order to
protect patentable information. If the reviewing party requests a delay, the
publishing party shall delay submission or presentation for a period not to
exceed eighteen (18) months from the filing date of the first patent
application covering the information contained in the proposed publication,
or shall modify such Publication to eliminate such patentable information. If
the reviewing party requests modifications to the publication, the publishing
party shall edit such publication to prevent disclosure or trade secret or
proprietary business information prior to submission of the publication or
presentation.

6.       REPRESENTATIONS AND WARRANTIES.

6.1      REPRESENTATIONS AND WARRANTIES OF EACH PARTY. Each of NeoGenesis and
Schering hereby represents, warrants and covenants to the other party hereto as
follows:

                  (a)  it is a corporation or entity duly organized and validly
existing under the laws of the state or other jurisdiction of its incorporation
or formation;

                  (b)  the execution, delivery and performance of this Agreement
by such party has been duly authorized by all requisite corporate action;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      33
<Page>

                  (c)  it has the power and authority to execute and deliver
this Agreement and to perform its obligations hereunder;

                  (d)  the execution, delivery and performance by such party of
this Agreement and its compliance with the terms and provisions hereof does not
and will not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) a loan agreement, guaranty,
financing agreement, agreement affecting a product or other agreement or
instrument binding or affecting it or its property; (ii) the provisions of its
charter or operative documents or bylaws; or (iii) any order, writ, injunction
or decree of any court or governmental authority entered against it or by which
any of its property is bound;

                  (e)  except for the governmental and regulatory approvals
required to market the Licensed Product(s), the execution, delivery and
performance of this Agreement by such party does not require the consent,
approval or authorization of, or notice, declaration, filing or registration
with, any governmental or regulatory authority and the execution, delivery or
performance of this Agreement will not violate any law, rule or regulation
applicable to such party;

                  (f)  this Agreement has been duly authorized, executed and
delivered and constitutes such party's legal, valid and binding obligation
enforceable against it in accordance with its terms subject, as to enforcement,
to bankruptcy, insolvency, reorganization and other laws of general
applicability relating to or affecting creditors' rights and to the availability
of particular remedies under general equity principles; and

                  (g)  it shall comply with all applicable material laws and
regulations relating to its activities under this Agreement.

         6.2      NEOGENESIS' REPRESENTATIONS. NeoGenesis hereby represents,
warrants and covenants to Schering as follows:

                  (a)  to the best of NeoGenesis' knowledge, as of the Effective
Date, NeoGenesis is the sole and exclusive owner of the NeoMorph Screening
Library, the NeoGenesis Patent Rights and the NeoGenesis Know-How free and clear
of all liens, charges and encumbrances and no other person, corporate or other
private entity, or governmental entity or subdivision thereof, has or shall have
any claim of ownership with respect thereto;

                  (b)  as of the Effective Date it has the full right, power and
authority to grant all of the right, title and interest in the licenses and
other rights granted to Schering under this Agreement;

                  (c)  to the best of NeoGenesis' knowledge, as of the Effective
Date the NeoMorph Screening Library, NeoGenesis Patent Rights and NeoGenesis
Know-How, and the use thereof in performance of the Screening Program as
contemplated hereunder, do not infringe on any intellectual property rights
owned or possessed by any third party;

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      34
<Page>

                  (d)  during the term of this Agreement, NeoGenesis shall not
grant or attempt to grant any licenses, options or other rights to any third
party that are contrary to or otherwise inconsistent with the licenses and other
rights granted to Schering hereunder;

                  (e)  as of the Effective Date there are no claims, judgments
or settlements against or owed by NeoGenesis or pending or, to the best of
NeoGenesis' knowledge, threatened claims or litigation against NeoGenesis
relating to the NeoMorph Screening Library, NeoGenesis Patent Rights and
NeoGenesis Know-How;

                  (f)  as of the Effective Date, it is in compliance in all
material respects with any agreements with third parties, and during the term of
this Agreement (i) it will use diligent efforts not to diminish the rights under
the NeoGenesis Patent Rights and NeoGenesis Know-How granted to Schering
hereunder, including without limitation, by not committing or permitting any
actions or omissions which would cause the breach of any agreements between
itself and third parties which provide for intellectual property rights
applicable to the performance of the Screening Program, and (ii) it will provide
Schering promptly with notice of any such alleged breach; and

                  (g)  during the term of this Agreement it will not use in any
capacity, in connection with any activities to be performed under this
Agreement, any individual who has been debarred pursuant to the United States
Food, Drug and Cosmetic Act.

         6.3      SCHERING'S REPRESENTATIONS. Schering hereby represents,
warrants and covenants to NeoGenesis as follows:

                  (a)  during the term of this Agreement it will not use in any
capacity, in connection with any services to be performed under this Agreement,
any individual who has been debarred pursuant to the United States Food, Drug
and Cosmetic Act;

                  (b)  to the best of Schering's knowledge, as of the Effective
Date it is the sole and exclusive owner or licensee of the Schering Patent
Rights and the Schering Know-How, all of which is free and clear of any liens,
charges and encumbrances, and no other person, corporate or other private
entity, or governmental entity or subdivision thereof, has or shall have any
claim of ownership with respect thereto;

                  (c)  to the best of Schering's knowledge, as of the Effective
Date it is the owner of the Targets and any other tangible materials to be
provided to NeoGenesis hereunder for use in the Screening Program;

                  (d)  to the best of Schering's knowledge, as of the Effective
Date, the use of the Targets in performance of the Screening Program as
contemplated hereunder, does not infringe a valid and enforceable claim of any
issued U.S. patent owned or possessed by any third party; and

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

                  (e)  as of the Effective Date, there are no claims, judgments
or settlements against or owed by Schering or pending or, to the best of
Schering's knowledge, threatened claims or litigation against Schering relating
to the Schering Patent Rights and Schering Know-How.

         6.4      DISCLAIMER.

                  (a)  EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.3, NeITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY, THE
NEOMORPH FOCUSED LIBRARIES, QSCD, THE COMPOUNDS, THE ACTIVE COMPOUNDS, THE
IMPROVED ACTIVE COMPOUNDS, THE SELECTED COMPOUNDS, THE DESIGNATED COMPOUNDS, THE
TARGETS, THE LICENSED PRODUCTS, THE NEOGENESIS KNOW-HOW, THE SCHERING KNOW-HOW,
THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS OR THE
SCHERING PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS UNDER THIS AGREEMENT.

                  (b)  THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS
AND SCHERING EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR
ANY CLAIM OR DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE
EXTENT PROVIDED IN SECTIONS 7.2-7.3.

7.       INDEMNIFICATION.

         7.1      INDEMNIFICATION BY SCHERING. Schering shall indemnify, defend
and hold harmless NeoGenesis and its Affiliates, and each of its and their
respective employees, officers, directors and agents from and against any and
all liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the discovery, development, manufacture, use, testing,
marketing, sale or other disposition of Designated Compounds and/or Licensed
Products by or on behalf of Schering or its Affiliates or sublicensees, (ii)
performance of the Screening Program by Schering, (iii) the use of any and all
Targets with respect to which screening or other research activities are
conducted in the Screening Program, or (iv) any breach by Schering of its
representations and warranties under this Agreement, except, in each case, to
the extent such liability, loss, claims, damage, cost or expense is caused by
the negligence or willful misconduct of NeoGenesis, its Affiliates, or any of
their respective employees, officers, directors or agents.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

         7.2      INDEMNIFICATION BY NEOGENESIS. NeoGenesis shall indemnify,
defend and hold harmless Schering and its Affiliates, and each of its and their
respective employees, officers, directors and agents from and against any and
all liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the performance of the Screening Program by NeoGenesis, except
to the extent directly related to the use of Targets provided by Schering, (ii)
any breach of NeoGenesis' contractual obligations to third parties, or (iii) any
breach by NeoGenesis of its representations and warranties made under this
Agreement, except, in each case, to the extent such liability, loss, claims,
damage, cost, and expense is caused by the negligence or willful misconduct of
Schering, its Affiliates, or any of their respective employees, officers,
directors or agents.

         7.3      PROCEDURE. As a condition to the indemnification provided for
under Sections 7.1 and 7.2, the indemnified party shall promptly notify the
party from whom indemnification is sought (the "INDEMNIFYING PARTY") in writing
of any claim or suit; PROVIDED, that failure to give such notice shall not
relieve Indemnifying Party of its indemnification obligations under this
Article 7, except to the extent such failure actually and materially prejudices
the rights of Indemnifying Party to defend against such claim or suit. The
Indemnifying Party shall have the right to assume the defense of any suit or
claim related to the liability if it has assumed responsibility for the suit or
claim in writing; however, if in the reasonable judgment of the indemnified
party, such suit or claim involves an issue or matter which could have a
materially adverse effect on the business operations or assets of the
indemnified party, the indemnified party may retain control of the defense or
settlement thereof by providing written notice of such effect to the
Indemnifying Party, but in no event shall such action or notice be construed as
a waiver of any indemnification rights that the indemnified party may have at
law or in equity. If the Indemnifying Party defends the suit or claim, the
indemnified party may participate in (but not control) the defense thereof at
its sole cost and expense. If Indemnifying Party elects to compromise or defend
a claim that is the subject of this Article 7, it shall notify the indemnified
party of its decision within thirty (30) days after delivery of the notice
described above (or sooner if the nature of the third party claim requires). If
Indemnifying Party elects not to defend the indemnified party or fails to
notify the indemnified party of its election as provided in this Section 7.3,
the indemnified party may pay, compromise or settle such claim (subject to the
provisions of Section 7.5) and the indemnified party shall be free to pursue
such remedies as may be available under applicable law to recover from
Indemnifying Party.

         7.4      LIMITATIONS ON LIABILITY. With respect to any claim by one
party against the other arising out of the performance or failure of performance
of the other party under this Agreement, the parties expressly agree that the
liability of such party to the other party for such breach shall be limited
under this Agreement or otherwise at law or equity to direct damages only and in
no event shall a party be liable for punitive, exemplary or consequential
damages; PROVIDED that this limitation shall not apply to the extent arising
under third party claims which are subject to indemnification under Section 7.1
or Section 7.2.

         7.5      SETTLEMENTS. Neither party may settle a claim or action
related to a liability, loss, claims, damage, cost or expense arising in
connection with this Agreement without the consent of the other party, which
consent shall not be unreasonably withheld, if such settlement would

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

impose any monetary obligation on the other party or require the other party to
submit to an injunction or otherwise limit the other party's rights under this
Agreement. Any payment made by a party to settle any such claim or action shall
be at its own cost and expense; PROVIDED, that in the event and to the extent
that an indemnified party enters into a settlement of a matter with respect to
which it believes it is entitled to indemnification under this Article 7 after
the other party has refused to assume the defense of such matter, the provisions
of this Section 7.5 shall not constitute a waiver of such party's right to seek
remedies from the other party concerning such matter.

         7.6      INSURANCE. Each party acknowledges and agrees that during the
term of this Agreement it shall maintain adequate insurance and/or a
self-insurance program for liability insurance, including products liability
and contractual liability insurance, to cover such party's obligations under
this Agreement. Each party shall provide the other party with evidence of such
insurance and/or self-insurance program, upon request.

8.       TERM AND TERMINATION

         8.1  TERM. This Agreement shall take effect as the Effective Date
and shall, unless sooner terminated in accordance with Section 8.2 or Section
9.5(a), expire on a Licensed Product-by -Licensed Product and country-by-country
basis upon the later of: (i) the expiration of the last-to-expire of the
NeoGenesis Patent Rights having a Valid Claim covering the Licensed Product in
such country, or (ii) [*] following the First Commercial Sale of the Licensed
Product in such country. Upon expiration of this Agreement with respect to a
Licensed Product in a given country, the licenses granted to Schering hereunder
with respect to such Licensed Product in such country shall become fully paid,
royalty-free, irrevocable licenses.

         8.2  TERMINATION.

                  (a)  Schering shall have the right to terminate this
Agreement, with or without cause at any time following the first anniversary of
the Effective Date upon one hundred and eighty (180) days written notice.

                  (b)  During the term of the Screening Program, either party
may terminate the Screening Program and this Agreement (i) upon thirty (30)
days written notice to the other party if the other party fails to pay any
amounts properly due and owing under this Agreement, unless such amount is paid
prior to the expiration of such thirty (30) day period, or (ii) upon ninety
(90) days written notice to the other party if the other party commits a
material breach of this Agreement (other than non-payment), unless such breach
is cured within the ninety (90) day notice period, or if such breach is not
capable of being cured within ninety (90) days unless such party during such
ninety (90) day period initiates actions reasonably expected to cure the breach
and thereafter diligently proceeds to cure the breach.

                  (c)  Following completion of the Screening Program, either
party may terminate this Agreement (i) upon thirty (30) days written notice to
the other party if the other

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      38
<Page>

party fails to pay any amounts properly due and owing under this Agreement,
unless such amount is paid prior to the expiration of such thirty (30) day
period, or (ii) upon ninety (90) days written notice to the other party if the
other party commits a material breach of this Agreement (other than
non-payment), unless such breach is cured within the ninety (90) day notice
period, or if such breach is not capable of being cured within ninety (90) days
unless such party during such ninety (90) day period initiates actions
reasonably expected to cure the breach and thereafter diligently proceeds to
cure the breach. Notwithstanding the foregoing, in the event that the
non-payment or breach is related to a Licensed Product, any such termination
shall be effective only with respect to such Licensed Product and this Agreement
shall remain in full force and effect with respect to any other Licensed
Products being developed and commercialized by Schering under this Agreement.

                  (d)  This Agreement may be terminated by either party upon the
filing or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for
the benefit of creditors by the other party, or in the event a receiver or
custodian is appointed for such party's business, or if a substantial portion of
such party's business is subject to attachment or similar process; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to
terminate shall only become effective if the proceeding is not dismissed within
sixty (60) days after the filing thereof.

         8.3  EFFECT OF TERMINATION.

                  (a)  Upon termination of this Agreement pursuant to Section
8.2: (i) NeoGenesis will terminate all tasks then in process in an orderly
manner, as soon as practical and in accordance with a schedule agreed to by
Schering and NeoGenesis; (ii) NeoGenesis shall deliver to Schering all materials
developed through the termination of this Agreement; (iii) Schering shall pay
NeoGenesis any monies due and owing NeoGenesis up to the time of termination for
services actually performed (including all work-in process), and (iv) within
thirty (30) days following termination (including expiration) of this Agreement,
NeoGenesis shall deliver to Schering a reasonably-detailed written report
describing the results of the research performed up to the date of such
termination. In addition, upon termination (including expiration) of this
Agreement each party shall return to the other party or certify in writing to
the other party that it has destroyed all Confidential Information of the other
party in its possession.

                  (b)  The licenses granted by NeoGenesis under Article 3 shall
survive any expiration or termination of the Screening Program or the
termination of this Agreement with respect to any Designated Compound or
Licensed Product for which the applicable service fees and milestone fees and
royalties have been paid (when due in accordance with the terms of this
Agreement) and Schering shall continue to have the right to develop, have
developed, make, have made, use, distribute, offer for sale, import, export and
sell Licensed Products relating to such Designated Compounds; PROVIDED that
Schering continues to pay NeoGenesis milestone fees and royalties as required by
Sections 4.3 and 4.4 and complies with Sections 4.5-4.8. In the event the
licenses granted to Schering under Article 3 terminates for any reason, each of
Schering's sublicensees at such time shall continue to have the rights and
license set forth in their

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

sublicense agreements, PROVIDED such sublicensee agrees in writing that
NeoGenesis is entitled to enforce all relevant provisions directly against such
sublicensee.

                  (c)  Nothing herein shall be construed to release either party
of any obligation which matured prior to the effective date of any termination.
Schering's liability for any charges, payments or expenses due to NeoGenesis
that accrued prior to the termination date shall not be extinguished by
termination, and such amounts (if not otherwise due on an earlier date) shall be
immediately due and payable on the termination date.

                  (d)  Termination of this Agreement by either party pursuant to
Section 8.2 or 9.5(a) hereof shall constitute termination of the International
Agreement under the corresponding provisions thereof.

         8.4      SURVIVAL. Articles 1, 5, 6, 7 and 9 and Sections 2.2(b),
2.2(c), 2.2(g), 2.5, 3.4, 3.5, 3.6, 3.7, 4.6, 4.7, 4.8 and 8.3(a-c), and the
second and third sentences of Section 2.1(c), shall survive any termination or
expiration of this Agreement.

9.       GENERAL PROVISIONS.
         9.1      DISPUTE RESOLUTION. Any controversy or dispute that arises
under or relates to this Agreement (with the exception to disputes relating to
the performance of the Screening Program which are governed by the terms of
Section 2.6(d)) shall be referred to the Oversight Committee (as defined in
Section 2.6(d)) for resolution. If the Oversight Committee is unable to resolve
the dispute within thirty (30) days, the dispute shall be resolved by binding
arbitration pursuant to the provisions of Schedule 9.1 (attached hereto).
Nothing herein shall prevent the parties from settling any dispute by mutual
agreement at any time.

         9.2      GOVERNING LAW. This Agreement shall be governed and construed
in accordance with the laws of the State of New York without regard for any
conflict of laws rule or provision thereof that would result in the application
of the substantive laws of any other jurisdiction. Notwithstanding the
foregoing, the parties (and the arbitrators) shall use United States (Federal)
patent and copyright laws for purposes of governing and construing Sections 3.5,
3.6 or 3.7 of this Agreement. The United Nations Convention on Contracts for the
International Sale of Goods shall not apply to the transactions contemplated by
this Agreement.

         9.3      AMENDMENT AND WAIVER. This Agreement may only be modified or
amended by a written instrument signed by authorized representatives of each
party. No provision of or right under this Agreement shall be deemed to have
been waived by any act or acquiescence on the part of either party, its agents
or employees, but only by an instrument in writing signed by an authorized
officer of each party. No waiver by either party of any breach of this Agreement
by the other party shall be effective as to any other breach, whether of the
same or any other term or condition and whether occurring before or after the
date of such waiver.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

         9.4      INDEPENDENT CONTRACTORS. Each party represents that it is
acting on its own behalf as an independent contractor and is not acting as an
agent for or on behalf of any third party. This Agreement and the relations
hereby established by and between Schering and NeoGenesis do not constitute a
partnership, joint venture, franchise, agency or contract of employment. Neither
party is granted, and neither party shall exercise, the right or authority to
assume or create any obligation or responsibility on behalf of or in the name of
the other party or its Affiliates. NeoGenesis shall be solely responsible for
compensating all its personnel and for payment of all related FICA, workers'
compensation, unemployment and withholding taxes.

         9.5      ASSIGNMENT. (a) This Agreement, and any of a party's rights
and obligations under this Agreement, may not be assigned, delegated, sold,
transferred, sublicensed (except as otherwise provided herein) or otherwise
disposed of, by operation of law or otherwise, to any third party without the
prior written consent of the other party; PROVIDED, that either party may assign
this Agreement to an Affiliate or in connection with the transfer or sale of all
or substantially all of its assets related to the division or the subject
business, or in the event of its merger or consolidation or change in control or
similar transaction PROVIDED, FURTHER, that in each instance the assignee
expressly assumes all obligations imposed on the assigning party by this
Agreement in writing. This Agreement shall be binding upon, and inure to the
benefit of, each party, its Affiliates, and its permitted successors and
assigns. Each party shall be responsible for the compliance by its Affiliates
with the terms and conditions of this Agreement.

                  (b)  In the event that any (i) third party or "group" (within
the meaning of Section 13(d) or 14(d) of the Exchange Act of 1934, as amended)
other than the current officers and directors of NeoGenesis or Schering, as the
case may be, has acquired, directly or indirectly, the beneficial ownership, by
way of merger, consolidation or otherwise of 50% of the voting power of
NeoGenesis or Schering, as the case may be, on a fully-diluted basis or (ii) the
sale, lease or transfer of all or substantially all of the assets of NeoGenesis
or Schering to any third party or group not controlled directly or indirectly by
such party (each, a "CHANGE IN CONTROL") during the term of the Screening
Program causes either party's rights and obligations hereunder to pass to any
third party, the other party shall have the right to terminate the Screening
Program and this Agreement upon written notice within thirty (30) days of
receipt of actual knowledge of such Change of Control, without providing the
party that is the subject of such Change in Control any opportunity to cure.
Thereafter, such party shall also have the right to terminate this Agreement if
the assignee of the party that is the subject of such Change in Control does not
provide the writing required under Section 9.5(a). In addition, if the
beneficial ownership (in the manner described in Section 9.5(b)(i)-(ii)) of more
than fifty percent (50%) of the voting or income interest in NeoGenesis or
Schering, as applicable, on a fully diluted basis, is acquired by a third party
or group that is reasonably regarded as a competitor of the other party, such
determination being made with reference to the products and services that such
third party then markets or for which it has made regulatory submissions with
the FDA or an equivalent Regulatory Authority in another Major Country or for
which it has publicly announced its intention to do either of the foregoing, the
other party shall have the right, but not the obligation, to terminate the
Screening Program with six (6) months notice to the party being acquired.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       41
<Page>

         9.6      NOTICES. Any notice required or permitted to be given or sent
under this Agreement shall be hand delivered or sent by express delivery
service or certified or registered mail, postage prepaid, or by facsimile
transmission (with written confirmation copy by registered first-class mail) to
the parties at the addresses and facsimile numbers indicated below.

         If to NeoGenesis, to:

                                 NeoGenesis Drug Discovery, Inc.
                                 840 Memorial Drive
                                 Cambridge, Massachusetts 02139
                                 Attention:  Satish Jindal, President and CSO
                                 Fax:  (617) 868-1515

         If to Schering, to:

                                 Schering Corporation
                                 2000 Galloping Hill Road
                                 Kenilworth, New Jersey  07033
                                 Attention: Vice President, Business Development
                                 Facsimile No.: (908) 298-7366

                           with copies to:

                                 Schering Corporation
                                 2000 Galloping Hill Road
                                 Kenilworth, New Jersey  07033
                                 Attention: Law Department - Staff Vice-
                                 President, Licensing
                                 Facsimile No.: (908) 298-2739

Any such notice shall be deemed to have been received on the earlier of the date
actually received or the date five (5) days after the same was posted or sent.
Either party may change its address or its facsimile number by giving the other
party written notice, delivered in accordance with this Section 9.6.

         9.7      PROVISIONS FOR INSOLVENCY.

                  (a)  All rights and licenses granted under or pursuant to this
Agreement by NeoGenesis to Schering are, for all purposes of Section 365(n) of
Title 11 of the United States Code ("TITLE 11"), licenses of rights to
"intellectual property" as defined in Title 11. NeoGenesis agrees during the
term of this Agreement to create and maintain current copies or, if not amenable
to copying, detailed descriptions or other appropriate embodiments, to the
extent feasible, of all such intellectual property. If a case is commenced by or
against NeoGenesis under Title 11, then, unless and until this Agreement is
rejected as provided in Title 11, NeoGenesis (in any capacity, including
debtor-in-possession) and its successors and assigns

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                      42
<Page>

(including, without limitation, a Title 11 Trustee (as defined therein)) shall,
as Schering may elect in a written request, immediately upon such request:

                  (i)   perform all of the obligations provided in this
                        Agreement to be performed by NeoGenesis including,
                        where applicable and without limitation, providing to
                        Schering portions of such intellectual property
                        (including embodiments thereof) held by NeoGenesis
                        and such successors and assigns or otherwise
                        available to them; or

                  (ii)  provide to Schering all such intellectual property
                        (including all embodiments thereof) held by
                        NeoGenesis and such successors and assigns or
                        otherwise available to them.

                  (b)  If a Title 11 case is commenced by or against NeoGenesis,
and this Agreement is rejected as provided in Title 11, and Schering elects to
retain its rights hereunder as provided in Title 11, then NeoGenesis (in any
capacity, including debtor-in-possession) and its successors and assigns
(including, without limitation, a Title 11 Trustee) shall provide to Schering
all such intellectual property (including all embodiments thereof) held by
NeoGenesis and such successors and assigns, or otherwise available to them,
immediately upon Schering's written request. Whenever NeoGenesis or any of its
successors or assigns provides to Schering any of the intellectual property
licensed hereunder (or any embodiment thereof) pursuant to this Section 9.7,
Schering shall have the right to perform the obligations of NeoGenesis hereunder
with respect to such intellectual property, but neither such provision nor such
performance by Schering shall release NeoGenesis from any such obligation or
liability for failing to perform it.

                  (c)  All rights, powers and remedies of Schering provided
herein are in addition to and not in substitution for any and all other rights,
powers and remedies now or hereafter existing at law or in equity (including,
without limitation, Title 11). In the event of the commencement of a Title 11
case by or against NeoGenesis, Schering, in addition to the rights, power and
remedies expressly provided herein, shall be entitled to exercise all other such
rights and powers and resort to all other such remedies as may now or hereafter
exist at law or in equity (including, without limitation, Title 11) in such
event. The parties agree that they intend the foregoing Schering rights to
extend to the maximum extent permitted by law, including, without limitation,
for purposes of Title 11:

                  (i)   the right of access to any intellectual property
                        (including all embodiments thereof) of NeoGenesis, or
                        any third party with whom NeoGenesis contracts to
                        perform an obligation of NeoGenesis under this
                        Agreement, and, in the case of the third party, which
                        is necessary for the development, registration,
                        manufacture and marketing of Designated Compounds
                        and/or Licensed Products; and

                  (ii)  the right to contract directly with any third party
                        described in (i) to complete the contracted work.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       43
<Page>

         9.8      SEVERABILITY. In the event any provision of this Agreement
shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other term or provision hereof. The parties agree that they will negotiate in
good faith to replace any provision hereof so held invalid, illegal or
unenforceable with a valid provision which is as similar as possible in
substance to the invalid, illegal or unenforceable provision.

         9.9      CAPTIONS. Captions of the sections and subsections of this
Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the meaning or
construction of the terms and conditions hereof.

         9.10     ENTIRE AGREEMENT. This Agreement (including the Attachments or
Schedules hereto) constitutes the entire understanding of the parties with
respect to the transactions and matters contemplated hereby and supersedes all
previous communications, representations, agreements and understandings, whether
written or verbal, relating to the subject matter hereof. No representations,
inducements, promises or agreements, whether oral or otherwise, between the
parties not contained in this Agreement shall be of any force or effect.

         9.11     RULES OF CONSTRUCTION. The parties agree that they have
participated equally in the formation of this Agreement and that the language
and terms of this Agreement shall not be construed against either party by
reason of the extent to which such party or its professional advisors
participated in the preparation of this Agreement.

         9.12     COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         9.13     FORCE MAJEURE. Failure of any party to perform its obligations
under this Agreement (except the obligation to make payments when properly due)
shall not subject such party to any liability or place them in breach of any
term or condition of this Agreement to the other party if such failure is due to
any cause beyond the reasonable control of such non-performing party ("FORCE
MAJEURE"), unless conclusive evidence to the contrary is provided. Causes of
non-performance constituting force majeure shall include, without limitation,
acts of God, fire, explosion, flood, drought, war, riot, sabotage, embargo,
strikes or other labor trouble, failure in whole or in part of suppliers to
deliver on schedule materials, equipment or machinery, interruption of or delay
in transportation, a national health emergency or compliance with any order or
regulation of any government entity acting with color of right. The party
affected shall promptly notify the other party of the condition constituting
force majeure as defined herein and shall exert reasonable efforts to eliminate,
cure and overcome any such causes and to resume performance of its obligations
with all possible speed; provided that nothing herein shall obligate a party to
settle on terms unsatisfactory to such party any strike, lockout or other labor
difficulty, any investigation or other proceeding by any public authority or any
litigation by any third party. If a condition constituting force majeure as
defined herein exists for more than ninety (90) consecutive days, the parties
shall meet to negotiate a mutually satisfactory resolution to the problem, if
practicable. If the parties cannot in good faith reach a satisfactory resolution
to the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       44
<Page>

problem within sixty (60) days of meeting, the matter shall be referred to
binding arbitration pursuant to Section 9.1.

         9.14     FURTHER ASSURANCES. Each party agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives.

NeoGenesis Drug discovery, INC.                  SCHERING CORPORATION

By: /s/ SATISH JINDAL                            By: /s/ DAVID POORVIN
   -------------------------------------            ----------------------
Satish Jindal                                    David Poorvin, Ph.D.
President and CSO                                Vice President

Date: AUGUST 2, 2001                             Date: AUGUST 2, 2001
     -----------------------------------              --------------------

297010_1

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       45<Page>

                                                                   Exhibit 10.14

                                    AGREEMENT
This Agreement (AGREEMENT) is entered into as of August 30, 2001 (EFFECTIVE
DATE) between NeoGenesis Drug Discovery, Inc., a Delaware corporation
(NEOGENESIS), and Tularik Inc. (TULARIK), a Delaware corporation, and sets forth
the terms and conditions that will apply to the provision by NeoGenesis to
Tularik of certain screening and analysis services.

                                   BACKGROUND
Tularik is interested in identifying potential pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high degree of chemical binding and functional activity to specific
protein targets. NeoGenesis has certain technology and know-how, including
screening processes and libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding activity to targets designated by Tularik from among the
NeoGenesis libraries of mass-encoded small molecule compounds and which have
activity in bioassays or functional assays. The terms and conditions set forth
below shall govern the performance of such collaborative effort.

1.   DEFINITIONS.

1.1  DEFINED TERMS. Capitalized terms used in this Agreement and not otherwise
defined herein shall have the meaning set forth below.

     AFFILIATE means with respect to either party, any Person that, directly or
indirectly, is controlled by, controls or is under common control with such
party. For purposes of this definition only, "CONTROL" means, with respect to
any Person, the direct or indirect ownership of more than [*] of the voting or
income interest in such Person or the possession otherwise, directly or
indirectly, of the power to direct the management or policies of such Person.

     ALIS means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against a target protein.

     APPLICABLE LAWS means all applicable laws, statutes, regulations and
ordinances, including without limitation the FD&C Act.

     COMMERCIALLY REASONABLE EFFORTS means (i) with respect to any objective by
any party, commercially reasonable, diligent, good faith efforts to accomplish
such objective as such party would normally use to accomplish a similar
objective under similar circumstances; and (ii) with respect to any objective
relating to the development or Commercialization of any Product or Shared
Product by any party, efforts and resources normally used by such party with
respect to a product owned by such party or to which such party has similar
rights which is of similar market potential at a similar stage in the
development or life of such product, taking into account issues of safety,
efficacy, product profile, the competitiveness of the marketplace, the
proprietary position of the product, the regulatory structure involved,
profitability of the product and other relevant commercial factors.

     COMMERCIALIZATION means any and all activities of importing, exporting,
marketing, promoting, distributing, offering for sale and selling a Product or
Shared Product or Independent Product. When used as a verb, COMMERCIALIZE means
to engage in Commercialization.

     CONFIDENTIAL INFORMATION means any proprietary or confidential information
of either party (including but not limited to all Tularik Intellectual Property
and all NeoGenesis Intellectual Property) disclosed to the other party pursuant
to this Agreement, except any portion thereof which: (i) is known to the
receiving party, as evidenced by the receiving party's prior written records,
before receipt thereof under this Agreement; (ii) is disclosed to the receiving
party by a third person who is under no obligation of confidentiality to the
disclosing party hereunder with respect to such information and who otherwise
has a right to make such disclosure; (iii) is or becomes generally known in the

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

public domain through no fault of the receiving party; or (iv) is independently
developed by the receiving party, as evidenced by the receiving party's written
records, without access to such information.

     CONTROL OR CONTROLLED means, with respect to any intellectual property
right, the possession (whether by ownership or license) by a party or an
Affiliate thereof of the ability to grant to the other party access or a license
as provided herein under such item or right without violating the terms of any
agreement or other arrangements between such party or its Affiliate and any
third party existing before, or acquired after, the Effective Date.

     COST OF GOODS means [*].

     COST OF MANUFACTURE means [*].

     DERIVATIVE COMPOUNDS means any analogs, homologs or isomers of a Designated
Screening Compound, a Designated Shared Compound and/or an Independent Compound,
as applicable.

     DESIGNATED COMPOUNDS means Designated Screening Compounds and Designated
Shared Compounds.

     DEVELOPMENT shall mean the development of any Shared Product occurring from
and after the filing of an IND, through and including approval of an NDA and any
other Regulatory Approvals required for the Manufacture and Commercialization of
such Shared Product in a country. Development shall not include Pre-Clinical
Development activities.

     DEVELOPMENT COSTS shall mean all costs and expenses reasonably resulting
directly from the Pre-Clinical Development of any Designated Shared Compound
or Development of any Shared Product, as well as Overhead costs of the
functions that directly support such Pre-Clinical Development or Development
(as calculated in accordance with GAAP and using the same allocation methods
that the party incurring such costs uses throughout its operations, but in
all events [*]), all as specified in the Development Plan and the Development
Budget. DEVELOPMENT COSTS shall include, without limitation: [*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

     DIRECT ADMINISTRATIVE EXPENSES means [*].

     DISTRIBUTION COSTS means [*].

     EXPENSES shall mean expenses incurred by a party to the extent allocable to
the Commercialization of Shared Products in all countries in the Territory,
calculated in accordance with GAAP. EXPENSES shall include, without limitation,
the following: [*].

     FDA means the United States Food and Drug Administration, or any successor
thereto.

     FD&C ACT means the United States Federal Food, Drug and Cosmetic Act of
1938 and applicable regulations promulgated thereunder, as amended from time to
time.

     FIELD means all preventative, therapeutic and diagnostic uses in humans.

     FIRST COMMERCIAL SALE of product(s) means any transfer for value in an
arms'-length transaction to an independent third party distributor, agent or end
user in a country within the Territory after obtaining all necessary Regulatory
Approvals as may be necessary for such transfer in such country.

     FORCE MAJEURE means any event beyond the control of the parties, including,
without limitation, power outages, fire, flood, riots, strikes, epidemics, war
(declared or undeclared and including the continuance, expansion or new outbreak
of any war or conflict now in existence), embargoes and governmental actions or
decrees.

     FTE means the equivalent of a full time (12) months (including normal
vacations, sick days and holidays) work of a person, carried out by one or more
employees or agents of a party.

     FTE RATE means an amount not to exceed [*] per FTE per year.

     GAAP shall mean United States Generally Accepted Accounting Principles,
consistently applied.

     GENERAL CORPORATE OVERHEAD shall mean [*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

     GOOD CLINICAL PRACTICES means the then current standards for clinical
trials for pharmaceuticals, as set forth in the FD&C Act and such standards of
good clinical practice as are required by the European Union and other
Regulatory Authorities in countries in which the relevant product is intended to
be sold, to the extent such standards are not in contravention with United
States Good Clinical Practices.

     GOOD LABORATORY PRACTICES or GLP means the then current standards for
laboratory activities for pharmaceuticals, as set forth in the FD&C Act and such
standards of good laboratory practice as are required by the European Union and
other Regulatory Authorities in countries in which the relevant product is
intended to be sold, to the extent such standards are not in contravention with
United States Good Laboratory Practices.

     GOOD MANUFACTURING PRACTICES means the current standards for the
manufacture of pharmaceuticals, as set forth in the FD&C Act and such standards
of good manufacturing practice as are required by the European Union and other
Regulatory Authorities in countries in which the relevant product is intended to
be sold, to the extent such standards are not in contravention with United
States Good Manufacturing Practices.

     IND means an investigational new drug application, as defined in the FD&C
Act, or any equivalent document filed with the FDA and necessary for beginning
clinical trials of any product in humans or any application or other
documentation filed with any Regulatory Authority of a country other than the
United States prior to beginning clinical trials of any product in humans in
that country.

     INVENTION(S) means discoveries, inventions, know-how, trade secrets,
techniques, methodologies, modifications, improvements, works of authorship,
designs and data (whether or not protectable under patent, copyright, trade
secrecy or similar laws).

     MAJOR COUNTRY mean the United States, the United Kingdom, France, Germany
or Japan, as the case may be.

     MANUFACTURING means any and all activities involved in the production of a
Designated Screening Compound, a Designated Shared Compound or an Independent
Compound (and Derivative Compounds thereof) or a Product or a Shared Product or
a Independent Product to be developed and/or Commercialized under this
Agreement. When used as a verb, MANUFACTURE means to engage in Manufacturing.

     MARKETING, ADVERTISING AND EDUCATION EXPENSES means [*].

     A MEDICINAL CHEMISTRY EFFORT begins, in the case of a Designated
Screening Compound, [*] of a Designated Screening Compound provided by
NeoGenesis, and, in the case of a Designated Shared Compound, [*](as
determined by the Steering Committee) [*] of a Designated Shared Compound
provided by NeoGenesis.

     NDA means a new drug application as defined in the FD&C Act and the
non-U.S. equivalent thereof.

     NEOGENESIS INTELLECTUAL PROPERTY means, individually and collectively, (a)
all Inventions that are conceived, discovered, developed, generated, created,
made or reduced to practice or tangible medium of expression solely by employees
or consultants of NeoGenesis at any time prior to the Effective Date, or after
the Effective Date if such Inventions are not based upon or related to the
performance of the Program; (b) any tangible materials provided by NeoGenesis to
Tularik for use in the conduct of the Program, together with, where applicable,
any analogs, derivatives, fragments, progeny, sub-cellular constituents or
expression products thereof; and (c) the NeoMorph

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

Screening Library, ALIS and QSCD. The term NeoGenesis Intellectual Property,
HOWEVER, does not include any techniques, methodologies, know-how, information
and data which is, as of the Effective Date, or later becomes, generally
available to the public, other than such techniques, methodologies, know-how,
information and data included in NeoGenesis Patent Rights.

     NEOGENESIS PATENT RIGHTS means those (a) patents and patent applications
covering NeoGenesis Intellectual Property and Program Intellectual Property
owned by or licensed to NeoGenesis that are Controlled by NeoGenesis at any time
during the term of this Agreement; and (b) all divisionals, continuations,
continuations-in-part, reissues, extensions, supplementary protection
certificates and foreign counterparts thereof. NeoGenesis shall list all
NeoGenesis Patent Rights on ATTACHMENT D, which will be updated by NeoGenesis no
less frequently than quarterly during the term of this Agreement.

     NEOMORPH CHEMISTRY means the process, proprietary to NeoGenesis, of forming
libraries and sub-libraries of discrete compounds by coupling a broad set of
diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     NEOMORPH FOCUSED LIBRARIES means those compounds synthesized by NeoGenesis
based upon Selected Compounds identified by Tularik.

     NEOMORPH SCREENING LIBRARY means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising approximately ten million
(10,000,000) different compounds.

     NET SALES means, with respect to any Product, Shared Product or Independent
Product, the aggregate gross amount received by Tularik, its Affiliates or any
of its sublicensees (in the case of a Product), by the parties, their Affiliates
or any of their sublicensees (in the case of a Shared Product) or by the
Independent Party, its Affiliates or any of its sublicensees (in the case of an
Independent Product) from unrelated third party distributors or agents (in each
case, who are not sublicensees), or end users in the Territory for the sale or
transfer for value of the applicable Product or Shared Product or Independent
Product LESS deductions for [*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

     OTHER ALLOWABLE EXPENSES means [*].

     OVERHEAD shall mean [*].

     PERSON means any individual, corporation, association, partnership (general
or limited), joint venture, trust, estate, limited liability company, limited
liability partnership, unincorporated organization, government (or any agency or
political subdivision thereof) or other legal entity or organization, other than
NeoGenesis or Tularik.

     PHASE I CLINICAL TRIALS means any human clinical trials, the principal
purpose of which is a preliminary determination of safety of a Product, Shared
Product or Independent Product, as the case may be, for its intended use in
healthy individuals or patients to support its continued testing in similar
clinical trials prescribed by the relevant Regulatory Authorities.

     PHASE II CLINICAL TRIALS means any human clinical trials for which a
Primary Endpoint is a preliminary determination of safety, biological activity,
efficacy or dose ranges of a Product, Shared Product or Independent Product, as
the case may be, in patients with the disease target being studied as required
by the relevant Regulatory Authorities.

     PHASE III CLINICAL TRIALS means any safety and/or efficacy clinical studies
of any Product, Shared Product or Independent Product, as the case may be, in
human patients with the disease target being studied to determine safety and
efficacy of such Product, Shared Product or Independent Product, as the case may
be, in patients as required by the relevant Regulatory Authorities.

     POST-REGULATORY APPROVAL CLINICAL STUDIES EXPENSES means [*].

     PRE-CLINICAL DEVELOPMENT means all aspects of all activities (including,
but not limited to: medicinal chemistry, cytotoxicity and target specificity,
chemical development/scale-up; formulation; stability; non-GLP, GLP, acute and
chronic toxicity studies; pharmacokinetics; absorption, distribution, metabolism
and excretion (ADME) studies; and safety pharmacology) that will be undertaken
with respect to a Designated Shared Compound or Independent Compound or
Derivative Compound thereof, as the case may be, that are necessary or desirable
to enable the filing of an IND for a Shared Product or Independent Product based
upon or incorporating such Designated Shared Compound or Independent Compound or
Derivative Compound thereof, including the preparation and filing of an IND.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

     PRE-LAUNCH EXPENSES means [*].

     PRIMARY ENDPOINT means, with respect to a Phase II Clinical Trial, the
point at which positive statistical significance has been achieved with respect
to the primary endpoint specified in the protocol for such trial.

     PRODUCT(S) means any product: (a) made up of, comprising or containing a
Designated Screening Compound or a Derivative Compound thereof; and (b) the
development, manufacture, use or sale of which, absent the license granted to
Tularik under Section 3.1 OR the rights assigned to Tularik under Section 3.2(d)
of this Agreement, would infringe the NeoGenesis Intellectual Property or
NeoGenesis Patent Rights or which make use of any Program Patent Rights with
respect to which NeoGenesis, its employees or agents is an inventor (as
determined under U.S. patent laws.).

     PROGRAM means the Screening Program and the activities undertaken in
connection with Section 4A with respect to Designated Shared Compounds,
Derivative Compounds thereof, Shared Products, Independent Compounds, Derivative
Compounds thereof and Independent Products.

     PROGRAM INTELLECTUAL PROPERTY means, individually and collectively, all
Inventions that are conceived, created, discovered, developed, generated, made
or reduced to practice or tangible medium of expression: (a) solely by one or
more employees or consultants of NeoGenesis at any time if such Inventions are
based upon or related to the performance of the Program; (b) jointly by one or
more employees or consultants of NeoGenesis and one or more employees or
consultants of Tularik at any time if such Inventions are based upon or related
to the performance of the Program; or (c) solely by one or more employees or
consultants of Tularik at any time if such Inventions are based upon or related
to the performance of the Program. Program Intellectual Property will be listed
in ATTACHMENT B, which shall be amended from time-to-time to include new Program
Intellectual Property, in accordance with Section 3.3.

     PROGRAM PATENT RIGHTS means (a) those patents and patent applications
covering Program Intellectual Property and (b) all divisionals, continuations,
continuations-in-part, reissues, extensions, supplementary protection
certificates and foreign counterparts thereof.

     QSCD means Quantized Surface Complimentary Diversity, a model proprietary
to NeoGenesis, pursuant to which discrete chemical compliments to the surfaces
of a Target are defined.

     R&D PROGRAM means on a Designated Screening Compound-by-Designated
Screening Compound and country-by-country basis the activities Tularik deems
necessary or desirable to be undertaken in connection with the research and
development of such Designated Screening Compound with the goal of obtaining
Regulatory Approval for a Product in such country (regardless of the country in
which such activities are conducted).

     RECALL EXPENSES means [*].

     REGULATORY APPROVALS means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
Manufacture, importation, marketing, promotion, pricing and sale of the
Product(s) or Shared Product(s) in such country.

     REGULATORY AUTHORITY means any national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity in the Territory, including, without limitation, the FDA.

     SCREENING PROGRAM means the screening program described in paragraphs 1-10
of ATTACHMENT A as the same may be amended by mutual written agreement of the
parties acting through the Steering Committee; but subject to the limitation
specified in Section 2.7(b)(i).

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

     SCREENING TARGETS means Targets selected by Tularik for which the screening
fee described in Section 4.2, the success payment described in Section 4.3, the
milestone payments described in Section 4.4 and the royalties described in
Section 4.5 are due from Tularik to NeoGenesis as specified in Section 4.

     SELLING AND PROMOTION EXPENSES means [*].

     SHARED PRODUCT(S) means any product made up of, comprising or containing a
Designated Shared Compound or a Derivative Compound thereof. SHARED PRODUCTS
shall not include Products.

     SHARED PRODUCT LOSSES means in any calendar year the excess, if any, by
which Expenses exceed Net Sales.

     SHARED PRODUCT PROFITS means in any calendar year the excess, if any, by
which Net Sales exceed Expenses.

     SHARED TARGETS means Targets proposed by Tularik and approved by NeoGenesis
for which no screening fee, success payments, milestones or royalties are due.
Instead, NeoGenesis and Tularik shall contribute equally to the further
research, Pre-Clinical Development and Development of compounds active against
Shared Targets, and all costs related to such activities in respect of such
Shared Targets, and NeoGenesis and Tularik shall share equally in the proceeds
of any resulting product(s), as described in Section 4A.

     SUBLICENSE REVENUES means revenues or other consideration received from
such sublicensee as consideration for the grant of such sublicense, less the
expenses directly attributable to supplying goods and services to such
sublicensees to enable their practice of such sublicenses (excluding all amounts
received for the purchase of an equity interest in, or as a loan to, a party, in
each case at the fair market value thereof.)

     SUBSTANTIAL COMPETITION means market penetration in a country with
respect to a Product by one or more third parties with a product [*].

     SUCCESS CRITERIA means [*].

     TARGET means a specific protein target(s) selected or proposed by Tularik,
as applicable, for which NeoGenesis will perform the Screening Program. A Target
may be either a Screening Target or a Shared Target. An Excluded Target is not a
Target for purposes of this Agreement until such time, if any, as it becomes a
Screening Target or a Shared Target.

     TERRITORY means all the countries of the world.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

     THIRD PARTY ROYALTIES means [*].

     TULARIK INTELLECTUAL PROPERTY means, individually and collectively, (a) all
Inventions that are conceived, discovered, developed, generated, created, made
or reduced to practice or tangible medium of expression solely by employees or
consultants of Tularik at any time prior to the Effective Date, or after the
Effective Date, if such Inventions are not based upon or related to the
performance of the Program; (b) any tangible materials provided by Tularik to
NeoGenesis for use in the conduct of the Program, together with, where
applicable, any analogs, derivatives, fragments, progeny, sub-cellular
constituents or expression products thereof; (c) the Targets or the uses
thereof; and (d) the functional and/or secondary assays provided by Tularik
under the Program. The term Tularik Intellectual Property, HOWEVER, does not
include any techniques, methodologies, know-how, information and data which is,
as of the Effective Date or later becomes, generally available to the public,
other than such techniques, methodologies, know-how, information and data
included in Tularik Patent Rights.

     TULARIK PATENT RIGHTS means (a) those patents and patent applications
covering Tularik Intellectual Property and Program Intellectual Property owned
by or licensed to Tularik that are Controlled by Tularik at any time during the
term of this Agreement which relate to or otherwise would be infringed by the
performance of the Screening Program or the Development, Manufacture, use,
importation or sale of any Designated Shared Compound or Shared Product and, to
the extent permitted under Section 4A.15, Independent Compounds and Independent
Products and (b) all divisionals, continuations, continuations-in-part,
reissues, extensions, supplementary protection certificates and foreign
counterparts thereof.

     VALID CLAIM means (i) a claim of an unexpired and issued patent which has
not been found to be invalid or unenforceable by a court or other authority of
competent jurisdiction in the subject country in a decision which is
unappealable or not appealed; or (ii) a claim of a pending application, which
application, taking into consideration the earliest priority date, has not been
pending for more than five (5) years.

1.2 OTHER DEFINED TERMS. The following terms shall have the meanings set forth
in the section appearing opposite such term:

<Table>
<S>                                             <C>
AGREEMENT                                       Recitals
BANKRUPTCY CODE                                 Section 3.1
COMPLETION OF SCREENING                         Section 4.2
CONVERTIBLE NOTE                                Section 4.1
DESIGNATED SCREENING COMPOUND(S)                Section 2.8
DESIGNATED SHARED COMPOUND(S)                   Section 4A.2
DEVELOPMENT BUDGET                              Section 4A.7
DEVELOPMENT PLAN                                Section 4A.7
DISCONTINUED COMPOUND(S)                        Section 4A.3
DISCRETE COMPOUND(S)                            ATTACHMENT A
DISPUTE NOTICE                                  Section 9.1
EFFECTIVE DATE                                  Recitals
EXCLUDED TARGET                                 Section 2.2
EXPANDED COLLABORATION                          Section 2.1
FINAL TARGET REPORT                             ATTACHMENT A
GENERIC RIGHTS                                  Section 3.2
INDEMNIFIED PARTY(IES)                          Section 7.2
INDEMNIFYING PARTY                              Section 7.2
INDEPENDENT COMPOUND(S)                         Section 4A.15
INDEPENDENT PARTY                               Section 4A.15
INDEPENDENT PRODUCT                             Section 4A.15
IPO                                             Section 4.1
LICENSED TECHNOLOGY                             Section 3.1
LOSSES                                          Section 7.2
MARKETING BUDGET                                Section 4A.23

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

MARKETING PLAN                                  Section 4A.23
NEOGENESIS                                      Recitals
NON-PROPOSED COMPOUND(S)                        Section 4A.4
NON-PROPOSED COMPOUND INTERESTED PARTY          Section 4A.4
OVERAGE THRESHOLD                               Section 4A.8
PRELIMINARY COMPOUND(S)                         ATTACHMENT A
PRIMARY ACTIVE COMPOUND(S)                      ATTACHMENT A
PROOF OF CONCEPT STAGE                          Section 2.1
RE-ENGAGEMENT AMOUNT                            Section 4A.16
RE-ENGAGEMENT EXPIRATION DATE                   Section 4A.16
RE-ENGAGEMENT NOTICE                            Section 4A.16
SELECTED COMPOUND(S)                            ATTACHMENT A
SELECTED SCREENING COMPOUND(S)                  ATTACHMENT A
SELECTED SHARED COMPOUND(S)                     ATTACHMENT A
SHARE OF LOSS                                   Section 4A.17
SHARE OF PROFIT                                 Section 4A.17
STEERING COMMITTEE                              Section 2.7
TERMINATED COUNTRIES                            Section 4A.23
TULARIK                                         Recitals
</Table>

2.   SCREENING PROGRAM; R&D PROGRAM; COMMERCIALIZATION

2.1  PROOF OF CONCEPT STAGE; EXPANDED COLLABORATION STAGE. (a) The parties shall
conduct an initial program encompassing [*] Targets (the PROOF OF CONCEPT STAGE)
as described in Section 2.1(b). If the Proof of Concept Stage meets the Success
Criteria or if elected by Tularik upon Tularik's notice to NeoGenesis that
Tularik desires to initiate an expanded collaboration regardless of achievement
of the Success Criteria during the Proof of Concept Stage or as set forth in the
last sentence of Section 4.1(c), the parties shall expand such collaboration for
an additional three (3) years as described in Section 2.1(c) (the EXPANDED
COLLABORATION). The parties shall enter into the Expanded Collaboration or not
enter into the Expanded Collaboration, as the case may be, not later than [*]
after the date the Success Criteria are satisfied or, if the Success Criteria
are not satisfied, not later than [*] after the completion by NeoGenesis of the
Proof of Concept Stage.

     (b) During the Proof of Concept Stage, Tularik shall provide NeoGenesis
with [*] Targets for screening: [*] Screening Targets and [*] Shared Targets.
Screening and, if elected by Tularik or the Steering Committee, as applicable,
optimization for each Target that is the subject of the Proof of Concept Stage
shall be completed within [*] following delivery of each Target to NeoGenesis,
such delivery to occur within [*] of the Effective Date. The [*] Targets and
their designation as Screening Targets or Shared Targets are identified in
ATTACHMENT C.

     (c) During the Expanded Collaboration (if any), Tularik shall select [*]
Targets as Screening Targets for the Expanded Collaboration. In addition, for
every [*] Screening Targets selected for the Expanded Collaboration, Tularik
shall propose [*] Shared Target to become the subject of the Expanded
Collaboration (up to a maximum of [*] Shared Targets during the Expanded
Collaboration). Timing for the screening of Screening Targets and Shared Targets
in the Expanded Collaboration shall be mutually agreed upon, but each such
screening shall be completed within [*] of delivery of the relevant Target to
NeoGenesis by Tularik.

     (d) Notwithstanding any provision of this Agreement to the contrary,
Tularik shall not be permitted to screen more than [*] Screening Targets in the
aggregate that [*].

     (e) The Proof of Concept Stage will have a duration of [*]. If
applicable, the Expanded Collaboration will have a duration of an additional
thirty six (36)-month period. The duration of the Screening Program will
equal the duration of the Proof of Concept Stage, and, if applicable, the
Expanded Collaboration.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

2.2  DISCLOSURE OF TARGETS. During the Program, Tularik shall from time to
time disclose Screening Targets selected by Tularik and/or Shared Targets
proposed by Tularik to NeoGenesis in writing. Within [*] of each disclosure
of a selected or proposed Target by Tularik, NeoGenesis shall notify Tularik
as to whether such Target is an Excluded Target. If NeoGenesis does not serve
such notice within the specified period, such Target shall not be an Excluded
Target. NeoGenesis may deem a Target as an Excluded Target if on the date
NeoGenesis receives such selected or proposed Target disclosure from Tularik:
(a) NeoGenesis is contractually prohibited from performing the screening
contemplated in this Agreement on such Target, (b) NeoGenesis has received a
request from a third party to provide screening on such Target and NeoGenesis
reasonably expects to commence such screening within [*] for such third
party, or (c) NeoGenesis has previously conducted screening on such Target
for another party (each, an EXCLUDED TARGET). Excluded Targets shall [*]
Screening Targets to be supplied by Tularik during the Expanded
Collaboration. Such Excluded Targets shall not, however, at Tularik's option,
[*] Screening Targets to be supplied during the Expanded Collaboration.
NeoGenesis will promptly notify Tularik if an Excluded Target that was
excluded pursuant to Section 2.2(b) does not become the subject of screening
at NeoGenesis within said [*] period Tularik may have such Excluded Target
deemed a Target with notice to NeoGenesis.

2.3  DELIVERY OF TARGET PROTEINS. Tularik shall deliver the Targets for the
Proof of Concept Stage as set forth in Section 2.1. In the Expanded
Collaboration, Tularik shall deliver to NeoGenesis for screening (a)
Screening Targets selected by Tularik within [*] of selection or (b) Shared
Targets proposed by Tularik that have been accepted by NeoGenesis within [*]
following written acceptance by NeoGenesis of such Shared Targets. Tularik
shall provide Targets in the quantities and formats specified in ATTACHMENT
A. Tularik shall also provide NeoGenesis at the time of delivery with a
written description of [*]. Tularik shall deliver the Targets FOB to
NeoGenesis' Cambridge, Massachusetts facility.

2.4  EXCLUSIVITY. Notwithstanding any other provision in this Agreement, any
Targets screened by NeoGenesis on behalf of Tularik during the Proof of Concept
Stage or the Expanded Collaboration, as either Screening Targets or Shared
Targets, shall not be screened for a third party or internally at NeoGenesis
(nor shall NeoGenesis research, develop, make, use or sell any products active
against such Targets) during the Screening Program and for a period of [*]
following completion of all work by NeoGenesis under the Screening Program with
respect to such Target. Notwithstanding the foregoing, NeoGenesis shall not
screen any Target proprietary to Tularik: (a) for a third party, except upon the
request of such third party and not as a result of any solicitation by
NeoGenesis with respect to any Target, for a period of [*] following completion
of all work by NeoGenesis under the Screening Program with respect to such
Target; or (b) internally at NeoGenesis for a period of [*] following completion
of all work by NeoGenesis under the Screening Program with respect to such
Target. It is understood and acknowledged by NeoGenesis that the restrictions
imposed by this Section 2.4 will operate independently of and in addition to any
patent rights that Tularik may hold in respect of any Target and that,
notwithstanding the preceding sentence, NeoGenesis shall not screen any Target
covered by patent rights owned or controlled by Tularik.

2.5  GRANT OF RESEARCH LICENSES. (a) Tularik hereby grants NeoGenesis a
nonexclusive, nontransferable, royalty-free license to use Tularik Intellectual
Property and Program Intellectual Property owned by Tularik (including Tularik
Patent Rights) solely for purposes of conducting the Screening Program and
performing NeoGenesis' obligations under the Screening Program. NeoGenesis will
not use Tularik Intellectual Property and Program Intellectual Property owned by
Tularik for any other purpose, without Tularik's prior written permission and
except as otherwise permitted by the licenses granted in Sections 3.1 and
3.2(f). NeoGenesis shall not (i) grant, or attempt to grant, a sublicense under
this Section 2.5 to use Tularik Intellectual Property or Program Intellectual
Property owned by Tularik to any Person without the express written consent of
Tularik or (ii) modify the Targets supplied by Tularik, including, without
limitation, the making of any derivatives, analogs, fragments or components
thereof. In the event that NeoGenesis does not consume all of the Targets
supplied by Tularik in performance of the Screening Program, NeoGenesis will
upon completion of the Screening Program with respect to each particular Target,
return to Tularik any quantities of such Target and any derivatives, analogs,
fragments or components thereof.

     (b) NeoGenesis hereby grants Tularik a nonexclusive, nontransferable,
royalty-free license to use NeoGenesis Intellectual Property and Program
Intellectual Property owned by NeoGenesis (including NeoGenesis Patent Rights)
solely for purposes of conducting the Screening Program, performing Tularik's
obligations under the Screening Program and identifying Designated Compounds
under Section 2.8. Tularik will not use NeoGenesis Intellectual

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

Property and Program Intellectual Property owned by NeoGenesis for any other
purpose, without NeoGenesis' prior written permission and except as otherwise
permitted by the licenses and assignments granted in Sections 3.1, 3.2(d),
3.2(e) and 3.2(i). Tularik shall not grant, or attempt to grant, a sublicense
under this Section 2.5 to use NeoGenesis Intellectual Property or Program
Intellectual Property owned by NeoGenesis to any Person without the express
written consent of NeoGenesis. In addition, Tularik shall not analyze the
structure of any Preliminary Compounds, Discrete Compounds or Primary Active
Compounds or otherwise seek to derive, independent of NeoGenesis, the structure
of such Preliminary Compounds, Discrete Compounds or Primary Active Compounds
until such time as Tularik designates Primary Active Compounds as Selected
Compounds in accordance with the procedure specified in ATTACHMENT A.

2.6  SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records
containing laboratory data generated in the course of the Screening Program to
enable it to furnish complete and accurate information to Tularik regarding the
Screening Program activities and results, including all Preliminary Compounds,
Primary Active Compounds and NeoMorph Focused Libraries identified in the
Screening Program and all Program Intellectual Property described in clauses (a)
or (b) of the Program Intellectual Property definition. All such written records
of NeoGenesis shall be open to inspection by Tularik during normal business
hours upon reasonable prior notice.

     (b) NeoGenesis shall provide Tularik with reasonably-detailed written
reports describing the results of the research performed pursuant to the
Screening Program including all Preliminary Compounds, Primary Active Compounds
and NeoMorph Focused Libraries identified in the Screening Program and Program
Intellectual Property described in clauses (a) or (b) of the Program
Intellectual Property definition. Such reports shall be delivered to Tularik at
least monthly during the Screening Program. Representatives of NeoGenesis will
make themselves reasonably available to discuss such reports and the progress of
the Screening Program. NeoGenesis will deliver a Final Target Report (as defined
in ATTACHMENT A) with respect to the Screening Program work performed on each
Target including a description of all the Preliminary Compounds, Primary Active
Compounds and NeoMorph Focused Libraries identified during the Screening Program
with respect to such Target.

2.7  STEERING COMMITTEE. (a) A Steering Committee (STEERING COMMITTEE) shall be
responsible for oversight of the Program. The Steering Committee shall consist
of four (4) members, two (2) members to be appointed by each of NeoGenesis and
Tularik, except as otherwise provided in Section 4A.7. Each party may, with
notice to the other, substitute any of its members serving on the Steering
Committee. The initial Tularik members shall be [*] and [*] and the initial
NeoGenesis members shall be [*] and [*]. Tularik shall have the right to appoint
one of its members to be the chairperson of the Steering Committee.

     (b) The Steering Committee shall be responsible for the management and
conduct of the Program and shall in particular: (i) consider, review and amend
ATTACHMENT A from time to time in such manner as may be appropriate; PROVIDED,
that the Steering Committee may not amend ATTACHMENT A in a manner that would
conflict with the time period for designating Designated Screening Compounds
specified in Section 2.8 or the time period for designating Designated Shared
Compounds specified in Section 4A.1 or the obligations specified in the last
sentence of Section 2.5(b), in each case without the prior written agreement of
both Tularik and NeoGenesis; (ii) monitor progress of the Program; (iii) report
regularly to the management of both parties upon the progress of the Program;
(iv) be the conduit for transfer of information between the parties; and (v)
conduct such other activities as set forth in Section 4A.

     (c) The Steering Committee shall hold meetings as mutually agreed by the
parties (but in no event less than eight (8) times during the term of the
Screening Program if the parties enter into the Expanded Collaboration, unless
mutually agreed by the parties) to review the Program. The first meeting of the
Steering Committee shall be held within forty five (45) days of the Effective
Date and shall be held in Cambridge, Massachusetts. Thereafter, meetings may be
held by telephone or video conference, PROVIDED THAT the parties shall meet in
person at least two (2) times during the Screening Program. Minutes of all
meetings setting forth decisions of the Steering Committee relative to the
Program shall be prepared by the host party and circulated to both parties
within twenty five (25) days after each meeting, but minutes shall not become
official until approved by both parties (which approval the parties shall use
reasonable efforts to give within thirty (30) days of receipt of such minutes).

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

     (d) The quorum for Steering Committee meetings shall be two (2) members,
provided there is at least one member from each of NeoGenesis and Tularik
present. The Steering Committee will render decisions [*]. Disagreements among
the Steering Committee regarding the Program will be resolved via good-faith
discussions; PROVIDED, that in the event of a disagreement that cannot be
resolved within thirty (30) days after the date on which the disagreement arose,
the matter shall be referred to Tularik's Chief Executive Officer and
NeoGenesis's Chief Executive Officer or their respective designees. Thereafter,
if any such disagreement is not resolved within forty five (45) days, then
Tularik will have the right to make the final decision, unless it is otherwise
expressly provided in Section 4A that a particular decision [*].

2.8  DESIGNATED SCREENING COMPOUNDS. (a) Within [*] following the delivery of
Selected Screening Compounds to Tularik for a particular Screening Target in
accordance with ATTACHMENT A and completion of optimization, if any,
performed by NeoGenesis on Selected Screening Compounds for such Screening
Target in accordance with ATTACHMENT A, Tularik shall notify NeoGenesis
whether it will classify any Selected Screening Compounds or compounds
arising out of NeoGenesis' optimization (if any) for such Screening Target as
candidates for further research (each, a DESIGNATED SCREENING COMPOUND). If
Tularik does not identify any Designated Screening Compound(s) against a
particular Screening Target within such period, the license granted Tularik
under Section 3.1 shall terminate and be of no further force or effect solely
with respect to Designated Screening Compounds and/or Products against the
applicable Screening Target, and no further payment from Tularik shall be due
with respect to such Screening Target. If Tularik does identify any
Designated Screening Compounds, such Designated Screening Compounds will be
subject to the license granted Tularik under Section 3.1 and shall no longer
be available to NeoGenesis or any third party in any NeoGenesis compound
library, including its NeoMorph Screening Library, or in any other manner.
Not more than [*] Designated Screening Compounds per Screening Target may be
taken from the Preliminary Compounds (without optimization through NeoMorph
Focused Library(ies)) and not more than a total of [*] Designated Screening
Compounds in the aggregate for all Screening Targets may be taken from the
Preliminary Compounds (without optimization through NeoMorph Focused
Library(ies)). Unless otherwise agreed by the parties, there shall be [*]
Designated Screening Compounds that may be taken from NeoMorph Focused
Library(ies); PROVIDED, all such Designated Screening Compounds have [*]. In
addition, Tularik may take up to [*] Designated Screening Compounds per
Screening Target from NeoMorph Focused Library(ies) which Designated
Screening Compounds [*].

     (b) Within [*] following receipt of notification from Tularik identifying
Designated Screening Compounds, NeoGenesis shall amend ATTACHMENT D to identify
any applicable NeoGenesis Patent Rights not previously identified to Tularik.

     (c) Tularik shall have the right, with notice to NeoGenesis, to
"undesignate" those Designated Screening Compounds Tularik considers unsuitable
for further development. When a Designated Screening Compound is undesignated,
Tularik shall have the right to replace that compound with a new Designated
Screening Compound to the extent that such replacement compound is not otherwise
subject to an obligation to any third party; PROVIDED that Tularik returns such
undesignated compound to NeoGenesis upon the receipt of such replacement
compound, any restrictions with respect to such undesignated compound shall
expire and NeoGenesis shall be permitted to use such undesignated compound for
any purpose not otherwise prohibited by this Agreement or any patent rights
owned or Controlled by Tularik. Tularik may not: (i) undesignate any Designated
Screening Compound for which it has filed any patent applications covering such
Designated Screening Compound; (ii) undesignate more than [*] Designated
Screening Compounds per Screening Target; or (iii) undesignate more than (A) [*]
Designated Screening Compounds in the aggregate for all Screening Targets if the
parties do not enter into the Expanded Collaboration or (B) [*] Designated
Screening Compounds in the aggregate for all Screening Targets if the parties
enter into the Expanded Collaboration.

2.9  LIMITATIONS ON NEOGENESIS. Under no circumstances shall NeoGenesis disclose
any of the results (including without limitation any NeoMorph Focused
Library(ies) created during the Screening Program) or data arising out of the
Screening Program regarding the effectiveness or ineffectiveness of the
compounds in its compound libraries against all or any of the Targets to any
third party, or otherwise use such information for its own benefit or the
benefit of any third party, without Tularik's prior written consent; it being
understood that the use of the NeoMorph Screening Library may result in the
independent generation of results or data similar to the results or data
generated in the course of the Screening Program and that the use of such
independently generated results or data, if otherwise

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

obtained and used in accordance with Section 2.4 and the other provisions of the
Agreement, shall not constitute a breach of these obligations; PROVIDED FURTHER,
that the obligations of NeoGenesis to not make any Designated Compound available
to NeoGenesis or any third party in NeoGenesis' compound libraries, including
its NeoMorph Screening Library, shall operate independently of the foregoing
exception. Subject to its obligations under the Screening Program, nothing in
the Agreement shall be construed to prohibit Tularik, alone or with third
parties, from performing screening for compounds active against Targets, from
performing any research and development efforts with respect to such compounds
or Targets or from making, using or selling any products resulting from such
research and development efforts, without compensation or further obligation to
NeoGenesis; PROVIDED, that no NeoGenesis Intellectual Property or Program
Intellectual Property owned by NeoGenesis (including any intellectual property
that is the subject of the assignment set forth in Section 3.2(d)) is used in
the development of such products.

2.10 PRODUCT DEVELOPMENT. Tularik, [*], shall be responsible for and shall
use its Commercially Reasonable Efforts to conduct the R&D Program.

2.11 MANUFACTURE OF PRODUCT. Tularik, [*], shall be responsible for and shall
use its Commercially Reasonable Efforts to Manufacture any Products in
accordance with the Regulatory Approvals.

2.12 REGULATORY MATTERS. Tularik, [*], shall be responsible for the
preparation and filing, with the appropriate Regulatory Authorities, of all
documents that are necessary to conduct clinical studies of Products in
connection with the R&D Program. Tularik shall be responsible for and shall
use Commercially Reasonable Efforts to file Regulatory Approval applications
and obtain applicable Regulatory Approvals for at least one Product for each
Screening Target in each of the Major Countries. Simultaneously with the
submission of each such regulatory filing, Tularik shall notify NeoGenesis,
in writing, that such regulatory filing has been made. Tularik shall be
responsible for reporting all adverse events associated with any Product to
the appropriate Regulatory Authorities in accordance with Applicable Laws.

2.13 MARKETING AND SALE. Tularik, [*], shall be responsible for the
Commercialization of Products in the Territory and shall use its Commercially
Reasonable Efforts to Commercialize each Product in each of the Major
Countries in which it has obtained necessary Regulatory Approvals. Tularik
shall be responsible for establishing the price of each such Product sold by
or on behalf of it pursuant to this Agreement.

2.14 THIRD PARTY LICENSES. Tularik, [*], shall be responsible for obtaining
any and all licenses from third parties necessary or desirable to perform the
R&D Program and/or to Commercialize any Product.

2.15 COMPLIANCE WITH LAW. Tularik shall conduct the R&D Program and conduct its
Manufacturing operations, and each party shall conduct its activities under the
Program, in a safe and prudent manner, in compliance with all Applicable Laws
(including, but not limited to, those relating to occupational safety and
health, public safety and health, protecting the environment, the disposal of
wastes, Good Clinical Practices, Good Laboratory Practices and Good
Manufacturing Practices), and in compliance with all applicable provisions of
this Agreement. Each party shall obtain all necessary registrations and permits
pertaining to its activities contemplated by this Agreement.

2.16 PERIODIC REVIEW. Tularik and NeoGenesis shall periodically meet, at such
times and places as are mutually agreed upon, and in person or by telephone
or videoconference as mutually agreed upon, for Tularik to provide NeoGenesis
with an update on the status of the progress of Tularik's R&D Program and
Commercialization of each Product, PROVIDED, HOWEVER, that such meetings
shall occur no more than [*] unless the parties agree, in writing, to meet
more or less often. Tularik and NeoGenesis shall each be responsible for its
own expenses incurred in connection with attending such meetings.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

3.   LICENSE; PROPRIETARY RIGHTS

3.1  GRANT OF LICENSE. (a) Subject to the terms and conditions of this
Agreement, NeoGenesis hereby grants to Tularik, and Tularik hereby accepts, a
worldwide right and license, without the right to sublicense (except as set
forth in the third sentence of this Section 3.1(a) with respect to Designated
Screening Compounds, Derivative Compounds thereof and Products), within the
Territory, to use (i) the NeoGenesis Intellectual Property and NeoGenesis
Patent Rights and (ii) the Program Intellectual Property owned by NeoGenesis,
in each case with application to the Field (collectively, the LICENSED
TECHNOLOGY) to the extent necessary or useful to research, develop, have
developed, make, have made, use, distribute, promote, market, offer for sale,
sell, have sold, import and export Designated Compounds, Derivative Compounds
thereof, Products and Shared Products and, to the extent permitted under
Section 4A.15, Independent Compounds, Derivative Compounds thereof and
Independent Products. The foregoing license shall be exclusive with respect
to Designated Screening Compounds, Derivative Compounds thereof and Products
and co-exclusive (with NeoGenesis) with respect to Designated Shared
Compounds, Derivative Compounds thereof, Shared Products, Independent
Compounds and Independent Products. Tularik may grant sublicenses of its
rights under this Section 3.1(a) with respect to Designated Screening
Compounds, Derivative Compounds thereof and Products; PROVIDED that Tularik:
[*].

     (b) Subject to the terms and conditions of this Agreement, Tularik hereby
grants to NeoGenesis, and NeoGenesis hereby accepts, a co-exclusive (with
Tularik), worldwide right and license, without the right to sublicense, within
the Territory, to use (i) the Tularik Intellectual Property and Tularik Patent
Rights and (ii) the Program Intellectual Property owned by Tularik, in each case
with application to the Field to the extent necessary or useful to research,
develop, have developed, make, have made, use, distribute, promote, market,
offer for sale, sell, have sold, import and export Designated Shared Compounds,
Derivative Compounds thereof and Shared Products and, to the extent permitted
under Section 4A.15, Independent Compounds, Derivative Compounds thereof and
Independent Products.

     (c) The licenses granted under this Section 3.1 shall be treated as a
license of rights to "intellectual property" (as defined in Section 101(56) of
Title 11 of the United States Code, as amended (the BANKRUPTCY CODE)) for
purposes of Section 365(n) of the Bankruptcy Code. The parties agree that the
party holding the license from the other party may elect to retain and may fully
exercise all of its rights and elections under the Bankruptcy Code, PROVIDED
that it abides by the terms of this Agreement.

     (d) Each party, as applicable, shall mark or have marked all containers or
packages of Products, Shared Products or Independent Products that are the
subject of the license granted under this Section 3.1 in accordance with the
patent marking laws of the jurisdiction in which such products are manufactured,
used or sold.

     (e) Unless sooner terminated in accordance with Section 8.2, the license
under Section 3.1(a) with respect to Designated Screening Compounds, Derivative
Compounds thereof and Products will remain in effect on a compound-by-compound,
Product-by-Product and country-by-country basis until the LATER OF: (i) the
expiration or revocation or complete rejection (in the case of a patent
application) of the last to expire or to be revoked or to be completely rejected
(in the case of a patent application) of the NeoGenesis Patent Rights (including
those NeoGenesis Patent Rights assigned to Tularik pursuant to Section 3.2(d))
covering the Designated Screening Compounds, Derivative Compounds thereof or
corresponding Products, as the case may be, in such country or (ii) in the case
of a particular Product, [*] following the First Commercial Sale of such
Product.

     (f) Subject to the next succeeding sentence and the provisions of Section
8.4, unless sooner terminated in accordance with Section 8.2, the licenses under
Sections 3.1(a) and 3.1(b) with respect to Designated Shared Compounds,
Derivative Compounds thereof, Shared Products, Independent Compounds, Derivative
Compounds thereof and Independent Products will remain in effect on a
compound-by-compound, product-by-product and country-by-country basis until the
earlier to occur of the first date on which: (i) Net Sales on Shared Products
and

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

Independent Products, as the case may be, shall be [*]; and (ii) neither
party is then pursuing research, Pre-Clinical Development or Development of
the applicable Designated Shared Compound, Derivative Compound thereof,
Shared Product, Independent Compound, Derivative Compound thereof or
Independent Product, in each case using Commercially Reasonable Efforts. If
either party elects to terminate participation in the Pre-Clinical
Development or Development of any Designated Shared Compounds, Derivative
Compound thereof or Shared Product in accordance with Section 4A.14, any
license granted to the non-participating party with respect to the applicable
Designated Shared Compound, Derivative Compound thereof or Shared Product
shall terminate until such time (if any) as a party resumes participation in
the Pre-Clinical Development or Development of such Designated Shared
Compound, Derivative Compound thereof or Shared Product, in which case such
license shall revive and be of full force and effect with respect to such
Designated Shared Compound, Derivative Compound thereof or Shared Product
until terminated in accordance with the first sentence of this Section 3.1(f).

3.2  PROPRIETARY RIGHTS. (a) This Agreement does not convey to NeoGenesis any
rights in any Tularik Intellectual Property, Tularik Patent Rights or any
other intellectual property, patents or patent applications of Tularik by
implication, estoppel or otherwise except for the rights expressly granted in
Sections 2.5, 3.1 and 3.2(f). Title to the Tularik Intellectual Property,
Tularik Patent Rights and any other intellectual property, patents or patent
applications of Tularik shall at all times remain vested in Tularik. This
Agreement does not convey to Tularik any rights in any NeoGenesis
Intellectual Property, NeoGenesis Patent Rights or any other intellectual
property, patents or patent applications of NeoGenesis by implication,
estoppel or otherwise except for the rights expressly granted in Sections
2.5, 3.1, 3.2(d), 3.2(e) and 3.2(i). Subject to Section 3.2(i) and 3.2(d),
title to the NeoGenesis Intellectual Property, NeoGenesis Patent Rights and
any other intellectual property, patents or patent applications of NeoGenesis
shall at all times remain vested in NeoGenesis. Title to and any interest in
Program Intellectual Property described [*] (including corresponding Program
Patent Rights) shall be the property of NeoGenesis. Except as described in
the eighth sentence of this Section 3.2(a), title to and any interest in
Program Intellectual Property described in [*] (including corresponding
Program Patent Rights) shall be [*]. Title to and any interest in Program
Intellectual Property described in clause (c) of the Program Intellectual
Property definition (including corresponding Program Patent Rights) shall be
[*]. Notwithstanding any of the foregoing, Program Intellectual Property,
regardless of inventorship, shall be: [*].

     (b) If required, patent counsel mutually acceptable to the parties and
selected by the Steering Committee shall determine inventorship of all Program
Intellectual Property in accordance with U.S. patent law (and other U.S.
intellectual property law, if applicable).

     (c) NeoGenesis shall retain the following rights with respect to the
following NeoGenesis Intellectual Property and Program Intellectual Property
owned by NeoGenesis:

         (i) Subject to Sections 2.2(last sentence), 2.4, 2.8, 2.9, 3.1(a),
         3.2(a)(first two sentences), 3.2(c)(ii)(A), 3.2(f), 4A.2(a)(last
         sentence) and 5.2, NeoGenesis may continue to use its NeoMorph
         Screening Library to screen target proteins for other parties; and

         (ii) NeoGenesis shall retain all rights and may continue to use
         Preliminary Compounds created as part of the Screening Program but not
         selected as Primary Active Compounds and Primary Active Compounds not
         selected as Selected Compounds; provided, however, that such
         Preliminary Compounds and Primary Active Compounds (A) may not be used
         against the Targets and (B) shall only be used in the event and to the
         extent they result from use of the NeoMorph Screening Library to screen
         target proteins for other parties.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

     (d) In addition to the license granted under Section 3.1 with respect to
Licensed Technology, NeoGenesis hereby assigns and agrees to assign to
Tularik all of NeoGenesis' right, title and interest in those Designated
Screening Compounds designated by Tularik in accordance with Section 2.8.
Such assigned Designated Screening Compounds and the corresponding NeoGenesis
Patent Rights shall, from the date of assignment by NeoGenesis, be treated as
Tularik Patent Rights for purposes of this Agreement (including Section
3.3(c) and Section 3.4) and such assigned Designated Screening Compounds and
the corresponding NeoGenesis Intellectual Property shall, from the date of
assignment by NeoGenesis, be treated as Tularik Intellectual Property for
purposes of this Agreement (including Section 3.4). The date of assignment
with respect to the Designated Screening Compounds shall be the date Tularik
notifies NeoGenesis that a particular Selected Screening Compound has been
designated as a Designated Screening Compound and pays the fee for such
Designated Screening Compound specified in Section 4.3. Notwithstanding any
provision of this Agreement to the contrary, Tularik shall remain obligated
to pay NeoGenesis in respect of all such assigned Designated Screening
Compounds (and any Derivative Compounds thereof and any corresponding
Product(s)) the milestone fees and royalties due NeoGenesis under Section 4.4
and Section 4.5 of this Agreement until the earlier of (i) such time as [*],
or (ii) the LATER OF the expiration or revocation or complete rejection (in
the case of a patent application) of the last to expire or to be revoked or
to be completely rejected (in the case of a patent application) of the patent
rights within the assigned NeoGenesis Patent Rights in this Section 3.2(d)
covering such assigned Designated Screening Compounds (and any Derivative
Compounds thereof and any corresponding Product(s)) or [*] following the
First Commercial Sale of such Product(s).

     (e) If, during the term of the Agreement, NeoGenesis has or obtains any
patent or other proprietary right in any Program Intellectual Property (by
ownership or license) that could be asserted to prevent Tularik from
practicing the Tularik Intellectual Property or Program Intellectual Property
owned by Tularik to research, develop, have developed, make, have made, use,
distribute, promote, market, offer for sale, sell, have sold, import and
export compounds, NeoGenesis will grant Tularik a non-exclusive, worldwide,
perpetual license (or sublicense, as the case may be), with the right to
sublicense, to such patent or other proprietary right to the extent necessary
or useful to practice the license granted under Section 3.1 and Tularik will
[*]; provided, however, that the foregoing shall not be construed to grant
Tularik any license to utilize NeoGenesis' NeoMorph Screening Library, ALIS
or QSCD except as otherwise expressly set forth in this Agreement.

     (f) Tularik hereby grants NeoGenesis (i) an irrevocable, exclusive (except
as to Tularik as described below in this Section 3.2(f)), fully-paid, perpetual
license, including the right to grant sublicenses, to any Generic Rights for
which NeoGenesis or its employees and/or agents are the sole inventor, and (ii)
an irrevocable, co-exclusive, fully-paid, perpetual license, including the right
to grant sublicenses, to any Generic Rights for which NeoGenesis or its
employees and/or agents are joint inventors, except that in each case Tularik
will [*].

     (g) Neither party shall use Program Intellectual Property owned by the
other party or Confidential Information of the other party outside of the
performance of the Program or except as otherwise expressly permitted in this
Agreement.

     (h) Both parties agree that Program Intellectual Property does not include
work done by either party with respect to a particular Screening Target after
the Screening Program activities are completed with respect to such Screening
Target.

     (i) In the event that NeoGenesis has a patent, has filed a patent
application or files a patent application outside the Program that encompasses a
Designated Compound and/or any Derivative Compound and NeoGenesis is not
obligated to exclusively license or assign such patent or patent application to
a third party pursuant to another agreement in existence at the Effective Date,
NeoGenesis shall be deemed to be subject to an obligation to assign such patent
or patent application (or, where possible, the relevant portion thereof) to
Tularik without the payment of

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

any additional consideration by Tularik but subject to the license granted
NeoGenesis by Tularik under Section 3.2(f) (if applicable). Nothing in this
Section 3.2(i) shall, by implication or otherwise, absolve NeoGenesis of
liability for breach of its representation and warranty set forth in Section
6.2(b).

3.3  DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Tularik shall
promptly disclose to the other in writing any Invention that might, under the
applicable U.S. patent laws, be patentable and constitutes Program Intellectual
Property. Such Program Intellectual Property will be added to ATTACHMENT B.
Within forty five (45) days following the date of such disclosure regarding the
existence of particular Program Intellectual Property that is [*], the
parties shall confer and mutually agree as to appropriate protection for such
Program Intellectual Property, including an application, preparation,
prosecution and maintenance strategy. Notwithstanding the provisions of this
Section 3.3, neither party shall file any Program Patent Right relating to
Program Intellectual Property that is [*].

     (b) NeoGenesis shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at NeoGenesis' sole expense, each of the NeoGenesis
Patent Rights throughout the Territory. NeoGenesis shall promptly furnish or
have furnished to Tularik copies of all patents, patent applications,
substantive patent office actions, and substantive responses received or filed
in connection with such applications (other than patents and patent applications
covering solely NeoGenesis Intellectual Property that is not licensed to Tularik
under Section 3.1 or assigned to Tularik under Section 3.2(d) or 3.2(i)). In the
case of patent applications and responses, copies will be furnished to Tularik
at least fifteen (15) days before filing or mailing, as the case may be. Tularik
may itself or through its attorney offer comments and suggestions with respect
to the matters that are the subject of this Section 3.3(b) and NeoGenesis agrees
to consider such comments and suggestions; PROVIDED that nothing herein shall
obligate NeoGenesis to adopt or follow such comments or suggestions. Tularik
shall cooperate in the preparation, filing, prosecution and maintenance of any
and all patent applications and patents covering Program Intellectual Property
owned by NeoGenesis. NeoGenesis shall promptly provide notice to Tularik as to
all matters that come to its attention that may affect the preparation, filing,
prosecution or maintenance of any patents or patent applications covering
Program Intellectual Property owned by NeoGenesis. NeoGenesis shall not seek
patent protection for any NeoGenesis Intellectual Property or Program
Intellectual Property owned by NeoGenesis that covers generic claims to any
class of compounds developed in the course of the Program until: (i) with
respect to the Screening Program, the earlier of (A) such time as Tularik has
designated Designated Screening Compounds in respect of such class of compounds
in accordance with Section 2.8 or (B) such time as the period of time for such
designation expires with respect to the Selected Screening Compounds derived
from such class of compounds; and (ii) with respect to activities conducted
under Section 4A, the date in Section 4A.2 for each party's election of
Designated Shared Compounds. In the event that NeoGenesis elects not to file for
patent protection under the NeoGenesis Patent Rights or elects not to prosecute
or maintain a patent or patent application under the NeoGenesis Patent Rights it
shall notify Tularik of such decision at least forty five (45) days prior to the
due date of any action or payment due. Tularik shall then have the right, but
not the obligation, to assume the responsibility therefor at its own cost and
expense.

     (c) Tularik shall have the sole right, but not the obligation, to
prepare, file, prosecute, and maintain, at Tularik's sole expense (except as
provided below), each of the Tularik Patent Rights throughout the Territory.
Tularik shall promptly furnish or have furnished to NeoGenesis copies of all
patents, patent applications, substantive patent office actions and
substantive responses relevant to Generic Rights received or filed in
connection with such applications. In the case of such patent applications
and responses, copies will be furnished to NeoGenesis at least 15 days before
filing or mailing, as the case may be. NeoGenesis may itself or through its
attorney offer comments and suggestions with respect to the matters that are
the subject of this Section 3.3(c) relating to Generic Rights and Tularik
agrees to consider such comments and suggestions; PROVIDED that nothing
herein shall obligate Tularik to adopt or follow such comments or
suggestions. NeoGenesis shall be responsible for all costs relating to the
preparation, filing, prosecution and maintenance of any and all patent
applications covering Generic Rights for which NeoGenesis, its employees or
agents is the sole inventor and [*] of the costs relating to the preparation,
filing, prosecution and maintenance of any and all patent applications
covering Generic Rights for which NeoGenesis, its employees or agents are [*].
NeoGenesis shall cooperate in the preparation, filing, prosecution and
maintenance of any and all patent applications and patents covering Program
Intellectual Property owned by Tularik or obtained by Tularik under Section
3.2(d). Tularik shall promptly provide notice to NeoGenesis as to all matters
that come to its attention that may affect the preparation, filing,
prosecution or maintenance of any patents or patent applications covering
Program Intellectual Property owned by Tularik relating to Generic Rights.
Notwithstanding

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

the provisions of this Section 3.3, Tularik shall not file any patent
application covering the Generic Rights without NeoGenesis' prior written
consent, with respect to the Screening Program, before the date specified in
Section 2.8 for Tularik's notice of selection of Designated Screening Compounds
or, with respect to activities conducted under Section 4A, the date in Section
4A.2 for each party's election of Designated Shared Compounds.

3.4  ENFORCEMENT. (a) NeoGenesis shall be solely responsible for defense and
enforcement of (i) NeoGenesis Intellectual Property and NeoGenesis Patent Rights
and (ii) Program Intellectual Property owned by NeoGenesis, but in each case
excluding Licensed Technology. Tularik shall be solely responsible for the
defense and enforcement of (A) Tularik Intellectual Property and Tularik Patent
Rights and (B) Program Intellectual Property owned by Tularik.

     (b) Tularik shall have the first option to pursue any enforcement or
defense of Licensed Technology; PROVIDED, that [*], keeps NeoGenesis
reasonably informed of its progress and provides NeoGenesis with copies of
any substantive documents related to such proceedings and reasonable notice
of all such proceedings. [*]. Tularik shall notify NeoGenesis of its decision
to exercise its right to enforce or defend Licensed Technology as soon as
possible, but not later than [*] following its discovery or receipt of notice
of the alleged infringement.

     (c) If (i) Tularik notifies NeoGenesis that it will not exercise its
option to enforce or defend any Licensed Technology in accordance with
Section 3.4(b); (ii) Tularik and NeoGenesis have not otherwise agreed not to
pursue or defend against such infringement for business reasons; (iii)
Tularik has not persuaded the alleged infringer to desist or the person
alleging the infringement to forebear, (iv) Tularik is not diligently
pursuing an infringement action or diligently defending the validity or
enforceability of Licensed Technology at issue; or (v) Tularik has not
provided NeoGenesis with evidence of bona fide negotiations of an acceptable
sublicense agreement with the alleged infringer or person alleging
infringement, then NeoGenesis shall have the right to pursue the alleged
infringer or take control of any action initiated by, or being defended by,
Tularik [*]. In any such case, Tularik will, wherever possible under
Applicable Law, substitute NeoGenesis as party plaintiff for purposes of
pursuing any alleged infringer, or as defendant for defending any Licensed
Technology.

     (d) Any recovery of damages with regard to Licensed Technology in any
suit handled by one party pursuant to Section 3.4(b) or Section 3.4(c) shall
be applied first in satisfaction of any unreimbursed expenses and legal fees
of the party handling the suit or settlement thereof. The balance of any
recovery obtained by settlement or otherwise relating to Designated Screening
Compounds, Derivative Compounds thereof and Products shall be distributed: [*].
No settlement, consent judgment or other voluntary final disposition of any
suit regarding Licensed Technology may be entered into without the consent of
the other party, which consent shall not be unreasonably withheld.

     (e) Notwithstanding the provisions of Section 3.4(b), in the event that
a declaratory judgment action alleging invalidity or non-infringement of any
of the patents within Licensed Technology that are within NeoGenesis Patent
Rights covering the NeoMorph Screening Library, ALIS or QSCD is filed,
NeoGenesis shall have the first option, within sixty (60) days after
notification of same, to assume defense of the action concerning such patents
at its expense, but Tularik shall be entitled to participate in such action,
[*].

     (f) In any infringement suit as either party may institute to enforce
Licensed Technology, or in any declaratory judgment action alleging
invalidity or non-infringement of any Licensed Technology brought against
NeoGenesis or Tularik, the other party shall, at the request [*] of the party
initiating or defending the suit or action,

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

cooperate and assist in all reasonable respects, having its employees testify
when requested and making available relevant records, papers, information,
specimens and the like.

     (g) Notwithstanding any provisions of Section 3.4 to the contrary, each
party shall promptly give written notice to the other of any certification of
which it becomes aware filed pursuant to the Waxman-Hatch Act (21 U.S.C.
Sections 355(b)(2)(A), or Sections 355(j)(2)(A)(vii)), or any amendment or
successor statute thereto, at least fourteen (14) days prior to expiration of
the forty five (45) day period set forth in 21 U.S.C. Sections 355(c)(3)(c)
(or any amendment or successor statute thereto), then Tularik shall have the
right to bring such an infringement action, in its sole discretion [*], in
its own name and/or in the name of NeoGenesis. Any recoveries obtained (by
settlement or otherwise) by either party as a result of any proceeding
against a third party infringer brought under this Section 3.4(g) shall be
used to reimburse each party for all litigation costs in connection with such
proceeding paid by that party and any remainder: [*]. If Tularik or its
sublicensee initiate suit pursuant to this Section 3.4(g), it will promptly
notify NeoGenesis.

4.   PRICING; PAYMENT

4.1  TECHNOLOGY ACCESS FEE. (a) Upon initiation of the Expanded
Collaboration, Tularik will be obligated to pay NeoGenesis a technology
access fee comprised of [*] cash PLUS a loan to NeoGenesis of [*] in exchange
for a note convertible into NeoGenesis equity on the terms below (CONVERTIBLE
NOTE). Such technology access fee shall be payable in two (2) installments.
The first installment will be comprised of [*] loan in exchange for the
Convertible Note payable upon initiation of the Expanded Collaboration.
Initiation of the Expanded Collaboration will take place within [*] following
the date the Success Criteria are achieved or the date Tularik opts to move
forward with the Expanded Collaboration, regardless of achievement of the
Success Criteria. The second installment will be comprised of [*] payable
upon the earlier of (i) [*] and (ii) the [*]anniversary of initiation of the
Expanded Collaboration. The second installment will not be payable unless the
first installment has been paid.

     (b) The convertible debt portion of such technology access fee will be
made pursuant to a Convertible Note Purchase Agreement between the parties
and a Convertible Note will be issued by NeoGenesis to Tularik. The
Convertible Note Purchase Agreement and the Convertible Note will be in the
form of ATTACHMENT E and will contain the specific terms described below. The
Convertible Note will bear interest at [*] per annum and, unless converted as
set forth below, all principal and accrued interest shall be due and payable
on the fourth anniversary of the issuance of the Convertible Note. The
principal and any accrued interest under the Convertible Note shall either [*].

     (c) [*].

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

4.2  SCREENING FEE. Tularik shall pay NeoGenesis a fee of [*] for each
Screening Target screened pursuant to the Screening Program. Such fee shall
be payable in two (2) installments - the first installment of [*] at the time
such Screening Target is delivered to NeoGenesis and the second installment
of [*] within [*]of Completion of Screening; provided, however, that the
amount of the second installment shall be reduced for a particular Screening
Target by [*] if Completion of Screening does not occur within [*] following
delivery of such Screening Target to NeoGenesis. COMPLETION OF SCREENING
shall be deemed to occur upon delivery of Selected Screening Compounds for a
Screening Target to Tularik (or, if Tularik does not designate any Selected
Screening Compound(s) for such Screening Target within [*] of receipt of the
Final Target Report for such Screening Target, including any supplement
thereto as described in Paragraph 7 of ATTACHMENT A, then at the end of such
[*] period). No payment shall be due NeoGenesis under this Section 4.2 with
respect to Shared Targets.

4.3  SUCCESS PAYMENTS. For each Screening Target, Tularik shall pay NeoGenesis a
success payment of [*] if at least one Designated Screening Compound is
identified by Tularik that shows activity against such Screening Target such
that Tularik initiates a Medicinal Chemistry Effort with respect to such
Designated Screening Compound. Such payment shall be made within [*] after the
initiation of a Medicinal Chemistry Effort by Tularik; PROVIDED, that Tularik
has [*] after the date Tularik identifies the Designated Screening Compound for
such Screening Target to determine whether or not to initiate a Medicinal
Chemistry Effort for such Designated Screening Compound. No payment shall be due
NeoGenesis under this Section 4.3 with respect to Shared Targets.

4.4  MILESTONES. (a) Tularik will pay NeoGenesis milestone payments in respect
of the first Product that is active against each Screening Target as specified
in this Section 4.4.

          (i)     Within thirty (30) days following the date on which Tularik
                  [*] Tularik will pay NeoGenesis [*]. Tularik shall promptly
                  notify NeoGenesis of the decision to [*].

          (ii)    Within thirty (30) days following the date on which [*]
                  relating to such Product, Tularik will pay NeoGenesis [*].

          (iii)   Within thirty (30) days following the date on which [*]
                  relating to such Product, Tularik will pay NeoGenesis [*].

          (iv)    Within thirty (30) days following the date on which [*]
                  relating to such Product, Tularik will pay NeoGenesis [*].

          (v)     Within thirty (30) days following the date on which [*],
                  Tularik will pay NeoGenesis [*].

     (b) The milestones identified in Section 4.4(a)(i)-(v) shall be due only
for the first Product that is active against a particular Screening Target,
regardless of (i) the number of Products that are active against such Screening
Target that are identified by the Screening Program or developed and/or
Commercialized by Tularik, and (ii) the number of times a Product hits such
milestone (e.g., if different indications are pursued for the same Product);
PROVIDED, that if the first Product that is active against a Screening Target
does not achieve any milestone(s), such non-achieved milestones shall be paid on
any subsequent Product that is active against such Screening Target and that
achieves such milestone. On the date any one milestone with respect to a Product
is achieved, all lower numbered unachieved milestones shall be deemed to have
been achieved with respect to that Product and shall be paid (except to the
extent

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

they have previously been paid with respect to another Product active against
the relevant Screening Target). No milestone payments shall be due NeoGenesis
under this Section 4.4 with respect to Products that are active against Shared
Targets.

4.5  ROYALTIES. (a) [*] commencing with the First Commercial Sale of each
Product that is active against a Screening Target screened pursuant to the
Screening Program in any country, Tularik shall pay to NeoGenesis royalties on
a Product-by-Product and country-by-country basis for the most recent [*]
period then ended, equal to (i) [*] of the portion of aggregate annual Net
Sales of such Product that [*] and (ii) [*] of the portion of aggregate annual
Net Sales of such Product that [*]. Annual Net Sales will be calculated on a
calendar year basis. Tularik shall pay royalties with respect to each Product
on a country-by-country basis for so long as the license under Section 3.1 as
applicable to such Product remains in effect in such country.

     (b) If a Product is not covered by a Valid Claim and Tularik notifies
NeoGenesis that there is Substantial Competition in a country with respect to
such Product in a calendar year, the foregoing royalty rates shall be reduced
for Net Sales in such country [*]. In the event that NeoGenesis disputes
Tularik's characterization of a country as one in which Substantial Competition
exists, the parties shall confer to resolve such matter before resorting to
litigation.

     (c) If Tularik is required to make payments (including, without
limitation, royalties, option fees or license fees) to one or more third
parties to obtain licenses or similar rights under patents owned by a third
party to avoid infringement by any Designated Screening Compound, Derivative
Compound thereof or Product (or the Manufacture thereof) of such third
party(ies)' patent-protected technology, then Tularik may, beginning from the
date of such third party payments, deduct [*] of the amount of such third
party payments in any calendar quarter from the royalties payable to
NeoGenesis in such calendar quarter; provided that such deductions shall not
exceed [*] of the royalties otherwise payable to NeoGenesis in such calendar
quarter with respect to such Product.

     (d) In the event that Tularik utilizes any Product against a target
protein that is not a Screening Target or a Shared Target (such that
NeoGenesis is paid pursuant to the provisions of Sections 4.4 and 4.5(a) or
Section 4A.9 in respect of such Product), then Tularik shall pay NeoGenesis
milestones and royalties in respect of such Product as used against such
other target in accordance with the provisions of Sections 4.4 and 4.5(a) at
a rate equal to [*] of the applicable milestones and royalties specified in
Sections 4.4 and 4.5(a).

4.6  REMITTANCE. (a) Subject to Section 4.6(c), all royalties and milestone
payments required under this Section 4 and royalty payments required under
Sections 4A.18 and 4A.19 shall be payable in full in the United States in United
States Dollars, regardless of the countries in which sales are made. For the
purpose of computing Net Sales for which a currency other than United States
Dollars is received, such currency shall be converted into United States Dollars
at the simple average of all Mondays' exchange rate for buying United States
Dollars set forth in THE WALL STREET JOURNAL for the calendar quarter in which
such sales were made.

     (b) In the event that any payment due either party under this Agreement is
not made when due, the amount due shall accrue interest beginning on the fifth
day following the final date on which such payment was due, calculated at the
annual rate equal to the prime interest rate reported in the WALL STREET JOURNAL
for the due date, or, if lower, the maximum rate permitted by law, calculated
from the due date until paid in full. Such payment when made shall be
accompanied by all interest so accrued. Said interest and the payment and
acceptance thereof shall not negate or waive the right of the party to whom
payment is due to any other remedy, legal or equitable, to which it may be
entitled because of the delinquency of the payment.

     (c) If at any time legal restrictions within any country in the Territory
prevent the conversion of the local currency and such currency cannot be removed
from such country such that prompt remittance by the party owing a royalty of
any royalties owed in respect of sales in such country is prevented, the party
owing a royalty shall make payment through any lawful means or methods that may
be available as such party shall reasonably determine. If royalties in any
country cannot be remitted within three (3) months after the end of the relevant
royalty period, then the party owing a royalty shall pay the other party in the
local currency of such country by deposit of the relevant royalties in a bank
account in such country designated by the other party.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

4.7  RECORDS. Tularik, its Affiliates and sublicensees shall keep and
maintain for a period of at least [*] from the date of each payment of
royalties under Section 4.5, records (prepared in accordance with GAAP)
sufficient to determine the amounts of Net Sales and payments due under
Section 4.5. Within forty-five (45) days following each March 31, June 30,
September 30 and December 31 in which payments are due under Section 4.5,
Tularik shall provide NeoGenesis with a report including at least: (a) the
quantities of Products that Tularik, its Affiliate(s) and sublicensee(s) sold
during the preceding quarter in each country in which Products or bundled
products containing Products were sold; (b) the monetary amount, in the
national currency of such country, of such sales; (c) actual Net Sales, by
country; (d) the currency conversion rate used and U.S. dollar-equivalent of
such sales; (e) the calculation of royalties thereon; (f) the then aggregate
Net Sales for each Product for the applicable calendar year; and (g) the
total royalties so computed and due NeoGenesis. Upon delivery of the report
due for the period ending December 31 of each year, Tularik shall also report
to NeoGenesis the aggregate royalties due NeoGenesis for the entire preceding
year.

4.8  INSPECTION. Tularik and its Affiliates shall, and Tularik shall provide
in any agreements with any sublicensees that such sublicensees shall, each
make its records available for inspection by an independent certified public
accountant, mutually agreed to by NeoGenesis and Tularik, during regular
business hours at such place or places where such records are customarily
kept, upon reasonable notice from NeoGenesis, to verify the accuracy of the
reports and payments required under this Section 4. Such inspection right
shall not be exercised more than [*] in any calendar year nor more than [*]
with respect to sales of Products in any given payment period. NeoGenesis
agrees to hold in confidence all information concerning royalty payments and
reports, and all information learned in the course of any inspection, except
to the extent necessary for NeoGenesis to reveal such information in order to
enforce its rights under this Agreement in a proceeding in accordance with
Section 9.1 or if disclosure is required by law, regulation or judicial
order. Any person or entity conducting such inspection will agree in writing
with NeoGenesis to treat all records reviewed in the course of the inspection
as the Confidential Information of Tularik under terms and conditions no less
restrictive than the terms contained in Section 5.2. The results of each
inspection shall be binding on both parties absent mathematical error.
NeoGenesis shall pay for such inspections, except that in the event there is
any upward adjustment in aggregate royalties payable for any year shown by
such inspection of more than [*] of the amount paid, Tularik shall pay for
such inspection.

4.9  TAXES. If, at any time, any jurisdiction within the Territory requires the
withholding of income taxes or other taxes imposed upon payments set forth in
this Section 4, Tularik shall make such withholding payments as required and
subtract such withholding payments from the payments to be made to NeoGenesis as
set forth in this Section 4, or, if applicable, NeoGenesis will reimburse
Tularik or its designee(s) for the amount of such withholding payments that are
not subtracted from the payments made to NeoGenesis as set forth in this Section
4, within fifteen (15) days of notice to NeoGenesis. Tularik shall provide
NeoGenesis with documentation of such withholding and payment in a manner that
is satisfactory for purposes of reporting to the U.S. Internal Revenue Service.
Any withholdings paid when due hereunder shall be for the account of NeoGenesis.
Withholding payments made by Tularik pursuant to this Section 4.9 shall be made
based upon financial information provided to Tularik by NeoGenesis, and to the
extent that such information is incorrect, NeoGenesis shall be liable for any
deficiency, and any fine, assessment or penalty imposed by any taxing authority
in the Territory for any deficiency in the amount of any such withholding or the
failure to make such withholding payment. If Tularik is required to pay any such
deficiency, or any fine, assessment or penalty for any such deficiency,
NeoGenesis shall promptly reimburse Tularik for such payments, within fifteen
(15) days of notice to NeoGenesis. The parties will cooperate to minimize, to
the extent legally permissible, the tax liabilities related to this Agreement.
Notwithstanding the foregoing, such cooperation shall not cause any adverse tax
consequences to be incurred by either party which would not have otherwise been
incurred under the provisions of this Agreement, including this Section 4.9.

4A.  SHARED TARGET OBLIGATIONS

4A.1 IDENTIFICATION OF DESIGNATED SHARED COMPOUND CANDIDATES BY STEERING
COMMITTEE. (a) Within [*] following the delivery of Selected Shared Compounds
for a particular Shared Target in accordance with ATTACHMENT A and completion of
optimization, if any, performed on Selected Shared Compounds for such Shared
Target in accordance with ATTACHMENT A, either party may propose to the Steering
Committee one or more Selected Shared Compounds or compounds arising out of
optimization (if any) for such Shared Target as candidates to become

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

Designated Shared Compounds. The Steering Committee will promptly determine
whether each such Selected Shared Compound is a suitable candidate for
Pre-Clinical Development.

     (b) Within [*] following receipt of notification from the Steering
Committee identifying candidates to become Designated Shared Compounds,
NeoGenesis shall amend ATTACHMENT D to identify any applicable NeoGenesis Patent
Rights not previously identified to the Steering Committee.

4A.2 ACCEPTANCE OF DESIGNATED SHARED COMPOUNDS. (a) If the Steering Committee
determines that a Selected Shared Compound is suitable for Pre-Clinical
Development, then, within [*] of such determination, each party shall provide to
the Steering Committee a written notice as to whether it elects to participate
in and, subject to Section 4A.8, commit resources to conduct, Pre-Clinical
Development and, if warranted based on the outcome of Pre-Clinical Development
activities, Development of such Selected Shared Compound pursuant to the
Development Plan and Development Budget. If both parties make an affirmative
election with respect to any Selected Shared Compound pursuant to this Section
4A.2, then such Selected Shared Compound shall become a DESIGNATED SHARED
COMPOUND. Thereafter, such Designated Shared Compounds will be subject to the
licenses granted pursuant to Section 3.1 and shall no longer be available to
NeoGenesis or any third party in any NeoGenesis compound library, including its
NeoMorph Screening Library, or in any other manner.

     (b) If the Steering Committee determines that a Selected Shared Compound is
not suitable for Pre-Clinical Development, then, within [*] of such
determination, each party shall provide to the Steering Committee a written
notice as to whether it elects to designate such Selected Shared Compound as a
Designated Shared Compound and participate in, and commit resources to conduct,
Pre-Clinical Development of such Selected Shared Compound, notwithstanding that
the Steering Committee has determined that such Selected Shared Compound is not
suitable for Pre-Clinical Development. If both parties make an affirmative
election with respect to whether any Selected Shared Compound shall be
designated a Designated Shared Compound as set forth in Section 4A.2(a), such
Selected Shared Compound shall become a Designated Shared Compound. If one party
makes an affirmative election and the other party makes a negative election with
respect to whether any Selected Shared Compound shall be designated a Designated
Shared Compound, the party making an affirmative election will have the right to
proceed independently to develop such compound as an Independent Compound or
Independent Product under Section 4A.15.

4A.3 DISCONTINUED COMPOUNDS. If neither party makes an affirmative election
with respect to any Selected Shared Compound being designated a Designated
Shared Compound pursuant to Section 4A.2, such Selected Shared Compound shall
be neither a Designated Shared Compound nor a compound that may be developed
under Section 4A.15, and Development of products based upon such non-elected
Selected Shared Compound (a DISCONTINUED COMPOUND) may only be subsequently
initiated by a party by notifying the other party of its interest in
initiating Pre-Clinical Development of such Discontinued Compound at any time
on or before [*]. If the other party indicates it is not interested in
participating in, and committing resources to, conduct Pre-Clinical
Development of such Discontinued Compound, the initiating party, upon notice
to the other party, may proceed with Pre-Clinical Development and Development
of such Discontinued Compound as an Independent Compound or an Independent
Product and the initiating party shall be deemed to be the Independent Party
therefor, as provided in Section 4A.15. If the other party indicates it is
interested in participating in and committing resources to conduct
Pre-Clinical Development of such Discontinued Compound, such Discontinued
Compound shall be designated as a Designated Shared Compound as set forth in
Section 4A.2(a). At any time after [*], either party may, upon written notice
to the other party, proceed with Pre-Clinical Development and Development of
a Discontinued Compound as an Independent Compound or an Independent Product,
and such party shall be deemed to be the Independent Party therefor, as
provided in Section 4A.15.

4A.4 NON-PROPOSED COMPOUNDS. If a Selected Shared Compound is not, at any
time, presented to the Steering Committee pursuant to Section 4A.1 (a
NON-PROPOSED COMPOUND), such Selected Shared Compound shall be neither a
Designated Shared Compound nor a compound that may be developed under Section
4A.15. If at any time on or before [*], a party hereunder (the NON-PROPOSED
COMPOUND INTERESTED PARTY) decides to initiate Pre-Clinical Development of
such Non-Proposed Compound, it shall provide written notice to the other
party of such interest and the reasons therefor. The other party will then
have [*] to indicate whether it also is interested in participating in and
committing resources to conduct Pre-Clinical

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

Development of such Non-Proposed Compound. If the other party is so
interested, such Non-Proposed Compound shall be designated a Designated
Shared Compound as set forth in Section 4A.2(a). If the other party is not so
interested, the Non-Proposed Compound Interested Party may proceed with
Pre-Clinical Development and Development of such Non-Proposed Compound as an
Independent Compound or an Independent Product and the Non-Proposed Compound
Interested Party shall be deemed to be the Independent Party therefor, as
provided in Section 4A.15. At any time after [*], either party may, upon
written notice to the other party, proceed with Pre-Clinical Development and
Development of a Non-Proposed Compound as an Independent Compound or an
Independent Product, and such party shall be deemed to be the Independent
Party therefor, as provided in Section 4A.15.

4A.5 PRE-CLINICAL DEVELOPMENT OF DESIGNATED SHARED COMPOUNDS. The parties, under
the direction of the Steering Committee, shall diligently conduct Pre-Clinical
Development with respect to any Designated Shared Compound in accordance with
the Development Plan. Unless otherwise agreed by the parties, each party shall
supply fifty percent (50%) of the total Pre-Clinical Development effort for each
Designated Shared Compound in the aggregate, as determined by the Steering
Committee. The costs of conducting such Pre-Clinical Development shall be shared
by the Parties as set forth in Section 4A.8.

4A.6 DEVELOPMENT OF SHARED PRODUCTS. The parties will use Commercially
Reasonable Efforts to conduct the Development of Shared Products in accordance
with the Development Plan. The role of each party in the Development process
will be determined by the Steering Committee as described in Section 4A.7, with
the parties intending that each party will provide advisory and supporting
services with respect to any phase of the process in which such party is not
actively or primarily involved. Unless otherwise agreed by the parties, each
party shall supply fifty percent (50%) of the total Development effort for each
Shared Product in the aggregate, as determined by the Steering Committee. The
costs of conducting such Development shall be shared by the Parties as set forth
in Section 4A.8. The Steering Committee will determine appropriate written
standards for measuring each party's required efforts and accounting procedures
to confirm and document each party's performance of its required efforts for any
Shared Product before the parties commence Development thereof. No clinical
trials involving any Shared Product shall be commenced by or on behalf of either
party without the prior approval of the Steering Committee. Nothing contained in
this Section 4A.6 shall be deemed to preclude either party from terminating its
participation in the collaborative Development of a Shared Product pursuant to
Section 4A.14. Any decision by a party not to participate in Development of a
Shared Product pursuant to Section 4A.2, 4A.3 or 4A.4 or to terminate
participation in the Development of a Shared Product pursuant to Section 4A.14,
shall not be deemed a breach of this Agreement. The parties will conduct
Pre-Clinical Development, Development, Manufacturing and Commercialization
activities in a manner calculated to minimize aggregate Development Costs for
such Shared Compound and Shared Product consistent with the Development Plan and
the Development Budget for such Shared Compound and Shared Product.

4A.7 DEVELOPMENT PLAN AND DEVELOPMENT BUDGET. Promptly following acceptance
of a Designated Shared Compound, the Steering Committee, which, for this
purpose and for the purposes set forth in Sections 4A.8-4A.10 and 4A.23,
shall also include an equal number of financial personnel from each party,
shall initiate preparation of the development plan for the Pre-Clinical
Development and Development of such Designated Shared Compound and
Development of any resulting Shared Product (the DEVELOPMENT PLAN) and a
budget (the DEVELOPMENT BUDGET) for proposed Development Costs therefor. The
initial Development Plan for a Designated Shared Compound shall set time
lines and priorities for the various Pre-Clinical Development and Development
activities [*], is to be responsible for each activity. The Development
Budget shall include a detailed short-term budget covering all proposed
Development Costs of the Development Plan expected during the initial [*] of
implementation of the Development Plan. Each Development Plan and Development
Budget shall be approved by the Steering Committee [*]. Both parties
recognize that the Development Plan and the Development Budget represent
projections only and will be subject to frequent changes during the
Pre-Clinical Development and Development process. Each such Development Plan
and Development Budget shall be updated as deemed appropriate by the Steering
Committee, but in no event less frequently than [*], and approved, [*], by
the Steering Committee not later than [*] prior to each [*] and [*] of each
applicable calendar year.

4A.8 FUNDING OF PRE-CLINICAL DEVELOPMENT AND DEVELOPMENT. Tularik shall be
responsible for fifty percent (50%) of the Development Costs and NeoGenesis
shall be responsible for the remaining fifty percent (50%) of

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

Development Costs for each Designated Shared Compound, Derivative Compound
thereof and resulting Shared Product throughout the Territory. In the event the
Development Costs incurred by a party during any calendar quarter exceed [*] of
the Development Costs set forth in the most recently approved Development Budget
for activities to be conducted by such party during such quarter (the OVERAGE
THRESHOLD), then the other party shall not be responsible for paying its fifty
percent (50%) share of any Development Costs in excess of the Overage Threshold
incurred by the party triggering such overage unless such overage had been
approved in advance, or is subsequently ratified, [*], by the Steering Committee
(in which case each of the parties shall be responsible for fifty percent (50%)
of all such Development Costs). In the event such overage has not been approved
or ratified [*] by the Steering Committee, the party incurring Development Costs
in a calendar quarter exceeding the Overage Threshold in such quarter shall be
responsible for all of the portion of the Development Costs in excess of the
Overage Threshold.

4A.9 FTE RATE. In preparing the Development Budget and determining Development
Costs, each party will use an FTE rate for such party's development personnel
mutually agreed to by the parties based on the then prevailing FTE rate for such
party.

4A.10 PAYMENT OF DEVELOPMENT COSTS. Within thirty (30) days after each calendar
quarter, each party shall provide the Steering Committee with detailed
information concerning the Development Costs incurred by such party during such
quarter pursuant to the Development Plan and the Development Budget. Promptly
after receipt thereof, the Steering Committee will determine the amount, if any,
that either party has paid in excess of the amount to be borne by such party for
such quarter pursuant to Section 4A.8, and shall so notify the parties. In the
event of an overpayment by a party of its share of Development Costs in a
particular calendar quarter, the other party shall pay to the party making the
overpayment the amount by which such other party underpaid within thirty (30)
days after the underpaying party's receipt of notice from the Steering Committee
that an overpayment has occurred.

4A.11 REGULATORY APPROVALS. Consistent with the Development Plan and Development
Budget and as directed by the Steering Committee, the parties (or their
Affiliates) will (a) prepare and file all documents that are necessary to
conduct clinical studies of Shared Products in connection with the Development
Plan and (b) use Commercially Reasonable Efforts to file applications for
Regulatory Approvals required before commercial sale or use of a Shared Product
as a drug in a country within the Territory and obtain Regulatory Approvals in
each country in the Territory in which the parties, either individually or
jointly, intend to Commercialize Shared Products in accordance with the
Development Plan. The Steering Committee will be responsible for designating a
party by unanimous agreement to be responsible for filing all regulatory
submissions in each country in the Territory in which Shared Products will be
Commercialized. The party not responsible for filing regulatory submissions for
a Shared Product in a country pursuant to this Agreement shall have a right to
cross-reference to all such filings made by the other party for such Shared
Product in any country. The parties will cooperate in the preparation of all
such regulatory filings and in obtaining Regulatory Approvals under this Section
4A.11, including without limitation providing access to each party's data and
information obtained under the Program and the Development Plan to the extent
necessary for obtaining Regulatory Approvals of Shared Products.

4A.12 LINE EXTENSIONS. NeoGenesis and Tularik may each prepare and submit to the
Steering Committee for consideration plans for Development of Shared Product
line extensions and the conduct of clinical trials covering indications other
than those for which Shared Products are then being Developed or Commercialized
in the Territory. Any such line extensions or any additional clinical trials for
additional indications will be subject to the approval and supervision of the
Steering Committee as part of the ongoing Development of such Shared Product.

4A.13 THIRD PARTY TECHNOLOGY; CONSENTS TO CERTAIN SUBLICENSES. If either party
becomes aware of (i) an opportunity to participate in research with a third
party that could advance the Pre-Clinical Development of a Designated Shared
Compound or Derivative Compound thereof or the Development of a Shared Product;
or (ii) an opportunity to obtain a license or other right owned or controlled by
a third party relating to the Manufacture, marketing, import, use or sale of a
Shared Product, it shall so notify the other party and the Steering Committee
will determine whether to pursue such opportunity. In the event that the parties
pursue such opportunity under subsection (i), they shall grant appropriate
licenses or sublicenses, as applicable, to such third party solely to perform
the tasks designated and approved by the Steering Committee for such third party
and provide for confidentiality and non-use obligations, and for ownership of or
licenses under such third party's inventions and related intellectual property
rights arising in the course of work performed by such third party pursuant to
this Agreement consistent with those

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

provided in the applicable provisions of this Agreement. If the parties, in
connection with any opportunity described in subsection (i) or (ii), incur
obligations to make payments to a third party, such payments shall be included
in the calculation of Expenses or Development Costs, as the case may be, of the
party making such payment. Neither party shall enter into any sublicense under
which such party shall receive any consideration from the relevant sublicensee
in the form of an equity investment in, or as a loan to, such party without the
other party's prior written consent, not to be unreasonably withheld.

4A.14 TERMINATION OF PARTICIPATION IN COLLABORATIVE DEVELOPMENT. (a) Either
party may elect, on a Designated Shared Compound-by-Designated Shared
Compound, Derivative Compound thereof-by-Derivative Compound thereof or
Shared Product-by-Shared Product basis, as the case may be, to terminate its
participation in, or to not participate in, the Pre-Clinical Development of a
given Designated Shared Compound or Derivative Compound thereof or
Development of a given Shared Product based upon or incorporating such
Designated Shared Compound or Derivative Compound thereof by written notice
to the other party: (i) [*] for such Designated Shared Compound or Derivative
Compound thereof; (ii) during the period commencing upon receipt by such
party of final reports covering all aspects of [*] for such Shared Product
and [*]; or (iii) during the period commencing [*] for such Shared Product
and ending [*]. After receipt of such notice by the other party in accordance
with this Section 4A.14, the party providing such notice shall no longer be
responsible for bearing further Development Costs for such Designated Shared
Compound or Derivative Compound thereof or Shared Product pursuant to Section
4A.8 (except as set forth in the next succeeding sentence), in which event
the other party will have the right to proceed independently to Develop such
Designated Shared Compound or Derivative Compound thereof or Shared Product
as an Independent Compound or Independent Product, and the party continuing
such Development shall thereafter be deemed to be the Independent Party
therefor, as provided in Section 4A.15. In the event a party gives notice
under this Section 4A.14, such non-Independent Party (i) will remain
responsible for its share of Development Costs for such Designated Shared
Compound or Derivative Compound thereof or Shared Product until [*], and (ii)
will make its personnel, relevant data and other resources available to the
Independent Party as necessary to effect an orderly transition of
Pre-Clinical Development and Development responsibilities, with the costs of
such personnel, relevant data and resources to be [*] a notice under this
Section 4A.14. In the event of a party's termination of participation in
Pre-Clinical Development or Development of a Designated Shared Compound or
Derivative Compound thereof or Shared Product in accordance with this Section
4A.14, such party shall [*] to the Independent Party all Regulatory Approval
submissions, including all applications relating to such Designated Shared
Compound, Derivative Compound thereof and/or Shared Products based upon or
incorporating such Designated Shared Compound or Derivative Compound thereof,
together with all materials and data related thereto in its possession.

     (b) If, at any time during Pre-Clinical Development or Development
activities, both parties elect, on a Designated Shared Compound-by-Designated
Shared Compound basis, Derivative Compound thereof-by-Derivative Compound
thereof basis or a Shared Product-by-Shared Product basis, as the case may be,
to terminate Pre-Clinical Development of a Designated Shared Compound or
Derivative Compound thereof or to terminate Development of a Shared Product, the
parties shall confer and mutually agree on a plan for seeking a purchaser for
the Designated Shared Compound, Derivative Compound thereof or Shared Product,
as applicable.

4A.15 INDEPENDENT DEVELOPMENT. (a) In the event (i) a party, pursuant to
Sections 4A.2, 4A.3, 4A.4 or 4A.14, elects not to, or does not, participate in
and commit resources to the pre-clinical development of a Selected Shared
Compound as a Designated Shared Compound, or the pre-clinical development of a
Discontinued Compound or a Non-Proposed Compound, or (ii) any party unilaterally
terminates its participation in the Pre-Clinical Development or Development of a
Designated Shared Compound, Derivative Compound thereof or Shared Product
pursuant to Section 4A.14, then the party that either made an affirmative
election to conduct such Pre-Clinical Development of such Selected Shared
Compound, or the pre-clinical development of a Discontinued Compound or a
Non-Proposed Compound, or is continuing Pre-Clinical Development or Development
of a Designated Shared Compound, Derivative Compound thereof or Shared Product
(in either case, the INDEPENDENT PARTY), shall have the right to practice the
licenses granted in Section 3.1 and to undertake pre-clinical development of a
Selected Shared

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

Compound, Discontinued Compound or Non-Proposed Compound or to continue
Pre-Clinical Development and Development of such Designated Shared Compound,
Derivative Compound thereof or Shared Product independently as an INDEPENDENT
COMPOUND or INDEPENDENT PRODUCT, [*]. Subject to reinstatement pursuant to
exercise of its Re-Engagement Option set forth in Section 4A.16, the
non-Independent Party's license under Section 3.1 shall be terminated with
respect to such Independent Compound or Independent Product. Neither party
may charge the services of its personnel or any third party to research or
develop an Independent Compound, Derivative Compound thereof or Independent
Product to the other party.

     (b) Until the earlier of the Re-Engagement Expiration Date or the date on
which the Independent Party receives a Re-Engagement Notice for an Independent
Compound, Derivative Compound thereof or an Independent Product from the
non-Independent Party, the Independent Party will (i) inform the other party of
all material information developed in its research and development of each
Independent Compound, Derivative Compound thereof or Independent Product; and
(ii) provide the other party a copy of all proposed regulatory submissions
relating to such Independent Compound, Derivative Compound thereof or
Independent Product at least thirty (30) days prior to submitting such filing to
the applicable Regulatory Authority.

     (c) In the event either party elects to proceed as an Independent Party,
subject to Section 4A.16, such Independent Party shall be entitled to develop
such Independent Compound or any Derivative Compound thereof and Commercialize
such Independent Product at its sole discretion, alone or with a third party
(subject to Section 4A.15(d)), with no obligation to the other party other than
the payment of royalties in accordance with Sections 4A.18 or 4A.19 and those
obligations imposed under Sections 4.6 and 4A.21.

     (d) The Independent Party may not sublicense any intellectual property
rights to the extent such right is necessary or useful to research, Develop,
have Developed, make, have made, use, distribute, promote, market, offer for
sale, sell, have sold, import and export an Independent Compound, Derivative
Compound thereof or Independent Product to any third party without the consent
of the non-Independent Party prior to the Re-Engagement Expiration Date for such
Independent Compound, Derivative Compound thereof or Independent Product.

     (e) If either party terminates its research, Development or
Commercialization of an Independent Compound, Derivative Compound thereof or an
Independent Product, then (i) it shall promptly so notify the other party, (ii)
such compound shall no longer be an Independent Compound, Derivative Compound
thereof and such product shall no longer be an Independent Product; (iii) the
licenses granted to such Independent Party by the non-Independent party for such
compound or product shall terminate upon such other party's receipt of such
notice; and (iv) the parties will confer and mutually agree on a plan for
seeking a purchaser for such Independent Compound, Derivative Compound thereof
or Independent Product, as applicable.

4A.16 RE-ENGAGEMENT OPTION. (a) Either party may elect to resume its
participation in the Pre-Clinical Development or Development of an
Independent Compound, Derivative Compound thereof or Independent Product
throughout the Territory by so notifying the Independent Party for such
Independent Compound, Derivative Compound thereof or Independent Product (the
RE-ENGAGEMENT NOTICE), at any time prior to the expiration of the [*] period
[*] (RE-ENGAGEMENT EXPIRATION DATE) for such Independent Compound, Derivative
Compound thereof or Independent Product. If a party so elects to resume
participation hereunder, such Independent Compound, Derivative Compound
thereof or Independent Product shall immediately cease to be an Independent
Compound, Derivative Compound thereof or Independent Product, as applicable,
and shall instead be designated a Designated Shared Compound or Shared
Product for all purposes under this Agreement, including but not limited to
calculating each party's responsibility for paying Development Costs and
Expenses and receiving the Share of Profit commencing upon and continuing
after the Independent Party's receipt of the Re-Engagement Notice.

     (b) If a party provides a Re-Engagement Notice pursuant to Section
4A.16(a), then such party shall pay to the Independent Party [*] of the
non-Independent Party's share, based on the allocation set forth in Section
4A.8, of the costs of Pre-Clinical Development and Development of the
Independent Compound, Derivative Compound thereof or Independent Product
incurred by the Independent Party after the date upon which it commenced
Pre-Clinical Development or Development of such compound or product as an
Independent Compound or Independent Product and prior to the date of the
Re-Engagement Notice, calculated as if such Independent Compound or Derivative

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

Compound thereof had been a Designated Shared Compound or such Independent
Product had been a Shared Product during such period of Pre-Clinical Development
and Development by the Independent Party therefor (the RE-ENGAGEMENT AMOUNT). In
calculating such amounts, the parties will use the FTE rate as set forth in
Section 4A.9. The non-Independent Party shall pay the Re-Engagement Amount in
[*] beginning on the [*] following the date upon which the Independent Party
receives the relevant Re-Engagement Notice.

4A.17 PROFITS AND LOSSES. Each party's SHARE OF PROFIT shall equal fifty percent
(50%) of all Shared Product Profits for all Shared Products sold in the
Territory, and each party's SHARE OF LOSS shall equal fifty percent (50%) of all
Shared Product Losses for all Shared Products sold in the Territory. Each party
shall be responsible for its Share of Loss and shall be entitled to receive its
Share of Profits. Each party shall also receive fifty percent (50%) of all
Sublicense Revenues in the Territory, which sublicense agreements shall conform
to the requirements of Section 4A.13. Shared Product Profits, Shared Product
Losses and Sublicense Revenues shall be determined and paid as set forth in
Section 4A.22.

4A.18 ROYALTIES PAYABLE ON SALES OF INDEPENDENT PRODUCTS AFTER REVOCATION OF
COMMERCIALIZATION RIGHTS. In the event a party elects to terminate its
participation in the Commercialization of a Shared Product in a country or
countries in the Territory pursuant to Section 4A.23(d), the parties shall
negotiate in good faith for a period of [*] following the non-terminating
party's receipt of such notice to determine the appropriate royalty to be paid
on Net Sales of such Shared Product as an Independent Product by the other party
as an Independent Party in such country or countries. In the event the parties
are unable to agree on the appropriate royalty pursuant to the immediately
preceding sentence, the Independent Party with respect to such Independent
Product shall pay to the other party a royalty on annual Net Sales of such
Independent Product in each such country in the Territory pursuant to Section
4A.19, except that the applicable royalty shall be: [*] of the portion of
aggregate annual Net Sales of such Independent Product in such country that is
[*] of the portion of annual aggregate Net Sales of such Independent Product in
such country that is [*]; and [*] of the portion of annual aggregate Net Sales
of such Independent Product in such country that is [*]. Such royalty will be
payable on [*] in respect of each country in which sales of such Shared Product
occur and in which a party has elected to terminate its participation in the
Commercialization of such Shared Product until the expiration of the license
granted to the non-terminating party under Section 3.1 with respect to such
Shared Product. Such royalty is subject to offsets as provided in the last
sentence of Section 4A.19.

4A.19 ROYALTIES PAYABLE BY THE INDEPENDENT PARTY OTHER THAN IN THE EVENT OF
REVOCATION OF PROMOTION RIGHTS. Except as otherwise provided in Section 4A.18,
the Independent Party will pay the non-Independent Party, in lieu of any Share
of Profits, a royalty on Net Sales of each Independent Product equal to:
     (a) [*] of Net Sales of such Independent Product if the non-Independent
         Party did not participate, or terminates its participation, in the
         Pre-Clinical Development of the relevant compound [*];
     (b) [*] of Net Sales of such Independent Product if the non-Independent
         Party terminates its participation in the Development of the relevant
         Designated Shared Compound pursuant to Section 4A.14 [*] but prior
         to the [*];
     (c) [*] of Net Sales of such Independent Product if the non-Independent
         Party terminates participation in the Development of the relevant
         Shared Product pursuant to Section 4A.14 [*]; or
     (d) [*] of Net Sales of such Independent Product if the non-Independent
         Party terminates participation in the Development of the relevant
         Shared Product pursuant to Section 4A.14 [*].

Such royalty shall be payable [*] in respect of each country in which sales
of such Independent Product occur until the expiration of the license granted
the Independent Party under Section 3.1 with respect to such Independent
Product. The Independent Party may offset [*] of any royalties it must pay to
third parties pursuant to any licenses necessary to Manufacture and
Commercialize Independent Products against royalties payable by the
Independent Party to the non-Independent Party; PROVIDED, HOWEVER, that in no
event shall the royalties payable by the Independent Party to the
non-Independent Party be reduced to less than [*] of the amounts that would
have otherwise been due under the percentages set forth in this Section 4A.19
or Section 4A.18, as applicable.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       29
<Page>

4A.20 TAXES. The burden of paying all withholding or similar taxes that may be
imposed by any governmental authority on royalty and Share of Profit payment
amounts provided in this Section 4A with respect to Shared Products shall be
shared equally by Tularik and NeoGenesis. The burden of paying all withholding
or similar taxes that may be imposed by any governmental authority on royalty
payment amounts provided in this Section 4A with respect to Independent Products
shall be paid by the party receiving such royalty, and the party making such
royalty payment shall make such withholding payments as required and subtract
such withholding payments from the payments to be made to the other party in
respect of such Independent Products, or, if applicable, the party receiving
such royalty payment will reimburse the other party or its designee(s) for the
amount of such withholding payments that are not subtracted from the payments
made to the party receiving such royalty payment as set forth in this Section
4A.20, within fifteen (15) days of notice from the party making such royalty
payment in respect of Independent Products. The party that makes any such
withholding payment shall provide the other party with documentation of such
withholding and payment in a manner that is satisfactory for purposes of
reporting to the U.S. Internal Revenue Service. Any withholdings paid when due
hereunder shall be for the account of the party receiving such royalty payment.
Withholding payments made by the party making such royalty payment in respect of
Independent Products pursuant to this Section 4A.20 shall be made based upon
financial information provided to such party by the party receiving such royalty
payment, and to the extent that such information is incorrect, the party
receiving such royalty payment shall be liable for any deficiency, and any fine,
assessment or penalty imposed by any taxing authority in the Territory for any
deficiency in the amount of any such withholding or the failure to make such
withholding payment. If the party making such royalty payment is required to pay
any such deficiency, or any fine, assessment or penalty for any such deficiency,
the party receiving such royalty payment shall promptly reimburse it for such
payments, within fifteen (15) days of notice to the party receiving such royalty
payment. The parties will cooperate to minimize, to the extent legally
permissible, the tax liabilities related to this Agreement. Notwithstanding the
foregoing, such cooperation shall not cause any adverse tax consequences to be
incurred by either party which would not have otherwise been incurred under the
provisions of this Agreement, including this Section 4A.20.

4A.21 RECORDS AND INSPECTION. (a) NeoGenesis and Tularik and, if applicable,
their respective Affiliates and sublicensees, each shall keep accurate books and
accounts of record (prepared in accordance with GAAP) in connection with the
Pre-Clinical Development, Development, Manufacture and/or Commercialization by
or for such party of all Designated Shared Compounds, Derivative Compounds
thereof, Shared Products, Independent Compounds, Derivative Compounds thereof
and Independent Products in the Territory in sufficient detail to permit
accurate determination of all figures necessary for verification of Development
Costs, royalties, Shared Product Profits, Shared Product Losses, Sublicense
Revenues, Expenses and other compensation required to be paid or expenses
required to be shared hereunder. NeoGenesis and Tularik shall maintain such
records for a period of three (3) years after the end of the year in which such
records were generated.

     (b) Each party and, if applicable, its Affiliates shall, and shall
provide in any agreements with any sublicensees that such sublicensees shall,
make such records available for inspection by an independent certified public
accountant, mutually agreed to by the inspecting party and the party being
inspected, during regular business hours at such place or places where such
records are customarily kept, upon reasonable notice from the inspecting
party, to verify the accuracy of the reports and any compensation required to
be paid or expenses required to be shared hereunder. Such inspection right
shall not be exercised more than once in any calendar year. The inspecting
party agrees to hold in confidence all information concerning payments,
expenses and reports, and all information learned in the course of any
inspection, except to the extent necessary for the inspecting party to reveal
such information in order to enforce its rights under this Agreement in a
proceeding in accordance with Section 9.1 or if disclosure is required by
law, regulation or judicial order. Any person or entity conducting such
inspection will agree in writing with the inspecting party to treat all
records reviewed in the course of the inspection as the Confidential
Information of the party being inspected under terms and conditions no less
restrictive than the terms contained in Section 5.2. The results of each
inspection shall be binding on both parties absent mathematical error. The
inspecting party shall pay for such inspections, except that in the event
there is any upward adjustment in aggregate amounts payable for any year
shown by such inspection of more than [*] of the amount paid, the party being
inspected shall pay for such inspection.

4A.22 SHARED PRODUCT REPORTING AND PAYMENTS OF THE PARTIES' SHARE OF
PROFIT/LOSS. (a) Payments and reporting for each Shared Product shall be made as
follows. Within forty five (45) days after the close of each

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

party's accounting year in which Shared Products are sold, or earlier if
possible, each party shall furnish to the other party a profit and loss
statement for such accounting year setting forth for each country in the
Territory in which Shared Products were developed or sold during such year, Net
Sales of each Shared Product, Expenses, Sublicense Revenues and all data on
which the determination of each party's Share of Profit, Share of Loss or share
of Sublicense Revenues was calculated. If either party owes an amount of Share
of Profit or Share of Loss to the other party pursuant to Section 4A.17, then it
shall make such payment within thirty (30) days after receipt of the profit and
loss statement, but in no event shall such payment be due earlier than sixty
(60) days after the end of the relevant period.

     (b) For the purposes of calculating Shared Product Profit or Shared Product
Loss for a Shared Product, a given item of cost or expense shall be allocated
only to one category of cost and expense and not to multiple categories. Each
party agrees to determine such costs and expenses hereunder with respect to
Shared Products using its standard accounting procedures, consistently applied,
to the maximum extent practical, as if such Shared Product were a solely owned
product of the party, except as specifically provided in this Agreement. The
parties also recognize that such procedures may change from time to time and
that any such changes may affect the definitions of the elements of the Shared
Product Profit or Shared Product Loss. The parties agree that, where such
changes are economically material to either party, adjustments shall be made to
compensate the affected party in order to preserve the same economics as
reflected under this Agreement under such party's accounting procedures in
effect as of the date on which the activity in question (for example,
Development, marketing or Manufacturing) first commences under this Agreement.
Transfers between a party and its Affiliates (or between such Affiliates) shall
not have effect for purposes of calculating revenues, costs, profits, royalties
or other payments or expenses under this Agreement.

4A.23 COMMERCIALIZATION. (a) The Steering Committee shall oversee and implement
all Commercialization activities in the Territory for Shared Products, based on
the principle of maximizing profits from sales of Shared Products. The Steering
Committee shall have the ability to determine whether the objective of
maximizing profits from sales of Shared Products in the Territory is best
achieved through, INTER ALIA, granting sublicenses to a third party or third
parties, creating or entering into joint ventures with third parties or jointly
Commercializing such Shared Products as provided in this Section 4A.23. In the
event the Steering Committee determines that the foregoing objective is best
achieved by activities other than as provided in this Section 4A.23, the
Steering Committee shall determine [*] the optimal alternative structure and the
duties, responsibilities and economic parameters for the parties and third
parties in such alternative structure.

     (b) No later than [*] for a Shared Product, the Steering Committee shall
commence preparation of a marketing plan (MARKETING PLAN) and a marketing
budget (MARKETING BUDGET) for such Shared Product. The Commercialization of a
Shared Product in the Territory will be governed by the Marketing Plan and
Marketing Budget. The Marketing Plan and Marketing Budget will describe
fully, to the extent practicable, the proposed plan for Commercialization of
the Shared Product in each country in which the parties Commercialize Shared
Products, including overall marketing strategy, marketing, sales and
promotion efforts to be performed by each party, market and sales forecasts,
pricing, reimbursement and discounting analysis and estimated launch date, as
well as preparation of advertising and other promotional materials to be used
in the promotion of Shared Products. The Marketing Plan will take into
consideration market conditions, regulatory factors and competition with
respect to the Shared Product. The Marketing Budget will include all
projected Expenses for the Shared Product. The initial Marketing Plan and
Marketing Budget shall be completed by the Steering Committee no later than
[*] for a Shared Product in any country in the Territory. Each such Marketing
Plan and Marketing Budget shall thereafter be updated by the Steering
Committee every six (6) months, or more frequently if agreed by the parties.

     (c) NeoGenesis and Tularik shall have the co-exclusive responsibility for
promoting such Shared Product in the Territory, except as otherwise provided in
Section 4A.23(a). Tularik and NeoGenesis shall each diligently perform its
respective obligations under the Marketing Plan and use Commercially Reasonable
Efforts to Commercialize Shared Products in the Territory pursuant to the terms
and conditions hereof. The parties intend that each party shall provide fifty
percent (50%) of the total promotional and marketing effort (including details,
if determined to be an appropriate sales activity for a party by the Steering
Committee) for each Shared Product being Commercialized by the parties in the
Territory, as determined by the Steering Committee. The Steering Committee will
determine appropriate written standards for measuring, and accounting procedures
to confirm and document, each party's

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       31
<Page>

marketing and promotional effort under the Marketing Plan, no later than [*]
for any Shared Product. Nothing contained in this Section 4A.23 shall be
deemed to preclude either party from relinquishing its right to participate
in the Commercialization of Shared Products in the Territory pursuant to
Section 4A.23(d), at any time.

     (d) Either party may terminate its participation in the
Commercialization of a Shared Product in any country in the Territory at any
time following [*] prior written notice to the other party. In such case, the
other party may continue Commercialization of such Shared Product as an
Independent Product, either alone or with a third party, and shall thereafter
be deemed to be an Independent Party for such Independent Product solely with
respect to such country or countries, effective as of the date of the
terminating party's notice hereunder, in which case the terminating party's
license under Section 3.1 shall be terminated in the country or countries in
which such party has terminated its participation in the Commercialization of
such Shared Product (the TERMINATED COUNTRIES). In the event a party elects
to cease participating in the Commercialization of a Shared Product in a
country in the Territory and the other party proceeds to Commercialize such
Shared Product in the Terminated Countries as an Independent Product, the
terminating party shall (i) [*] to the Independent Party all regulatory
submissions and Regulatory Approvals in such country relating to such former
Shared Product, together with all materials and data related thereto in its
possession, and (ii) [*] to the Independent Party all other relevant
information that will enable such Independent Party to Commercialize such
former Shared Product as an Independent Product in such country. A
non-Independent Party may not reinitiate its participation in the
Commercialization of a Shared Product in any country in the Territory in
which it relinquished such right hereunder. Any relinquishment of a party's
right to Commercialize Shared Products pursuant to this Section 4A.23(d)
shall not be a breach of this Agreement. If both parties terminate their
participation in the Commercialization of a Shared Product, the parties will
confer and mutually agree on a plan for seeking a third party to conduct such
Commercialization.

     (e) The parties shall disseminate in the Territory only those
promotional and advertising materials that have been provided or approved for
use by the Steering Committee, and the cost of producing such materials shall
be an Expense of [*]. All such materials shall be consistent with the
relevant Marketing Plan and Marketing Budget approved, [*], by the Steering
Committee and neither party shall make any claims or representations in
respect of the Shared Products outside the scope of those previously approved
by the Steering Committee.

     (f) The Steering Committee shall designate a party as being primarily
responsible for each country in the Territory for booking sales, establishing
pricing for Shared Products based upon the market analyses performed by the
parties under the direction of the Steering Committee, obtaining necessary
pricing approvals, handling returns and customer complaints and providing
samples. In addition, the Steering Committee shall determine the policies and
procedures necessary to implement the foregoing, including coordination of the
parties' efforts to train sales and marketing representatives for Shared
Products.

4A.24 TRADEMARKS. (a) The parties shall mutually select the trademark or
trademarks for a Shared Product. To the extent commercially reasonable and
appropriate, a single trademark shall be used for each Shared Product in all
countries in the Territory. To the extent the parties determine that the use of
a single trademark for a given Shared Product is impractical or not advisable
given cultural and other differences among countries in the Territory, the
parties shall agree on the appropriate trademark for a Shared Product for use
within different countries within the Territory; PROVIDED that in no event shall
different trademarks be used for the same Shared Product within the same country
in the Territory (unless such Shared Product is being sold for more than one
indication and the parties mutually agree.) Each trademark shall be used only in
connection with the applicable Shared Product and shall not be used by either
party on, or in connection with, any other product. The Steering Committee shall
determine which party shall own each trademark used to promote Shared Products
in the Territory and assign responsibility to one or both parties for searching
candidate trademark names and filing, prosecuting, maintaining and all
reasonable steps necessary in defending each Shared Product trademark
application(s) and/or trademark(s) (as applicable).

     (b) The party owning a given trademark and related intellectual property
rights in a country in the Territory shall, and hereby does, grant to the other
party a nonexclusive, royalty-free license, with the right to grant sublicenses
only with the prior written consent of the granting party, not to be
unreasonably withheld, to use such trademark to

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       32
<Page>

promote and Commercialize Shared Products as permitted under this Agreement,
provided that the party receiving such license shall refrain from taking any
actions that may dilute or otherwise reduce the value of such trademark. The
parties shall approve all trade dress, logos, slogans, designs and copyrights
used on and in connection with any Shared Product in the Territory. During the
term of this Agreement, the Screening Committee shall approve all printed
materials bearing each trademark for a Shared Product in the Territory,
including but not limited to business materials, printed materials, advertising
materials, promotional materials and any such other materials that may reference
or incorporate such trademark.

     (c) In the event that any action or proceeding is brought against either or
both NeoGenesis or Tularik with respect to a Shared Product trademark in the
Territory or relating to any alleged infringement of a third party's trademark,
trade dress or similar intellectual property rights in the Territory arising out
of the parties' promotion or Commercialization of Shared Products pursuant to
this Agreement, each party shall promptly notify the other and cooperate in the
defense of any such action or proceeding, as applicable. The parties shall agree
on the management of such action. In the event Tularik or NeoGenesis becomes
aware of any actual or threatened violation of any trademark for a Shared
Product in any country in the Territory, that party shall promptly notify the
other party and the Steering Committee shall promptly discuss how to proceed in
connection with such actual or threatened violation. Any expenses incurred by
either or both parties for searching candidate trademark names, filing,
prosecuting, maintaining, defending and enforcing trademark application(s)
and/or trademark(s) (as applicable) for Shared Products shall be included as an
element of [*].

4A.25 SUPPLY OF SHARED PRODUCT. The Steering Committee shall be responsible for
determining the sources of, and arrangements for, the clinical and commercial
Manufacture and supply of Designated Shared Compounds and Shared Products in a
manner designed to result in long-term profit maximization for such Shared
Products. The Steering Committee shall endeavor to establish multiple sources of
bulk material and fill and finish services and to establish policies for the
maintenance of inventories of key intermediates, bulk material and finished
products and for such other matters as necessary or useful to assure such supply
of Shared Products in the Territory. The Independent Party shall arrange for the
Manufacture and supply of Independent Compounds, Derivative Compounds thereof
and Independent Products, in both bulk and finished form.

4A.26 SPECIFICATIONS FOR SHARED PRODUCTS. The parties shall designate one of the
parties to be responsible for establishing, subject to approval by the Steering
Committee, the specifications for bulk and finished Shared Product, and
providing and maintaining any necessary documentation, certificates of analysis
and test results, for each Shared Product. Copies of all such specifications and
other information and documentation will be provided promptly to each party. In
addition, notice of, and results and data from, all FDA (or its foreign
equivalent) audits relating to the Manufacture of Shared Products will be
provided to each party.

4A.27 TERMS OF MANUFACTURE AND SUPPLY. The parties shall establish procedures
acceptable to both parties regarding forecasting of and ordering for each
party's requirements of the Shared Products in the Territory.

4A.28 SIDE EFFECTS AND ADVERSE EVENTS. During the term of this Agreement, each
party shall promptly advise the other by telephone, telefax or overnight
delivery service of every serious or unexpected side effect, adverse reaction or
injury that has been brought to that party's attention and which is alleged to
have been caused by a Shared Product. For each country in the Territory, the
party that has the responsibility for filing the Regulatory Approval and the IND
(or foreign equivalent) in such country for such Shared Product shall have all
rights and responsibilities to report such side effect, adverse reaction or
injury to the appropriate Regulatory Authority(ies) as required by Applicable
Laws. The parties shall establish a procedure for such reporting obligations
prior to commencement of Phase I Clinical Trials for the first Shared Product.

4A.29 COMMUNICATION WITH REGULATORY AGENCIES. If a party is contacted by the
FDA or any equivalent regulatory agency in any country in the Territory
during the term of this Agreement pertaining to a Shared Product, Tularik and
NeoGenesis shall promptly, but always within [*], notify and consult with one
another. The party that has responsibility for regulatory filings for a
Shared Product shall provide an appropriate response to such contact after
such consultation with the other party, except where an earlier response may
be required by law or to assure patient safety.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       33
<Page>

4A.30 SHARED PRODUCT RECALL. In the event that NeoGenesis or Tularik
determines that an event, incident or circumstance has occurred that may
result in the need for a recall or other removal of any Shared Product or any
lot or lots thereof from the market in a country within the Territory, it
shall promptly advise and consult with the other party with respect thereto.
Thereafter, on a country-by-country basis, the owner of the Regulatory
Approval for such Shared Product in a country shall, in its sole discretion
(except as otherwise required by such government authority), have the right
to order a recall or other removal after such consultation, and the other
party shall co-operate with such recall. Any expenses related to a recall in
the Territory for a Shared Product shall be [*].

5.   CONFIDENTIALITY

5.1 PUBLICITY. The parties shall agree upon the text and the exact timing of an
initial public announcement relating to the transactions contemplated by this
Agreement as soon as practicable after the Effective Date (such agreement not to
be unreasonably withheld or delayed). Each party may thereafter disclose to
third parties the specific information contained in such public announcement
without the need for further approval by the other party. Thereafter, unless
permitted by the preceding sentence, each party agrees not to issue any press
release or other public statement, written or oral, to the public, the press,
the stockholders or otherwise, relating to this Agreement that has not
previously been approved in writing by the other party. Nothing in this Section
5.1 shall prohibit a party from making such disclosures to the extent required
under applicable federal or state securities laws or any rule or regulation of
any nationally recognized securities exchange. In such event, however, the
disclosing party shall use good faith efforts to notify and consult with the
other party prior to such disclosure and, where applicable, shall diligently
seek confidential treatment to the extent such treatment is available under
applicable securities laws.

5.2  CONFIDENTIALITY. (a) Except as permitted in accordance with Section 5.1,
either party may only disclose the general nature, but not the specific
financial or other material terms, of this Agreement without the prior consent
of the other party; PROVIDED that either party may provide a copy of this
Agreement or disclose the terms of this Agreement (i) to any finance provider in
conjunction with a financing transaction, if such finance provider agrees to
keep this Agreement confidential, (ii) to enforce its rights under this
Agreement in a proceeding in accordance with Section 9.1, (iii) to any legal or
financial advisor of such party, or (iv) in response to a subpoena or other
validly issued administrative or judicial process requesting disclosure of same;
PROVIDED, the party that receives such order or process provides prompt notice
to the disclosing party before making any disclosure (to the extent possible)
and permits the disclosing party to oppose or narrow such request for disclosure
and supports any of disclosing party's reasonable efforts to oppose such request
(at disclosing party's expense) and shall disclose the terms of this Agreement
only in the event of a final judgment or administrative order requiring such
disclosure, and only to the extent necessary to comply with such request.

     (b) Confidential Information of each party and Program Intellectual
Property owned by such party will be used by the other party solely for the
purposes permitted by this Agreement. All Confidential Information and any
Program Intellectual Property owned by a party will be received and held in
confidence by the receiving party, subject to the provisions of this Agreement.
Each party acknowledges that, except for the rights expressly granted under this
Agreement, it will not obtain any rights of any sort in or to the Confidential
Information of the other party as a result of such disclosure and that any such
rights must be the subject of separate written agreement(s).

     (c) Each party will restrict disclosure of the other party's Confidential
Information and any Program Intellectual Property owned by such party to those
of its employees and consultants to whom it is necessary or useful to disclose
such Confidential Information and Program Intellectual Property in connection
with the purposes permitted under this Agreement. Each party shall use
reasonable efforts, including at least efforts fully commensurate with those
employed by the party for the protection of its own Confidential Information, to
protect the Confidential Information and Program Intellectual Property of the
other party.

     (d) Either disclosing party may at any time notify the receiving party
that such receiving party must return to the disclosing party the disclosing
party's Confidential Information and any Program Intellectual Property owned
by such party. Each party hereby agrees to, [*]: (i) return all documents and
tangible

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       34
<Page>

items it or its employees or agents have received or created pursuant to this
Agreement pertaining, referring or relating to the other party's Confidential
Information and any Program Intellectual Property owned by such party; and (ii)
return or certify (in a writing attested to by a duly authorized officer of such
party) destruction of all copies, summaries, modifications or adaptations that
such party or its employees or agents have made from the materials provided by
the disclosing party; provided, however, that a party is permitted to retain one
copy of such materials in its legal files to be used to verify compliance with
its obligations hereunder.

     (e) Nothing herein shall prevent a receiving party from disclosing all or
part of the Confidential Information and any Program Intellectual Property owned
by the disclosing party in response to a subpoena or other validly issued
administrative or judicial process requesting disclosure of same; PROVIDED, the
party that receives such order or process provides prompt notice to the
disclosing party before making any disclosure (to the extent possible) and
permits the disclosing party to oppose or narrow such request for disclosure and
supports any of the disclosing party's reasonable efforts to oppose such request
(at disclosing party's expense) and shall disclose such Confidential Information
or Program Intellectual Property only in the event of a final judgement or
administrative order requiring such disclosure, and only to the extent necessary
to comply with such request.

5.3  PUBLICATIONS. Each party recognizes that the publication of papers
regarding results of the Screening Program, including oral presentations and
abstracts, may be beneficial to both parties provided such publications are
subject to reasonable controls to protect Confidential Information. In
particular, it is the intent of the parties to maintain the confidentiality of
any Confidential Information regarding the compounds included in any patent
application until such patent application has been published. Accordingly, each
party shall have the right to review and comment upon any paper proposed for
publication by the other party regarding results of the Screening Program
hereunder, including oral presentations and abstracts, which utilizes data
generated from the Screening Program and/or includes Confidential Information
of the other party. Before any such paper is submitted for publication, the
party proposing publication shall deliver a complete copy to the other party at
least thirty (30) days prior to submitting the paper to a publisher. The
receiving party shall review any such paper and give its comments to the
publishing party within twenty (20) days of the delivery of such paper to the
receiving party. With respect to oral presentation materials, the parties shall
make reasonable efforts to expedite review of such materials, and shall return
such items as soon as practicable to the disclosing party with appropriate
comments, if any, but in no event later than twenty (20) days from the date of
delivery to the receiving party. The disclosing party shall comply with the
other party's request to delete references to such other party's Confidential
Information in any such paper and agrees to withhold publication of same for an
additional one hundred eighty (180) days (or longer if necessary) in order to
permit the parties to obtain patent protection, if either of the parties deem
it necessary, in accordance with the terms of this Agreement. If there is a
dispute regarding publications, such dispute shall be resolved by the Steering
Committee.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

6.   REPRESENTATIONS AND WARRANTIES.

6.1  AUTHORIZATION; ENFORCEABILITY. Each of Tularik and NeoGenesis represent and
warrant to the other that: (a) it is a corporation duly organized and validly
existing under the laws of its jurisdiction of organization and has all
requisite power and authority to enter into this Agreement; (b) it is duly
authorized by all requisite action to execute, deliver and perform this
Agreement and to consummate the transactions contemplated hereby, and that the
same do not conflict or cause a default with respect to such party's obligations
under any other agreement; (c) it has duly executed and delivered this
Agreement; and (d) it is authorized to disclose any and all Confidential
Information made available to the other party pursuant to this Agreement.

6.2  PERFORMANCE. (a) NeoGenesis hereby represents and warrants to Tularik that:
(i) NeoGenesis shall perform the Screening Program using qualified personnel and
in a good and workmanlike manner consistent with industry standards of companies
that are comparable to NeoGenesis performing similar activities under similar
circumstances; and (ii) as of the Effective Date, there is no agreement known to
NeoGenesis to which it is a party and by which it is bound that would conflict
with or be breached by NeoGenesis granting Tularik the licenses in Sections 2.5,
3.1 and 3.2(e) and the assignments in Section 3.2(d) and 3.2(i).

     (b) NeoGenesis hereby represents and warrants to Tularik that it has not
sought, and will not seek, patent protection on any of the compounds that will
be screened in the conduct of the Screening Program.

     (c) Tularik hereby represents and warrants to NeoGenesis that, as of the
Effective Date, there is no agreement known to Tularik to which it is a party
and by which it is bound that would conflict with or be breached by Tularik
granting NeoGenesis the licenses in Sections 2.5, 3.1 and 3.2(f).

6.3  DISCLAIMER. (A) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO ANY MATTER WHATSOEVER, INCLUDING BUT NOT
LIMITED TO, THE NEOMORPH SCREENING LIBRARY, THE NEOMORPH FOCUSED LIBRARIES,
QSCD, THE PRELIMINARY COMPOUNDS, THE PRIMARY ACTIVE COMPOUNDS, THE SELECTED
COMPOUNDS, THE DESIGNATED COMPOUNDS, THE TARGETS, THE PRODUCTS, THE SHARED
PRODUCTS, THE NEOGENESIS INTELLECTUAL PROPERTY, THE TULARIK INTELLECTUAL
PROPERTY, THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS,
THE TULARIK PATENT RIGHTS OR PROGRAM PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS
UNDER THIS AGREEMENT.

     (B) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS AND TULARIK
EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED
IN SECTIONS 7.2-7.3.

7.   RISK ALLOCATION

7.1  LIMITATION OF LIABILITY. EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS
UNDER SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH
RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED,
UNDER ANY THEORY OF LIABILITY.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

7.2  THIRD PARTY CLAIMS (EXCLUDING INFRINGEMENT). Subject to the provisions of
Section 7.4, each of NeoGenesis and Tularik (each, in such capacity, an
INDEMNIFYING PARTY) will defend, indemnify and hold harmless the other party,
its subsidiaries, parent corporations, affiliates, officers, directors,
partners, members, shareholders, employees, agents, and their successors and
assigns (each, in such capacity, an INDEMNIFIED PARTY) from and against any
claim, suit, demand, loss, damage, expense (including reasonable attorneys' fees
of Indemnified Party(ies) and those that may be asserted by a third party) or
liability including but not limited to claims for death or personal injury
(collectively, LOSSES) imposed upon the Indemnified Party(ies) by any third
party arising from or related to: (i) any material breach of the Indemnifying
Party's representations and warranties under this Agreement; or (ii) any
negligence or intentional misconduct by the Indemnifying Party (or its
employees, agents, representatives, Affiliates, licensees, sublicensees or
distributors) in performing its obligations under this Agreement; or (iii) the
labeling, packaging, package insert, other materials or promotional claims with
respect to any Shared Product or Independent Product or the Development,
testing, Manufacturing, Commercialization, use or other disposition of any
Shared Product or Independent Product by the Indemnifying Party or by an
Affiliate, licensee, sublicensee, distributor or agent of the Indemnifying
Party; or (iv) (with respect to Tularik as an Indemnifying Party) the labeling,
packaging, package insert, other materials or promotional claims with respect to
any Product or the development, testing, Manufacturing, Commercialization, use
or other disposition of any Product by Tularik or by an Affiliate, licensee,
sublicensee, distributor or agent of Tularik. The foregoing indemnification
action shall not apply in the event and to the extent that such Losses arose as
a result of any Indemnified Party's negligence, intentional misconduct or breach
of this Agreement.

7.3  INFRINGEMENT INDEMNIFICATION. (a) Subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless the Tularik Indemnified
Party(ies) from and against any Losses imposed upon them by any third party and
arising from or related to a third party claim that use of NeoGenesis
Intellectual Property or practice of the NeoGenesis Patent Rights by Tularik in
accordance with the terms of this Agreement violates or infringes the
intellectual property rights of any third party. NeoGenesis shall have no
liability or obligation to Tularik under this Section 7.3(a) in the event and to
the extent that the alleged infringement results from willful misconduct or
negligent acts or omissions of Tularik or its Affiliates, or its or their
respective employees, officers, directors or agents.

     (b) Subject to the provisions of Section 7.4, Tularik shall defend,
indemnify and hold harmless the NeoGenesis Indemnified Party(ies) from and
against any Losses imposed upon them by any third party and arising from or
related to a third party claim that use of the Tularik Intellectual Property or
practice of the Tularik Patent Rights by NeoGenesis in accordance with the terms
of this Agreement violates or infringes the intellectual property rights of any
third party. Tularik shall have no obligation or liability to NeoGenesis under
this Section 7.3(b) in the event and to the extent that the alleged infringement
(i) is covered by Section 7.3(a) or (ii) results from willful misconduct or
negligent acts or omissions of NeoGenesis or its Affiliates, or its or their
respective employees, officers, directors or agents.

7.4  PROCEDURE. To receive the benefit of indemnification under Sections 7.2 or
7.3, the Indemnified Party must (a) promptly notify the Indemnifying Party of a
claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations except where, and solely
to the extent that, such failure actually and materially prejudices the rights
of Indemnifying Party; (b) provide reasonable cooperation to the Indemnifying
Party (and its insurer), as reasonably requested, at Indemnifying Party's cost
and expense; and (c) tender to the Indemnifying Party (and its insurer) full
authority to defend or settle the claim or suit; PROVIDED that no settlement
requiring any admission by the Indemnified Party or that imposes any obligation
on the Indemnified Party shall be made without the Indemnified Party's consent.
Neither party has any obligation to indemnify the other party in connection with
any settlement made without the Indemnifying Party's written consent. The
Indemnified Party has the right to participate at its own expense in the claim
or suit and in selecting counsel therefor.

8.   TERM AND TERMINATION

8.1  TERM. This Agreement shall take effect as of the Effective Date and shall
remain in effect until the expiration of the last to expire of the licenses
granted hereunder, unless sooner terminated in accordance with Section 8.2.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

8.2  TERMINATION. (a) NeoGenesis may suspend work pursuant to the Screening
Program or terminate the Screening Program with thirty (30) days' notice to
Tularik if Tularik fails to pay fees not contested in good faith due under the
Agreement or commits a material breach, unless the nonpayment or breach is cured
within the thirty (30)-day notice period. Tularik may terminate the Screening
Program with thirty (30) days' notice to NeoGenesis if NeoGenesis commits a
material breach unless the breach is cured within the thirty (30)-day notice
period.

     (b) Either party may terminate the license under Section 3.1 with sixty
(60) days' notice if the other party commits a material breach (including
non-payment), unless the breach is cured within the sixty (60)-day notice
period; PROVIDED that if more than one compound is being developed or
commercialized by a party or its Affiliates hereunder, and the other party
terminates this Agreement pursuant to this Section 8.2(b) due to a breach
relating only to a single compound, then the terminating party shall be entitled
to terminate this Agreement only with respect to the applicable compound.

     (c) The parties may terminate this Agreement, or the license under Section
3.1 on a compound-by-compound, product-by-product or country-by-country basis,
at any time upon mutual written agreement of the parties.

     (d) Tularik shall have the right to terminate the license set forth in
Section 3.1 on a Designated Screening Compound-by-Designated Screening Compound,
Derivative Compound thereof-by-Derivative Compound thereof, Product-by-Product
or country-by-country basis at any time upon notice to NeoGenesis.

     (e) If voluntary or involuntary proceedings by or against a party are
instituted in bankruptcy under any insolvency law, or a receiver or custodian is
appointed for such party, or proceedings are instituted by or against such party
for corporate reorganization or the dissolution of such party, which
proceedings, if involuntary, shall not have been dismissed within sixty (60)
days after the date of filing, or if such party makes an assignment for the
benefit of creditors, or substantially all of the assets of such party are
seized or attached and not released within sixty (60) days thereafter, the other
party may immediately terminate this Agreement effective upon notice of such
termination.

     8.3 EFFECT OF TERMINATION. (a) Upon termination (including expiration) of
this Agreement: (i) the parties will terminate all tasks then in process in an
orderly manner, as soon as practical and in accordance with a schedule agreed to
by Tularik and NeoGenesis; (ii) if termination occurs prior to completion of the
Screening Program then NeoGenesis shall deliver to Tularik all materials
developed through the termination of this Agreement; (iii) each party shall pay
to the other party any uncontested monies due and owing up to the time of
termination; and (iv) within thirty (30) days following termination (including
expiration) of this Agreement, NeoGenesis shall deliver to Tularik a
reasonably-detailed written report describing the results of the research
performed under the Screening Program up to the date of such termination.

     (b) Upon termination (including expiration) of this Agreement each party
shall return to the other party or certify in writing to the other party that it
has destroyed all documents and other tangible items it or its employees or
agents have received or created pertaining, referring or relating to the
Confidential Information or Program Intellectual Property owned by the other
party; provided, however, that a party is permitted to retain one copy of such
materials in its legal files to be used to verify compliance with its
obligations hereunder.

     (c) The license granted by NeoGenesis under Section 3.1(a) shall survive
any expiration or termination of the Screening Program or this Agreement with
respect to any Designated Compound, Derivative Compound thereof, Product and
Shared Product for which the applicable fees and milestone fees and royalties or
the amounts due under Section 4A, as applicable, have been paid and with respect
to any Independent Compound, Derivative Compound thereof and Independent Product
for which the amounts due under Section 4A have been paid (in each case in
accordance with the terms of this Agreement); PROVIDED that Tularik continues to
pay NeoGenesis the fees and royalties as required by Sections 4.3, 4.4 and 4.5
and complies with Sections 4.6-4.9, or to pay NeoGenesis the amounts due under
Section 4A, as applicable. The license granted by Tularik under Section 3.1(b)
shall survive any expiration or termination of this Agreement with respect to
any Designated Shared Compound, Derivative Compound thereof, Shared Product,
Independent Compound, Derivative Compound thereof and Independent Product for
which the amounts due under Section 4A have been paid (in accordance with the
terms of this Agreement). The license granted under Section 3.1 shall not
survive termination or expiration of the Screening

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       38
<Page>

Program or this Agreement with respect to Designated Compounds, Derivative
Compounds thereof, Products, Shared Products, Independent Compounds, Derivative
Compounds thereof and Independent Products for which the applicable fees and
milestone fees and royalties or the amounts due under Section 4A, as applicable,
have not been paid in accordance with this Agreement. In the event the license
granted to Tularik under Section 3.1 terminates for any reason, each of
Tularik's sublicensees at such time shall continue to have the rights and
license set forth in their sublicense agreements, PROVIDED such sublicensee
agrees in writing that NeoGenesis is entitled to enforce all relevant provisions
directly against such sublicensee.

     (d) Except as otherwise provided herein, neither party shall be liable to
the other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section 8.

     (e) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination. Either
party's liability for any uncontested charges, payments or expenses due to the
other party that accrued prior to the termination date shall not be extinguished
by termination, and such amounts (if not otherwise due on an earlier date) shall
be immediately due and payable on the termination date.

8.4  SURVIVAL. [*].

9.   GENERAL PROVISIONS.

9.1  ISSUE RESOLUTION. The parties shall use their best efforts to resolve any
controversy or dispute that arises under or relates to this Agreement through
good faith discussions. The parties shall initiate such discussions using the
following procedure. Either party shall notify the other party of the nature of
the controversy or dispute, providing sufficient detail to permit the other
party to understand same (a DISPUTE NOTICE). The representatives of the parties
shall meet within thirty (30) days after the date that the non-sending party
receives the Dispute Notice to attempt in good faith to reach an agreement about
the nature of the dispute and a resolution of the dispute. Pending resolution of
any dispute covered by this Section 9.1, both parties will continue their
performance under this Agreement including, without limitation, the payment of
all amounts due to the other party that are not in dispute.

9.2  GOVERNING LAW. This Agreement shall be governed and construed in accordance
with the internal, substantive laws of the State of Delaware to the exclusion of
any choice or conflict of laws rule or provision that would result in the
application of the substantive law of any other jurisdiction. Notwithstanding
the foregoing, the parties shall use United States (Federal) patent laws, as
applicable, for purposes of governing and construing Sections 3.2-3.4 of this
Agreement. The United Nations Convention on Contracts for the International Sale
of Goods shall not apply to the transactions contemplated by this Agreement.

9.3  AMENDMENT AND WAIVER. No provision of or right under this Agreement shall
be deemed to have been waived by any act or acquiescence on the part of either
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by either party of any breach of
this Agreement by the other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before
or after the date of such waiver.

9.4  INDEPENDENT CONTRACTORS. Each party represents that it is acting on its own
behalf as an independent contractor and is not acting as an agent for or on
behalf of any third party. This Agreement and the relations hereby established
by and between Tularik and NeoGenesis do not constitute a partnership, joint
venture, franchise, agency or contract of employment. Neither party is granted,
and neither party shall exercise, the right or authority to assume or create any
obligation or responsibility on behalf of or in the name of the other party or
its Affiliates. Each party

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

shall be solely responsible for compensating all its personnel and for payment
of all related FICA, workers' compensation, unemployment and withholding taxes.
Neither party shall provide the other party's personnel with any benefits,
including but not limited to compensation for insurance premiums, paid sick
leave or retirement benefits.

9.5  ASSIGNMENT. Neither party may assign this Agreement or any of its rights
and obligations under this Agreement without the prior written consent of the
other party; PROVIDED, that either party may assign this Agreement to (a) any
Person to which such party transfers all or substantially all of its assets or
with which such party is consolidated or merged; (b) any Person that owns a
majority of the voting stock of such party; or (c) a single Person of which
such party owns a majority of the voting stock; PROVIDED, FURTHER, that in each
instance the assignee expressly assumes all obligations imposed on the
assigning party by this Agreement in writing and the other party is notified in
advance of such assignment.

9.6  SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

9.7  NOTICES. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be in writing and shall be
deemed given when delivered personally or mailed by certified or registered
mail, postage prepaid (such mailed notice to be effective on the date which is
three (3) business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one
business day after it is deposited with such courier), or sent by telefax (such
notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) to the address set forth on
the signature page to this Agreement or to such other place as any party may
designate as to itself by written notice to the other party.

9.8  SEVERABILITY. In the event any provision of this Agreement shall for any
reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith or
will permit a court to replace any provision hereof so held invalid, illegal or
unenforceable with a valid provision which is as similar as possible in
substance to the invalid, illegal or unenforceable provision.

9.9  CAPTIONS. Captions of the sections and subsections of this Agreement are
for reference purposes only and do not constitute terms or conditions of this
Agreement and shall not limit or affect the meaning or construction of the
terms and conditions hereof.

9.10 WORD MEANINGS. Words such as HEREIN, HEREINAFTER, HEREOF and HEREUNDER
refer to this Agreement as a whole and not merely to a section or paragraph in
which such words appear, unless the context otherwise requires. The singular
shall include the plural, and each masculine, feminine and neuter reference
shall include and refer also to the others, unless the context otherwise
requires.

9.11 ENTIRE AGREEMENT. The terms and provisions contained in this Agreement
(including the Attachments) constitute the entire understanding of the parties
with respect to the transactions and matters contemplated hereby and supersede
all previous communications, representations, agreements and understandings
relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the parties not contained in
this Agreement shall be of any force or effect. No agreement or understanding
extending this Agreement or varying its terms (including any inconsistent terms
in any purchase order, acknowledgment or similar form) shall be binding upon
either party unless it is in a writing specifically referring to this Agreement
and signed by a duly authorized representative of the applicable party.

9.12 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

9.13 COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

9.14 FORCE MAJEURE. Except as otherwise provided in this Agreement, in the event
that a delay or failure of a party to comply with any obligation created by this
Agreement is caused by a Force Majeure condition, that obligation shall be
suspended during the continuance of the Force Majeure condition.

9.15 FURTHER ASSURANCES. Each party covenants and agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

NEOGENESIS DRUG DISCOVERY, INC.         TULARIK INC.

BY: /s/  ROBERT ADELMAN                 BY: /s/ WILLIAM J. RIEFLIN
-------------------------------------   ----------------------------------------
Robert Adelman                          William J. Rieflin
Vice President, Business Development    Executive Vice President, Administration

NOTICE ADDRESS:                         NOTICE ADDRESS:
NeoGenesis Drug Discovery, Inc.         Tularik Inc.
840 Memorial Drive                      Two Corporate Drive
Cambridge, MA 02139                     South San Francisco, CA 94080
Phone:  617.868.1500                    Phone: 650.825.7000
Fax:  617.868.1515                      Fax: 650.825.7303

* = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
    SEPARATELY WITH THE COMMISSION.

                                       41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]